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Thesis Abstract 
Introduction 
Potentially inappropriate prescribing (PIP) is an umbrella term which encompasses 
prescribing of medications:  
(i) With no indication 
(ii) For the wrong indication 
(iii) With a high risk of an adverse drug event (ADE) 
(iv) That are unnecessarily expensive 
(v) For too short or too long a period.  
PIP also includes the failure to prescribe appropriate drug therapy when it may be 
of benefit to the patient. PIP is a major contributor to ADEs, adverse drug reactions 
(ADRs), hospitalisations, patient harm and overall increased healthcare costs. Older 
patients are particularly susceptible to PIP due to multiple comorbidities, multiple 
medications and declining renal and hepatic function leading to altered 
pharmacodynamic and pharmacokinetic properties of drugs. Rates of PIP in 
primary, secondary and long-term care as high as 40%, 58% and 70% respectively 
have been reported. ADRs, one of the more serious consequences of PIP, are in 
their own right, a major contributor to hospitalisations and increase costs, 
especially amongst the older population. Patients over 65 years of age are 
estimated to be 4 times more likely to experience an ADR than their younger 
counterparts. While much quantitative research has taken place to quantify the 
problem of PIP, little in the way of qualitative research exists to identify the 
xxi 
 
fundamental causes of this phenomenon. As a result, interventions aimed at 
addressing PIP have had only modest success.  
The overall aim of this thesis was to identify , develop and implement strategies 
with the potential to prevent PIP and ADRs in older patients. 
The objectives were:  
(i) to explore the causative factors of PIP and related outcomes through 
qualitative research 
(ii) use these findings to determine the types of interventions that would be 
suitable for the purpose of preventing PIP 
(iii) develop an intervention informed by this research 
(iv)  explore other possible intervention types identified for suitability and 
applicability with regards to preventing PIP and related outcomes. 
Methods 
Since this work was to be informed by qualitative research, a systematic review of 
the qualitative literature on PIP was undertaken to determine what work had 
already been done, and to create a context in which later research could be 
compared. The meta-synthesis was conducted using the meta-ethnographic 
approach developed by Noblit and Hare. The ENTREQ (Enhancing transparency in 
reporting the synthesis of qualitative research) statement, a framework 
for reporting the synthesis of qualitative health research, was used to guide how 
the results were reported, as well as the PRISMA checklist. 
xxii 
 
An empirical qualitative study was then carried out in four hospitals in the Munster 
region of Ireland. Semi-structured interviews were used to explore doctors’ 
perspectives on the barriers to appropriate prescribing in older hospitalised 
patients. To identify possible areas of intervention, the theoretical domains 
framework (TDF), an overarching theoretical framework combining 128 constructs 
from 33 theories of behaviour change was used to analyse the data. The TDF 
consists of 12 ‘theoretical domains’. The domains identified in the TDF were then 
mapped to the behavior change wheel to identify suitable intervention types. 
One of the intervention types identified was ‘training’. Therefore, for the next stage 
of the work, a randomised controlled trial (RCT) was developed to assess the impact 
of an online educational module on doctors’ knowledge and confidence with 
regards to prescribing for older patients. Doctors in both control and intervention 
groups completed assessment at baseline. Similar assessments were then 
completed 4 weeks post intervention and again at 12 weeks. 
Other suitable intervention types identified by the previous qualitative work 
included ‘enablement’ and ‘environmental restructuring’. Therefore, the next stage 
of the work involved exploring the potential for a frailty index score as a means of 
altering doctors’ working environments in such a way as to enable them to readily 
identify patients at increased risk of PIP and ADRs. A frailty index was developed 
and applied retrospectively to a database of 711 patients. The relationship between 
patients’ frailty index scores, appropriateness of prescribing and likelihood of 
experiencing an ADR was explored. This was followed by another prospective 
observational study, testing these findings in another patient group. 
xxiii 
 
Finally, and again, targeting ‘enablement’ as a suitable intervention type, the 
potential for the Structured HIstory taking of Medication use (SHiM) tool to enable 
doctors to optimise prescribing for older patients and reduce adverse events was 
explored. SHiM was applied to 123 hospitalised patients in a prospective 
observational study. Whether or not the findings from SHiM would optimise 
prescribing and reduce clinically significant adverse events was explored. 
Results 
The meta-synthesis returned 7 relevant papers, highlighting the lack of qualitative 
work published in the area of PIP. Four key concepts emerged from the 7 papers as 
being contributory factors to PIP:  
(i) Desire to please the patient 
(ii) Feeling of being forced to prescribe 
(iii) Tension between experience and guidelines 
(iv) Prescriber fear. 
Ultimately it was shown that in many situations, prescribers suffer from ‘self-
perceived restrictions’ leading to a sense of powerlessness to prescribe 
appropriately for older patients. This forces prescribers to rely on what they know 
and have done before, which leads to the PIP that has been identified in previous 
quantitative studies.  
Four over-arching themes also emerged from the empirical qualitative study as 
being contributory to PIP. They were;  
(i) Lack of education in the area of geriatric pharmacotherapy 
xxiv 
 
(ii) prescribing environment that is conducive to PIP 
(iii) Poor information technology (IT) infrastructure 
(iv) Lack of collaboration between the various levels of patient care.  
 
5 domains within the TDF were found to be relevant:  
(i) Environmental  context  and  resources 
(ii) Memory/attention  and  decision  processes 
(iii) Knowledge 
(iv) Skills  
(v) Social influences.  
When these were mapped to the behavior change wheel, the intervention types 
deemed suitable to address PIP were training, environmental restructuring,    
restrictions,    persuasion,    incentivisation,    modelling    and    enablement. 
In the RCT, the online educational module resulted in a highly significant 22% 
difference in test scores between intervention and control groups 4 weeks post-
intervention. This improvement was maintained at 12 weeks. The module also 
improved doctors’ confidence levels with regards to prescribing for older patients. 
The study reinforced findings from the qualitative research that doctors do not 
receive enough specific geriatric pharmacotherapy training as undergraduates.  
The two studies exploring the use of a frailty index score as an indicator of patients 
at increased risk of PIP/ADRs showed that there is a significant positive relationship 
between a patient’s frailty status and their likelihood of experiencing PIP/ADRs. A 
xxv 
 
frailty index threshold of 0.16 was identified; patients above this threshold were at 
least twice as likely to experience PIP/ADRs.  
SHiM was found to be a useful tool in terms of reconciling patients’ medications. 
However, the evidence for it being capable of preventing clinically relevant adverse 
events was poor. While SHiM uncovered 200 discrepancies between the medication 
list obtained by the physician and what the patient was actually taking at home, 
only 1% of adverse events experienced by patients during their hospital stay would 
have been prevented by application of SHiM. 
 
Conclusion 
Qualitative research in this thesis has proposed novel theories relating to the 
causative factors of PIP in older patients. In doing so, it has identified several areas 
for intervention and laid down a road map for future research. This work has also 
shown that relatively simple educational interventions are vital for equipping 
doctors to prescribe appropriately for older patients. It has also illustrated the 
potential benefit of interventions based on providing doctors with simple but 
relevant indicators which might identify patients at risk of PIP/ADRs. 
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1.1 The ageing population  
Within the 34 member countries of the Organisation for Economic Co-operation 
and Development (OECD), people born today have an average life expectancy of 
80.1 years [1]. This is a 10 year increase from just 45 years ago. Sixty-five year olds 
today have an average life expectancy of 19.25 years, almost a 6 year increase from 
1960. Of these extra 19 years, 9 are likely to be ‘healthy years’ [2]. In 1960, 8.6% of 
the OECD population was aged 65 or older. Today, that figure is 15.4% and set to 
rise to 27.2% by 2050 [3, 4]. These statistics clearly illustrate that our population is 
ageing. With an ageing population come many socioeconomic burdens and 
increased pressures at all levels of care.  
In primary care, General Practitioners (GPs) care for more and more patients over 
the age of 65. Escalating time pressures, coupled with a rising workload and intense 
scrutiny older patients’ treatment regimens demand, have resulted in many GPs 
feeling overwhelmed and incapable of providing the level of care required for older 
patients [5, 6]. In secondary care in 2011, 43% of total hospital inpatient 
expenditure in the OECD countries was on patients over 65 years of age [7]. We are 
also seeing a reduction in available hospital beds with figures dropping from 7.2 per 
1,000 population in 2000, to 5.9 per 1,000 in 2010 [8]. In the long term care sector 
there has been 4% growth in expenditure on institutional care since 2000, which 
aligns with the 5% growth in the  number of long term care patients over the age of 
65 since 2000 [9]. These figures paint a picture of increasingly stressed health care 
systems pushed to breaking point by the ageing population, and are as much a 
representation of the Irish healthcare system as they are the global picture.  
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Figure 1.1 illustrates how the world’s population is changing and is set to change in 
the future. 
 
Figure 1.1 Trends in the share of the population aged over 80 years, 1960-2050 [10] 
 
It is not just the number of older patients that is the problem. The complexity and 
potential adversity of their healthcare management also places a strain on both 
healthcare professionals and the State alike. Older patients, particularly those aged 
over 80 years, commonly suffer from multiple co-morbidities and consequently, 
take multiple medications. Recent studies investigating medication usage in Irish 
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patients over 65 have reported average number of regular medications to be 
between 5 and 8 per patient [11-14]. Physiological, age-related changes commonly 
result in altered pharmacokinetic and pharmacodynamic properties of these 
medications. Consequently, older patients are a vulnerable demographic group in 
terms of drug-drug interactions, drug-disease interactions, potentially inappropriate 
prescribing (PIP) and adverse drug reactions (ADRs).  
 
1.2 Potentially inappropriate prescribing (PIP) 
PIP is a term used to describe a range of sub-optimal prescribing practices and is 
particularly prevalent amongst the older population. In essence, it includes;  
(i) the prescribing of potentially inappropriate medications (PIMs) that 
carry an unacceptable risk of ADR when a safer alternative is available 
(ii) the prescribing of medications at a dose or duration unsuitable for older 
patients and 
(iii) the under-prescribing of medications which may benefit an older 
patient. These latter cases are commonly referred to as potential 
prescribing omissions (PPOs) [15, 16].  
PIP prevalence rates of 21%, 51% and 70% in primary, secondary and long-term 
care respectively have been reported in Ireland alone [11, 13, 17]. Further afield, 
PIP prevalence studies have shown rates amongst older patients to be high also e.g. 
USA (42%), Asia (40.4%), Australia (32.3%), Europe (30.4%), South America (28%) 
and Canada (16.3%) [11, 18-22]. PIP has been well established as a major 
5 
 
contributory factor to hospitalisations, ADRs and increased costs [11, 23-27]. In 
2010, Cahir et al. performed a cost analysis of PIP in Ireland. They reported that in 
one year, the total cost of PIP in terms of medication costs was €45 million, which 
equated to 9% of the overall expenditure on pharmaceuticals in those aged 70 
years  and over [28].  This doesn’t take into account other costs associated with PIP 
such as increased length of hospital stays or hospitalisations due to ADRs. 
 
One of the most serious consequences of PIP is the occurrence of ADRs. An ADR is 
defined as “any response to a medicine that is noxious or unintended attributable to 
a medicine, which occurs at a dose which is normally for use in human beings, for 
the purpose of prophylaxis, diagnosis, therapy or modification of a physiological 
function” [29, 30]. An adverse drug event (ADE), refers to “any injury occurring at 
the time a drug is used, whether or not it is identified as a cause of the injury” [29]. 
An ADR is a special type of ADE in which a causative relationship can be readily 
shown. ADRs have been reported to be between the 4th and 6th leading cause of 
death in hospitalised patients in the US [31].  Older patients in particular are 4 
times more likely to experiences an ADR than the general adult population [32-34]. 
Historically, there has been some uncertainty as to whether or not PIP is a 
contributory factor to ADR occurrence [24, 35-39]. However, in more recent studies 
a clear relationship between the two has been identified [40-42]. It has been 
reported that ADR rates in patients seen at admission are as high as 35% [43], while 
46% of inpatients experience an ADR [31]. 46% of older inpatients also experience 
ADRs [44]. As well as being a significant causative factor of hospital admissions [45-
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48], ADRs are a major cause of increased health-care utilisation [23] through 
increased lengths of stay and increased costs. ADRs have been shown to result in an 
average of 2 additional days in hospital [49].  Davies et al. reported that in the UK, 
inpatient ADRs resulted in an extra 2000 bed days per annum [49], which equated 
to a cost of £171 million. This figure rises to £1 billion when all ADRs are accounted 
for [50]. Considering that 57% of ADRs are thought to be avoidable, ADRs represent 
a major healthcare problem that, for the most-part, could possibly be prevented 
[51].  
 
1.3 Older patients susceptibility to PIP 
 
As mentioned earlier, older patients are particularly vulnerable to PIP and 
associated outcomes such as ADRs. With an increasing burden of co-morbidities as 
patients’ age, prescribers find themselves under increasing pressure to prescribe 
multiple medications. Best practice dictates that any decision a prescriber makes 
with regards to commencing a medication for a patient, should be evidence-based 
and the indication for which the drug is being prescribed is well established through 
evidence based on randomised controlled trials (RCTs). The difficulty when 
prescribing for older patients however, is that they are often excluded from such 
trials due to their often complex health status and multiple morbidities [52]. 
Therefore the situation arises where a clinician must prescribe without the 
evidence base he/she might have for someone in the younger adult population.  
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In addition to this, with ageing comes declining renal function and liver function, 
volume of distribution of lipid-soluble drugs increase, and sensitivity to several 
classes of drugs is often altered. These age-related pharmacokinetic and 
pharmacodynamics changes mean that older patients experience increased inter-
individual variability with regards to how they metabolise drugs and how drugs 
affect them physiologically [53].  
 
These age-related pharmacokinetic and pharmacodynamic changes affect drugs 
which are common treatments for co-morbidities often seen in older patients. For 
example, digoxin is a commonly prescribed treatment for congestive heart failure. 
However, in older patients, the time taken to reach steady-state plasma 
concentrations increases from 7 days (in a younger adult) to 12 days [54]. Volume 
of distribution is reduced in older patients, therefore requiring a reduction in 
loading dose in older patients, and because it is predominantly cleared through the 
kidneys, the overall daily dose often needs to be reduced in older patients due to 
their age-related decline in renal function [53-55]. Similarly, plasma concentrations 
of angiotensin converting enzyme (ACE) inhibitors are increased in older patients 
with reduced renal function thereby often necessitating a reduction in dose [56, 
57]. Older patients are particularly vulnerable to adverse effects from neuroleptic 
medications. Delirium, extrapyramidal symptoms, arrhythmias, and postural 
hypotension are all side effects which are more prevalent in older patients due to 
altered pharmacokinetics and pharmacodynamics [58, 59] as well as increased 
sedation at lower doses of benzodiazepines [60-62].  
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These age-related changes, coupled with lack of evidence for the use of many drugs 
in older patients render these patients significantly more susceptible to PIP and PIP-
related adverse outcomes than their younger counterparts. While most prescribers 
are of course well aware of the prescribing complexities of older patients, it is the 
variation between patients that often causes problems. The unpredictability of how 
drugs will affect any particular patient, or how an older patient will respond to a 
drug often presents a challenge to the prescrier in terms of prescribing the right 
medication at the right dose [53]. 
 
1.4 Interventions to address PIP and ADRs 
Given the issues of greater levels of multi-morbidity and complex polypharmacy in 
an ageing global population, it is not surprising that PIP and ADR detection and 
reduction has been the focus of several intervention studies [14, 16, 52]. However, 
to date, little progress has been made in achieving significant improvements in 
appropriateness of prescribing in older patients on a global scale. The main 
strategies employed to address PIP and it’s outcomes are detailed in the following 
section. 
1.4.1 Methods of detection 
In order to significantly reduce PIP and PIP related outcomes, robust methods of PIP 
detection must be applied. Historically, there have been several attempts to 
develop validated criteria to identify PIP. However, lack of transferability and 
validation by randomised controlled trials (RCTs) means that much of these efforts 
have not had the kind of effect that is required [52].  
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Criteria fall into two categories; explicit and implicit. Explicit criteria usually consist 
of a list of drugs, drug classes and doses which have been reported in the literature, 
or agreed upon by consensus methods to be potentially inappropriate in older 
patients. Implicit criteria are far more judgment based and rely more on the 
prescriber’s knowledge. They are time-consuming and rather tedious to use, 
however they do focus more on the patient and address their drug therapy at a 
more individual level [52].  
The first explicit tool for identifying PIP was Beers’ criteria, published in 1991 [63]. 
Originally designed for use in nursing homes, the criteria consisted of a list of 30 
drugs which were either to be completely avoided or avoided at certain 
doses/durations. Beers’ criteria were updated three times in 1997, 2003 and 
2012[64-66], and now consist of 53 medications divided into three categories:  
(i) Medications to be avoided in older patients-independent of diagnoses or 
conditions 
(ii) Medications to be avoided in older patients due to drug-disease 
interactions  
(iii) Drugs to be used with caution in older patients.  
They are widely utilised in the US and have also been applied in several European 
studies. In Ireland, a study using the Beers’ criteria reported PIP prevalence of 32% 
in secondary care [36] while rates of 20%, 66% and 40% in primary, secondary and 
long-term care have been reported in other European sites [48, 67, 68]. However, 
Beers’ criteria have several important limitations. They are very much focused on 
the US prescriber. Many of the drugs included are not available in Europe. Several 
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are not commonly prescribed for older patients and there is much disagreement 
surrounding the identification of some of the medications as drugs which should be 
avoided in all situations [52]. Drug-drug interactions, prescribing of two drugs from 
the same pharmacological class and PPOs are not accounted for. Considering that 
there have not been any RCTs assessing Beer’s criteria’s capacity to improve 
outcomes such as ADRs and hospitalisations, consequently, they have not found 
their way into common clinical usage. 
Given the short-comings of Beers’ criteria, O’ Mahony et al. devised new PIP 
criteria. Following validation by Delphi consensus methods, the STOPP/START 
criteria were published in 2008 [69] and updated in 2014 [70]. The latest iteration 
of Screening Tool of Older Persons’ Prescriptions (STOPP) consists of 87 prescribing 
scenarios, categorised by disease area, which are potentially inappropriate in older 
patients, and include common drug-drug and drug-disease interactions. The 
Screening Tool to Alert doctors to Right Treatment (START) consists of 34 
prescribing scenarios, categorised by physiological systems, where certain 
medications should be considered for an older patient. STOPP/START has been 
extensively researched in several countries in 5 continents and has shown good 
inter-rater reliability between physicians and pharmacists [11, 71-73]. Studies have 
explored the use of the criteria in all levels of care [13, 17, 36] and have shown 
implementation of the guidelines to result in sustained improvement in medication 
appropriateness and superior performance in terms of PIP detection and ADR 
prevention when compared to Beers’ criteria [16, 24]. STOPP/START has established 
itself as the principle tool in PIP detection, certainly outside of the US, but to 
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maintain its clinical relevance, the criteria will require regular up-dating and 
validation.  
Other explicit tools have been developed around the world including: the Improved 
Prescribing in the Elderly Tool (IPET) [74], the Prescribing Appropriateness Index 
(PAI) [75], Zhan’s Criteria [76], the French Consensus Panel List [77], the Australian 
Prescribing Indicators Tool [78], the Norwegian General Practice Criteria (NORGEP) 
[79], the PRISCUS List [80], the Thailand criteria [81] and the Rancourt criteria [82]. 
A recent review has highlighted the pros and cons of these various tools [52]. Lack 
of under-prescribing criteria, lack of availability of drugs outside the country of 
origin, lack of studies outside the country of origin, lack of drug-drug interaction 
data and lack of transferability are common drawbacks for most of these explicit 
criteria sets.  
Unlike the explicit criteria described above, implicit prescribing criteria are not 
focused on particular drugs or disease areas. They consist of quality indicators of 
prescribing that a prescriber or pharmacist must use their own judgment to apply 
to a person’s prescription. The most commonly utilised and cited of these is the 
Medication Appropriateness Index (MAI) [83]. The MAI consists of ten criteria which 
must be applied to each medication on a patient’s prescription. The MAI poses 
questions like: “Is this medication effective for the condition?”; “Are the directions 
practical?”; “Is the duration of therapy acceptable?”. Medications are rated 
according to each of the criteria and the sum of all the ratings provides a 
measurement of the overall appropriateness of that drug. This process is then 
repeated for each drug. The MAI has been extensively used in research to assess 
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prescribing appropriateness as an outcome in many studies [41, 84-86]. These 
studies have shown that the MAI tool has good inter-rater reliability amongst 
pharmacists and doctors and performs better than Beers’ criteria with regards to 
predicting adverse drug events [41]. However, it is generally regarded as a 
laborious, time-consuming tool and does not account for under-prescribing. The 
Assessment of underutilization of medication (AOU) tool [87] however, solely 
identifies prescribing omissions. Again, the AOU tool has shown good inter-rater 
reliability but with more robust tools available now, particularly those which can 
identify both inappropriate prescribing and under-prescribing, the AOU is not 
commonly reported in the literature.  
 
1.4.2 Comprehensive geriatric assessment  
Considering the complexity of older patients’ prescriptions, as well as the fact that 
they may well be under the care of multiple healthcare professionals due to the 
presence of multiple co-morbidities, it would seem logical that the care of an older 
patient should be overseen by a team of multiple healthcare professionals with 
different areas of expertise. The Multidisciplinary Team (MDT) approach involves a 
group of healthcare professionals working together to assess older patients’ 
treatment plans including their medication regimen. In this way, the knowledge and 
expertise of each of the members of the MDT team is channelled in order to 
improve the overall quality of patient care, improve appropriateness of prescribing 
and minimise ADRs [35, 88]. 
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In terms of older patients, an MDT will usually comprise a geriatrician working with 
a number of other specialist healthcare professionals (HCPs) from different aspects 
of geriatric medicine, i.e. nurses, physiotherapists, occupational therapists and 
pharmacists enabling them to perform a comprehensive geriatric assessment 
(CGA). The purpose of a CGA is not simply to examine a patient’s prescription. The 
MDT takes a holistic approach to the care of older patients and their therapies, 
looking at all aspects, as well as their medications [89]. For example, a patient’s 
cognitive and functional capacities will be assessed when making decisions about 
their future care and formulating a treatment plan. This type of approach addresses 
one of the key areas which render older patients vulnerable to PIP and PIP related 
outcomes i.e. complexity of care. Typically, older patients take multiple 
medications, often prescribed by multiple doctors, for multiple diseases. Without 
an appropriately trained and experienced person overseeing the therapy as a 
whole, it is highly likely that some degree of PIP will be present. A CGA performed 
by an MDT therefore is undoubtedly beneficial to older patients and doctors alike 
[89-91]. 
 
Several RCTs have shown that CGA improves prescribing appropriateness [89, 90, 
92]. Schmader et al. reported reductions in potentially inappropriate medications 
(PIMs) as well as PPOs resulting from CGA [90]. Similarly, Saltvedt et al. showed a 
reduction in drug-drug interactions and in prescribing of drugs with high ADR risk in 
older patients receiving CGA [93]. These results are not surprising given the detailed 
nature of CGA. However, this approach is again time-consuming and staff-intensive. 
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Although, CGAs are not standard practice globally, nevertheless where CGA is in 
common practice it has been shown to be a powerful tool in not only improving 
prescribing appropriateness but also positively influencing other key clinical 
outcomes. This is the case in Belgium for example, where every hospitalised patient 
over 65 years of age undergoes CGA. A recent Belgian study illustrated the value of 
CGA in identifying patients at risk of hospital readmission post discharge [94].  
1.4.3 Expert pharmacist review 
With their expertise in medicines and medicines management, pharmacists are a 
logical choice when looking for health care professionals to reduce PIP and ADRs. 
An expert pharmacist review involves the pharmacist applying a standardised 
assessment to older patients’ prescriptions and liaising with the prescribers to 
optimise the prescription. Generally, this is mainly available in hospital settings 
although community-based models do exist also. Pharmacists have been the focus 
of several initiatives aiming to improve prescribing appropriateness in the past e.g. 
(i) Medications review 
(ii) Participation in MDTs 
(iii) Participation in ward rounds 
(iv) Provision of patient counselling 
(v) Delivery of educational sessions to both the patients and the prescriber 
[88, 95-100].  
Such interventions have been proven to be effective at improving prescribing 
appropriateness in older hospitalised patients [14, 96].  
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A number of RCTs have illustrated the benefit of expert pharmacist led assessments 
[89, 95, 96, 98, 101]. Hanlon et al. reported a 24% decrease in MAI scores after 
three months in the intervention group. Not only was this maintained at twelve 
months but actually improved further to 28% [98]. Crotty et al. also showed an 
improvement in MAI scores [101] as did Spinewine et al [95] arising from expert 
pharmacist review. However no studies were able to show a significant difference 
in ADEs, falls, behaviour or cognition. Like CGA, expert pharmacist review is clearly 
of benefit, but is costly and resource intensive and is therefore a luxury rather than 
standard clinical practice. Also, there are no published RCTs reporting a clear link 
between expert pharmacist review and improved outcomes such as reduced 
incidence rates of ADEs. However, a recent RCT has shown that an expert 
pharmacist review in acutely ill older people significantly reduces incident ADR 
rates in hospital (20.9% event rate in control group versus 13.9% in intervention 
group) giving a relative ADR risk reduction of 33.3% [102]. This study incorporated 
pharmacist review with CGA and computerised decision supports systems (CDSS) 
which are described in more detail later in this chapter. 
 
Medication usage reviews (MURs) are another obvious role for pharmacists in 
medication optimisation in older people. However, while certainly useful in settings 
where there may be a pharmacist trained in geriatric pharmacotherapy, MURs are 
not particularly helpful in everyday practice. This is because not all pharmacists are 
trained in geriatric pharmacotherapy and MURs may not be standardised or 
regulated such that there is much inconsistency with regards to information 
gleaned in an MUR and results achieved. Furthermore, there is no evidence that 
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MURs, whether standardised or not, actually improve prescribing appropriateness 
or reduce ADEs [52]. 
 
1.4.4 Prescriber education 
If there is to be improved prescribing for older patients, then constant and up to 
date education of prescribers will always be paramount. It is not surprising 
therefore that educational interventions are one of the more common methods 
employed to improve prescribing appropriateness [103-105].  There are a number 
of different approaches to be considered when designing an educational 
intervention. Firstly, there is the traditional lecture based educational session and 
the related printed material disseminated to participants. Alternatively, there are 
more interactive interventions which involve participation and direct feedback.  A 
number of studies have shown the latter to be more effective [106-108]. It is 
interesting to note that of the interventions described in the literature to date, few 
of the authors have elaborated on the reasons for choosing the type of intervention 
they chose. It is also interesting to note that while most report positive results,  the 
evidence to-date relating to their overall effectiveness is mixed [99, 107-117]. 
To date, almost all of the educational interventions aiming to improve prescribing 
appropriateness in older patients have only been concerned with one drug or drug 
class. For example, Eide et al. explored the effect of pharmacist-led educational 
meetings with clinicians on the frequency and appropriateness of hypnotic 
medicines prescribed for older patients [117]. Fossey et al. used a similar approach 
to reduce the number of hypnotics prescribed [114]. Stein et al. used 30 minute 
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educational sessions to reduce the volume of NSAIDs prescribed for more than 
seven days in older patients [108]. Very few educational interventions address 
prescribing in general. While focusing all attention on one drug class does certainly 
benefit prescribers and their knowledge of that medicine, studies such as these are 
misplaced if what is required is general geriatric pharmacotherapy training.  
 
1.4.5 Computerised decision-support systems 
Computerised decision-support systems (CDSS) are computer applications designed 
to aid clinicians in making diagnostic and therapeutic decisions in patient care. The 
potential for such systems is considerable with respect to optimising prescribing in 
older patients. Unfortunately, Ireland is poorly developed compared to several 
European countries and North America in terms of healthcare information 
technology. The great majority of patient records in Ireland are still paper based. 
The tragedy in this is that the tools outlined above to detect PIP such as the 
STOPP/START criteria, are now starting to be coded and formatted in such a way 
that they could be implemented electronically as a CDSS [118].To do this however, 
they need to be able to link to the patient records electronically, which cannot 
currently be done in most sites in Ireland. In other countries however where this is 
possible, studies have shown just how effective CDSS can be, showing reductions in 
potentially inappropriate medications (PIMs), improvements in doses and 
reductions in falls [119-121]. While electronic systems for identifying drug-drug 
interactions have been in use for some time, CDSS is not yet in regular usage to 
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make recommendations on appropriateness of therapy since there is little firm 
evidence as of yet that CDSS can improve outcomes such as ADE occurrence rates.  
Despite this, there is little doubt that CDSS and similar products will play an 
important role in prescribing optimisation in the future. Since doctors are caring for 
increasing numbers of patients over the age of 65, “it is unrealistic to expect the 
majority of clinicians who prescribe for older people on a regular basis to possess 
the knowledge and experience and thereby have it inform their judgement when 
prescribing” [52]. However, if tools like STOPP/START were available as commercial 
electronic software, evidence based electronic prescribing could be enhanced and 
provided quickly to the benefit of patients and doctors alike.  
Advances are being made with regards to electronic application of STOPP/START. In 
2012, a European research consortium received European Commission Seventh 
Framework Programme (FP7) funding to conduct a randomised controlled trial to 
develop, and test the efficacy of, a highly-powered and efficient software engine 
capable of individually screening the clinical status and pharmacological and non- 
pharmacological therapy of older people with multi-morbidity. The purpose of 
which is to define optimal drug therapy, highlight ADR risk, indicate best value drug 
brand for selection and provide advice on appropriate non-pharmacological 
therapy. The project entitled ‘Development and clinical trials of a new Software 
ENgine for the Assessment & optimization of drug and non-drug Therapy in Older 
peRsons (SENATOR)’ is being led by a University College Cork (UCC) research team, 
and includes five other sites around Europe, including the Scotland, Spain, Iceland, 
Italy and Belgium (www.senator-project.eu). The STOPP/START criteria have been 
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incorporated into the software engine and will therefore form the basis of 
recommendations on optimal drug therapy. The software will also advise clinicians 
on drug-drug and drug-disease interactions as well as non-pharmacological 
therapies which may benefit the patient e.g occupational therapy, physiotherapy or 
dietician intervention. The primary objective of the SENATOR project is to reduce 
incidence rates of ADRs in older patients, hospitalised with acute illness and will run 
until 2017. As mentioned earlier, research into CDSS has yet to show this as an 
achievable outcome.  
Another project entitled ‘Optimising Therapy to prevent avoidable hospital 
admissions in the Multi-morbid elderly (OPERAM)’ has also recently received 
funding from the European Commission and Horizon 2020 scheme, and involves the 
same research team in UCC leading the SENATOR project. As with SENATOR, 
OPERAM will focus on addressing the pharmacotherapy optimisation needs of older 
patients with multi-morbid illnesses. The primary aim of OPERAM is to reduce re-
hospitalization, composite health care and prescription costs in older patients in 
European. At the centre of the OPERAM project will be an RCT which aims to test 
the clinical and economic effectiveness of a new medication optimisation software 
package in elderly hospitalised patients in four academic teaching hospitals 
(University Hospital Berne, Cork University Hospital, Utrecht University Medical 
Centre and Saint Luc University Hospital Brussels). 
OPERAM is closely linked to the outcomes of the SENATOR project. The OPERAM 
clinical trial will also involve a prescribing software intervention for older people 
with multi-morbidity which will be based on the second version of the 
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STOPP/START criteria. Given the potential of CDSS in general, and STOPP/START 
criteria in particular, it is likely that CDSS will complete clinical trials and pre-market 
validation in the coming years. The various intervention strategies that have been 
employed to date to address PIP are summarised in Table 1.
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Table 1.1: Summary of intervention studies to date addressing PIP 
 
 
 
 
 
 
 
Intervention 
Type 
Study title Authors/Year/Country Summary of findings from 
all studies 
Advantages Disadvantages 
Detection 
criteria 
STOPP (Screening Tool of Older Persons' 
potentially inappropriate Prescriptions): 
application to acutely ill elderly patients and 
comparison with Beers' criteria 
 
Prevention of potentially inappropriate 
prescribing for elderly patients: a randomized 
controlled trial using STOPP/START criteria 
 
The accuracy of medication histories in the 
hospital medical records of elderly persons 
Gallagher et 
al./2008/Ireland 
[36] 
 
 
Gallagher et 
al./2011/Ireland 
[16]
 
 
Beers et al./1999/USA 
[122]
 
STOPP/START guidelines 
most comprehensive in 
terms of research and 
applicability to other 
countries. Have shown good 
improvements in prescribing 
appropriateness. Has shown 
reduction in PIMs in 71% of 
patients  
Concise. Most are 
consensus validated. 
Many highlight drug-
drug interactions. 
Most address 
commonly 
prescribed drugs.  
Most lack transferability and 
studies outside country of origin. 
Under-prescribing not addresses 
in most. Large amounts of clinical 
data required to apply some 
criteria. Time consuming 
CGA An outreach geriatric 
medication advisory service in residential aged 
care: a randomised controlled trial of case 
conferencing 
 
Effects of geriatric evaluation 
and management on adverse drug reactions and 
suboptimal prescribing in the frail elderly 
 
Multifactorial intervention to prevent recurrent 
cardiovascular events in patients 75 years or 
older: the Drugs and Evidence-Based 
Medicine in the Elderly (DEBATE) study: a 
randomized controlled trial 
 
Crotty et 
al./2004/Australia
[89]
 
 
 
Schmader et 
al./2004/USA
[90]
 
 
Strandberg et 
al./2006/Finland 
[92] 
 
55% improvement in MAI 
scores. Decreased risk of 
ADEs and decreased use of 
unnecessary drugs. 
Patients’ therapy is 
approached from a 
multidisciplinary 
view. Patients’ 
cognitive and 
functional capacities 
are taken into 
account.  
 
Time consuming. Resource 
intensive. Limited to hospital 
settings. 
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Table 1.1 Contd 
Intervention 
Type 
 
 
Study title Authors/year/co
untry 
Main findings from 
available studies 
Advantages Disadvantages 
Pharmacist 
review 
Prevention of adverse drug reactions in 
hospitalised older patients using a software-
supported structured pharmacist 
intervention: a randomised controlled trial. 
 
 
Does the addition of a pharmacist transition 
coordinator improve evidence based 
medication management and health 
outcomes in older adults moving from 
hospital to a long-term care facility? 
Results of a randomized controlled trial 
 
 
Effect of a collaborative 
approach on the quality of prescribing for 
geriatric 
inpatients: a randomized controlled trial 
O’Sullivan et 
al./2013/Ireland 
[102]
 
 
 
Crotty et 
al./2004/Australia
[101] 
 
 
Spinewine et 
al./2007/Belgium 
[96] 
 
 
 
24% improvement in MAI 
scores. Improvement in 
MAI scores was 
maintained at 12 months.  
No significant difference in 
ADEs except for most 
recent study which 
showed 7% reduction in 
ADR rates 
Pharmacist is ideally placed to 
optimised older patients 
prescriptions. Can easily liaise 
with physicians and make 
recommendations regarding 
patients’ prescriptions.  
Not all pharmacists trained in 
geriatric pharmacotherapy. 
Resource intensive. No research 
showing improvement in ADE 
incidence rates. 
Prescriber 
education 
 
 
 
Effect of an educational intervention on 
optimizing antibiotic prescribing in long-term 
care facilities 
 
 
Inappropriate medication use in the elderly: 
results from a quality improvement project 
in 99 primary care practices 
 
Assessing the effects of an intervention by a 
pharmacist on prescribing and 
administration of hypnotics in nursing 
homes 
 
 
 
Monette et 
al./2007/Canada 
[115] 
 
Wessell et 
al./2008/USA 
[116] 
 
Eide et 
al./2001/Norway 
[117]
 
Reduced usage of PIMs. 
Improvements in overall 
prescribing 
appropriateness [109-
112].  
Direct interaction with the 
prescribers. Can be cost-
effective and utilise less 
resources.  
Much variation between types of 
educational interventions. Most 
studies tend to focus on particular 
drug classes rather than 
prescribing in general. 
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Intervention 
Type 
 
 
Study title Authors/year/co
untry 
Main findings from 
available studies 
Advantages Disadvantages 
CDSS 
 
 
 
Prevention of adverse drug reactions in 
hospitalised older patients using a 
software-supported structured 
pharmacist intervention: a randomised 
controlled trial. 
 
Computerized clinical decision support 
during medication ordering for long-term 
care residents with renal insufficiency 
 
Effect of computerized provider order 
entry with clinical decision support on 
adverse drug events in the long-term 
care setting 
O’Sullivan et 
al./2013/Ireland 
[102]
 
 
Field et 
al./2009/USA 
[123]
 
 
 
Gurwitz et 
al./2008/USA 
[121]
 
Reduction in initiation of 
PIMs. Overall 
improvement in 
prescribing 
appropriateness. 
Significant reduction in 
ADEs in most recent study 
[102] 
Clinicians automatically 
provided with evidenced based 
recommendations helping them 
to make more informed 
decisions. Clinicians with less 
knowledge/experience can feel 
more confident about their 
prescribing decisions.  
In general, CDSS do not advise on 
appropriateness of prescribing. 
Depend on quality of computer 
programming. Costly and difficult 
to implement on a large scale. 
 
Key: RCT=Randomised controlled trial CGA=Comprehensive geriatric assessment CDSS=Computerised decision support systems MAI=Medication 
appropriateness index  ADE=Adverse drug event ADR=Adverse Drug Reaction PIM=Potentially inappropriate medication
Table 1.1 Contd 
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1.5 Evolution of interventions in healthcare 
Healthcare intervention trials occupy much of the medical literature today. These 
range from simple ‘before and after’ studies quantifying the effect of a new policy, 
process or drug [124], to more complex RCTs comprising multiple components 
which may act both independently and interdependently of each other [125]. The 
method of delivery has understandably seen a shift in recent years from face to 
face interactions to interventions delivered via the internet [126-137]. Reasons 
proposed by authors for choosing internet based interventions include: reducing 
cost and increasing convenience for users; reducing health service costs; reducing 
isolation of users; the need for timely information; reduction of stigma; increased 
user and supplier control of the intervention [124].  
 
One of the most significant ongoing changes in intervention research is the process 
by which intervention studies are informed. Historically, many intervention studies 
have not described in detail why the intervention type was chosen. In more recent 
times however there has been much research published regarding intervention 
mapping [138-142], i.e. tailoring the intervention to specifically target the barriers 
associated with the behaviour in question. The identification of these barriers is the 
key step in this process, and one which has only recently begun to receive 
attention. 
 
Barriers to best practice can be identified through qualitative research. Qualitative 
methodologies are being used more and more to uncover the causative factors of 
various healthcare problems and to gain insights into healthcare professionals’ 
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attitudes and other factors which affect their decision making [143-150]. In this 
way, the processes that lead to sub-optimal practice are uncovered, and can then 
form the basis of an intervention. Figure 1.2 illustrates how qualitative research 
studies have become more prevalent in recent years. 
 
 
 
 
 
Figure 1.2 Increasing trend of qualitative healthcare studies in recent years (Pubmed) 
 
Figure 1.2 shows that before the mid 1980’s, very little qualitative research was 
taking place in healthcare. However since then, with increasing literature 
highlighting the potential of qualitative methodologies [151, 152], there has been 
an exponential increase in the number of studies employing such methods.  
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Qualitative research was first used by sociologists and anthropologists in the early 
twentieth century. It remained a research tool of the social sciences for many years 
until the 1960s, when the development of grounded theory and ethnography saw 
qualitative methods being implemented in other areas of research qualitative 
research. Researchers, including healthcare professionals, have in recent decades 
seen to see the benefits of this type of research and are modifying these 
approaches to the study needs of their own areas.  
 
Qualitative research is sometimes thought of as the alternative to quantitative 
methods as it does not aim to quantify outcomes with statistics and figures. 
Qualitative research is inductive in nature and relies on interviews, surveys, focus 
groups and observation for data collection [151]. In healthcare research, the 
interview is the most commonly utilised tool. There are three types of interviews: 
structured, semi-structured and unstructured. The semi-structured interview is 
more commonly used in health care-related qualitative research [151]. It is typically 
based on a topic guide that provides a flexible and loose structure of open-ended 
questions to explore experiences and attitudes. The topic guide is, as the name 
suggests, just a guide, and the interview is steered more by the interviewees’ 
responses and descriptions of their own experiences and attitudes.  
 
Both quantitative and qualitative research have particular strengths and limitations, 
but recently, researchers have recognised that it is not a case of choosing one over 
the other, but rather using the two to complement each other [153]. Murphy et al. 
comment that “true understanding in medicine cannot be achieved without adding 
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qualitative methods to the research arsenal” [154]. For instance RCTs are the 
standard means of testing the effect of an intervention or a treatment. However, 
should one wish to determine why results from research or well established best 
practices are not being implemented, qualitative methods are more suited to elicit 
participants beliefs and own experiences with regards to the practice in question 
[151]. Similarly, before designing an intervention based on quantitative methods, a 
qualitative study identifying participants beliefs and opinions as to the barriers that 
exist to best practice being implemented can inform that intervention and 
ultimately enhance efficacy [139]. The type of question being asked should guide 
the methodologies used [155]. Put simply, quantitative research addresses 
questions such as ‘how much and how often? Qualitative research explores the 
reasons why. To really investigate and address a problem, both types of questions 
need to be asked.  
 
Although qualitative research is used increasingly in healthcare, there is very little 
qualitative research into PIP in older people [156]. Most of the studies in the 
literature only focus on a particular drug class rather than prescribing in general 
[156]. As stated earlier in this chapter, to date, few of the intervention studies 
aiming to reduce PIP in older patients have been informed by previous qualitative 
studies. It cannot be said with certainty that this is a contributory factor to the 
mild/moderate level of success of such interventions. However, with qualitative 
research in general, and interventions informed by qualitative research in 
particular, proving to be successful in other areas of healthcare, including 
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prescribing [157-162], it is reasonable to propose that future intervention designs 
targeting PIP, should have an element of qualitative inquiry.  
1.6 Summary 
PIP in older patients is a major global healthcare problem today. The global 
population is ageing and with this comes a greater burden of diseases, increased 
numbers of medications and increased strain on health systems and resources. All 
these factors make for favourable circumstances for PIP to occur, indicating that 
the problem is only going to worsen in the years to come in tandem with global 
ageing. Some strategies implemented to date to counteract PIP have shown 
promise but many have also shown lack of applicability to everyday practice. To 
enhance the efficacy of future interventions, qualitative research is needed to 
identify the barriers to appropriate prescribing. In this way, interventions can be 
tailored to address the specific causative factors of PIP and ultimately improve 
prescribing appropriateness for older patients. 
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2. A meta-synthesis of potentially 
inappropriate prescribing in older 
patients 
 
Chapter description 
The quantitative aspect of this thesis was to be informed by qualitative research. 
Therefore, a systematic review of the qualitative research already published was 
deemed appropriate. 
 
The work of this chapter has been published as Cullinan S, O’Mahony D, Fleming A, 
Byrne S. A Meta-Synthesis of Potentially Inappropriate Prescribing in Older Patients. 
Drugs & Aging. 2014;31(8):631-8. http://dx.doi.org/10.1007/s40266-014-0190-4 
(Appendix I)
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2.1 Introduction 
 
Potentially inappropriate prescribing (PIP) is commonly seen amongst the older 
population. There are various factors that make this group more susceptible to PIP, 
principally multiple co-morbidities and related polypharmacy [13, 163]. PIP  
includes both prescribing of potentially inappropriate medications (PIMs) i.e. 
introducing a medication that poses more risk than benefit when a safer alternative 
is available, as well as potential prescribing omissions (PPOs) [11, 13, 17, 52, 164] i.e 
the omission of medications that would likely benefit the patient. In primary care, 
recent studies show that 20-40% of older patients have PIP [13, 163, 164]. The 
prevalence of PIP in older people ranges from 33% to 58% in the hospital setting 
[11, 52] and from 44% to 70% in long term care facilities [17]. The common 
consequences of PIP are adverse drug reactions (ADRs), adverse drug events 
(ADEs), increased hospitalisation and inefficient use of resources [41, 165, 166]. 
Consequently, PIP places a large economic strain on the health care system and 
intangible costs on individuals. 
Quantitative data such as these have highlighted the issue of PIP and attracted 
attention to its economic implications. However, very little attention has been 
focused on why it is occurring. This chapter aims to synthesise qualitative studies 
that explore PIP in older patients in an effort to understand the psychological and 
behavioural basis of PIP applied to older people and to generate a new theory to 
guide future intervention studies aimed at PIP prevention. The small number of 
qualitative studies in the published literature has never previously been analysed in 
a meta-synthesis such as this before. Application of qualitative research methods in 
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a variety of health care research domains [167] has provided important insights and 
understanding with relevance to clinical practice. 
As with meta-analysis of data from quantitative studies, meta-synthesis of 
qualitative studies involves a recognised methodology for combining the themes 
from several studies. However, unlike a meta-analysis, a qualitative synthesis aims 
to interpret the thematic findings from the original studies so as to be able to 
generate new, all-encompassing theory not previously identified [167-170]. To do 
this, a technique called meta-ethnography [171] was employed, which has been 
used to good effect in health care research [167, 170, 172, 173]. 
2.2 Methods 
The seven step model of meta-ethnography (Figure 2.1) was used, i.e.  
In step 1, a clear statement of the specific research question was agreed. 
In step 2, a search strategy to identify suitable articles was developed. Four 
databases were systematically searched for papers published up to the end of April 
2013 (no start date was specified): PubMed, Embase, CINAHL and Web of 
Knowledge. The following terms were used: Qualitative AND (Inappropriate* OR 
Appropriat* OR Safe) AND (Elderly OR Aged OR Geriatric* OR Old*) AND Prescri*. 
The reference lists of papers identified were then searched for other suitable 
papers that should be included in the meta-synthesis.  
Papers were deemed suitable for inclusion if they used qualitative methods, 
explored some area of PIP in patients over 65 years of age, were published in 
English and had available published abstracts. Two co-researchers then read articles 
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that were deemed potentially relevant after the abstract review. Articles meeting 
inclusion criteria were included in the final review.  
The quality of the final papers was assessed by two researchers using the Critical 
Appraisal Skills Programme (CASP) (Appendix II). The CASP tool assesses qualitative 
papers on the basis of the results presented, the validity of the results and the 
potential implications of the results locally. The CASP methodology was employed 
as it has been used to good effect previously in healthcare research studies [167, 
169, 172, 174]. The purpose of using CASP was not to eliminate published papers, 
but rather to make sure the papers that were used were of high quality, and to 
ensure low quality papers were not contributing to our final synthesis.  
Step 3 involved reading the studies. The terms first order, second order and third 
order constructs relate to the different levels of interpretation within a meta-
synthesis. First order constructs relate to the raw data in the empirical studies i.e 
the original participants’ interpretations of a certain experience. Second order 
constructs are the common themes/categories that the original authors identified 
amongst these participants and used as their results/findings. Third order 
constructs are the new interpretations that those performing the synthesis  must 
identify by compiling all the second order constructs from the selected studies, 
translating them into each other to determine  if in fact they  concur in terms of 
thematic content, and then reinterpreting them to generate new theory. The 
papers were read carefully by two researchers, including the present author. The 
key findings from each paper, as presented by the authors, were listed as the 
second order constructs.  
33 
 
In step 4 , it was determined how the studies were related to each other by listing 
key concepts that represented the whole data set. 
In step 5, the papers were translated into each other. There are numerous forms of 
final synthesis within meta-ethnography, the choice of which depends on how the 
papers are related to each other [171]. As it became apparent that concepts from 
one study would encompass others, if not all the other studies, ‘reciprocal 
translation’ was used followed by ‘line of argument’ synthesis. Each key concept 
was compared across the published papers, to determine what each paper stated 
about that concept. In this way, the papers were translated into one another.  
Step 6 involved  examining what each paper  stated about each concept, and 
reinterpreting these to produce third order constructs, linked together in a final 
‘line of argument synthesis’. The aim of a ‘line of argument’ is to create a coherent 
theme that may explain what all the studies have reported in one holistic theme, 
taking into account the fact that each study may have explored different aspects of 
the phenomenon [175].  
Finally, in step 7, the results of the synthesis were expressed in tables, figures and 
text. The ENTREQ (Enhancing transparency in reporting the synthesis of qualitative 
research) [176] statement, a framework 
for reporting the synthesis of qualitative health research, was used to guide how 
the results were reported. 
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Figure 2.1: Flow diagram of meta-ethnography process 
Common concepts representing 
the entire data set are identified 
Where are these concepts 
evident in each paper? List 
illustrative excerpts. Are the 
papers actually saying the same 
thing but in different 
ways/contexts? 
Explain these illustrative 
excerpts in a one-line 
summation that applies across 
all the studies 
Re-interpret the third order 
constructs to create a coherent 
argument explaining what all the 
studies have reported in one 
holistic theme. 
Reciprocal translation 
Create third order constructs 
Line of argument synthesis 
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2.3 Results 
The PRISMA checklist was followed with regards to the writing of this study (see 
appendix III).  
The search of the electronic databases identified 864 papers, leaving 624 after 
duplicates were removed (Figure 2.2). After title and abstract review, a further 576 
studies were removed: 348 did not use qualitative methods, 176 did not involve 
PIP, 44 did not deal with patients over 65 and 8 had no abstracts available. Sixteen 
full papers were retrieved for review. Of these, 10 were eliminated because they 
did not use qualitative methods. One additional paper was identified from the 
references list of another paper and included. This left seven papers for inclusion in 
final synthesis (Table 2.1). 
All seven papers were of high quality according to the CASP criteria; all of the 
papers met most of the criteria for inclusion in the analysis. Common weaknesses 
were ‘reflexivity’ (the awareness of the researcher's contribution to the 
construction of meanings throughout the research process), which none of the 
papers mentioned, ‘data collection’ (none of the papers justified methods chosen 
or discussed saturation of data) and ‘statement of findings’ (the majority of papers 
did not apply triangulation i.e the use of multiple data sources). 
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Figure 2.2: PRISMA flow diagram of literature review process 
 
PubMed, Embase, CINAHL and Web of Knowledge searched using following 
terms: Qualitative AND (Inappropriate* OR Appropriat* OR Safe) AND (Elderly 
OR Aged OR Geriatric* OR Old) AND Prescri*. Reference lists of papers also 
searched. 
846 Papers 
624 Papers 
16 Papers 
7 Papers 
Duplicates removed 
Title/abstract review 
Full article review 
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Table 2.1: Characteristics of papers identified 
  
Paper title (year of 
publication) 
 
Authors 
 
Country 
 
Sample size (n) 
 
Methodology 
 
Method(s) 
1 Prescribing psychotropic medication for 
elderly patients: some physicians 
perspectives (1999) 
Damestoy 
et al
[157] 
 
Canada 9 doctors Grounded theory.  Semi-structured 
interviews 
2 Appropriateness of use of medicines in 
elderly inpatients: qualitative study 
(2005) 
Spinewine 
et al
[177]
 
Belgium 5 doctors 
4 nurses 
3 pharmacists 
17 patients 
Grounded theory.  Semi-structured 
interviews, focus 
groups and 
observation 
3 Physicians’ perspectives on prescribing 
benzodiazepines for older adults: a 
qualitative study (2007) 
Cook et 
al
[158]
 
USA 33 GPs Narrative analysis.  Semi-structured 
interviews. 
4 GPs’ approach to insulin prescribing in 
older patients: a qualitative study 
(2008) 
Agarwal et 
al
[159]
 
Canada 21 GPs Grounded theory.  Semi-structured 
interviews. 
5 Factors influencing the prescribing of 
medications by old age psychiatrists for 
behavioural and psychological 
symptoms of dementia: a qualitative 
study (2008) 
Wood-
Mitchell et 
al
[160]
 
England 8 consultant 
Psychiatrists 
Grounded theory. Semi-structured 
interviews. 
6 Long-term prescribing of 
antidepressants in the older population: 
a qualitative study (2010) 
Dickinson 
et al[161] 
England 36 patients 
10 GPs 
Framework analysis.  Semi-structured 
interviews. 
7 Primary care providers’ perspective on 
prescribing opioids to older adults with 
chronic non-cancer pain: a qualitative 
study (2011) 
Spitz et 
al[162] 
USA 23 doctors 
3 nurse practitioners 
Thematic analysis.  Focus groups 
GP=General practitioner 
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2.3.1 Reciprocal translation 
Four key concepts that reflected the findings in the 7 papers were identified from 
the meta-synthesis as being contributory factors to PIP:  
(i) Desire to please the patient 
(ii) Feeling of being forced to prescribe  
(iii) Tension between experience and guidelines 
(iv) Prescriber fear.  
The reciprocal translation and final synthesis are presented below. Each of these 
thematic concepts is described in greater detail. Excerpts consisting of original 
quotes from participants (first order constructs) as well as authors’ findings (second 
order constructs),  from the original papers are presented in Table 2.2 along with 
third order interpretations to illustrate how the four themes were identified. 
2.3.1.1 Desire to please the patient 
In the majority of papers, there was a clear underlying theme of ‘wanting to please 
the patient’. This usually meant prescribing outside the guidelines. As Dickinson et 
al. stated in their paper exploring inappropriate long-term prescribing of 
antidepressants, ‘..in many circumstances it is easier to follow the path of least 
resistance and let them (i.e. PIP decisions) be..’[161]. This was a common viewpoint 
expressed by the doctors they interviewed. They noted that patients were happy 
with their antidepressants and as a result doctors were generally satisfied with the 
pharmacotherapy. They also observed that the doctors recognised the problem of 
prescribing medication even though the problem may be social rather than 
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psychiatric in nature. However, due to some patients’ resistance to non-
pharmacological treatments, they proceeded with prescribing the medication 
anyway.  
Agarwal et al. refers to this resistance from patients’ in their study of GPs’ approach 
to insulin prescribing in older patients [159]. When asked why insulin is often 
under-prescribed in this population, the consensus was that ‘GPs felt older patients 
would be less receptive to medication regimen changes’.  Spitz et al examined 
underuse of opioids in older patients for non-cancer pain [162]. In this study, the 
patient was also a common barrier to appropriate prescribing, apparently as a 
result of older patients’ reluctance to consider opioid analgesia for this category of 
pain. The physician participants in this study also commented that this resistance 
acted as a barrier to prescribing these medications to future patients.  
The concept of prescribing to please the patient was most evident in the paper by 
Cook et al [158] who explored prescribers’ attitudes to prescribing benzodiazepines 
for older adults. It is generally accepted that these medications should only be used 
for brief periods in older patients and for symptomatic relief only [178, 179]. The 
participants in this study spoke of the problems they experienced in the past with 
trying to wean patients off benzodiazepines and how this affected their future 
prescribing patterns.  The participants again spoke of  ‘the path of least resistance’ 
and how much quicker and easier it is just to prescribe what the patient wants, 
rather than spend  significant amounts of time trying to persuade patients towards 
a different approach to managing insomnia and anxiety. They furthermore 
identified the possibility of the patients switching to another physician as a reason 
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for inappropriate prescribing. This was also reported by Damestoy et al, who 
studied physicians’ perspectives on prescribing psychotropic medication for older 
patients [157]. The participants described how otherwise quiet and timid patients 
became aggressive and demanding when their anxiolytic use was questioned. 
2.3.1.2 Forced to prescribe 
One consequence of this need to please the patient was that prescribers often felt 
they were forced into prescribing, or not prescribing medications, in a manner they 
knew did not adhere to guidelines. This concept could therefore have been 
integrated into the previous one, however upon consideration it was decided it 
should stand alone, as there were several factors leading prescribers to feeling 
forced to prescribe, other than the need to please the patient e.g. poor quality of 
treatment resources. Wood-Mitchell et al explored prescribing of medications for 
dementia in older patients [160]. They observed that many of the prescribers felt 
they were seeing too many referred patients due to a lack of support services for 
these patients.  According to many prescribers, there was too much reliance on 
medication as a quick and  ’easy’ treatment for these patients and the development 
of non-pharmacological treatments was deployed less frequently as a result. Also, 
the quality of care settings was important in the prescribers’ decision process. Low 
quality training of care staff and ‘under-stimulating environments’ were thought to 
result in challenging behaviours in demented patients. These low quality care 
facilities are then unable to cope with disturbed patient behaviour and are more 
likely to refer the patients for assessment with a view to pharmacotherapy for their 
disturbed behaviour. The physician prescribers then feel they have no choice but to 
prescribe due the lack of services already mentioned.  
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Agarwal et al also reported this lack of confidence amongst prescribers in some 
long term care settings [159]. In relation to not prescribing insulin, GPs’ knowledge 
of some care facilities hindered them from starting a patient on insulin due to the 
doctor’s lack of confidence in the support the patient would receive in care. Lack of 
therapeutic alternatives was another factor leading to physicians feeling forced to 
offer pharmacotherapy. Damestoy et al described how doctors felt that non-
pharmacological treatments were insufficient for conditions such as anxiety [157], 
indicating that many doctors ‘considered them to be ineffective (and 
that)….psychotherapeutic approaches were doomed to failure’. This was echoed by 
Wood-Mitchell et al [160]. And again by Dickinson et al, indicating long waiting lists 
for cognitive behavioural therapy [161]. Damestoy et al [157] also identified a 
feeling of isolation amongst prescribers, once again forcing them to prescribe in 
some situations where they realize that psychotropic medications are not 
appropriate. This theme  of ‘isolation’ was also picked up by Spitz et al [162] 
reporting that doctors desired more peer support to enable them to prescribe 
appropriately. Looking at these studies, it can be seen that prescribers usually know 
what appropriate treatment is, but feel unable to follow through. 
2.3.1.3 Experience VS Guidelines 
In all but one of the papers, it was clear that prescribers were well aware of the 
potentially inappropriate nature of some of their prescribing. They were, for the 
most part, aware of the treatment guidelines and they all agreed as to what the 
best practise was. However, in general, they varied greatly in their actual 
prescribing practise. Although they accepted the precepts of the guidelines, they 
perceived a significant problem in implementing them in real life. The end result 
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was reversion to previous practises, and what they were familiar with. Lack of 
evidence supporting some guidelines also influenced prescribers in favour of 
his/her own experiential evidence as reported by Woods-Mitchell et al [160]. 
Conversely, Agarwal et al [159] reported that a prescribers’ lack of experience can 
have a similar effect in relation to under-prescribing of insulin.   
Cook et al [158] found that many prescribers considered that guidelines were ‘out 
of touch with real world problems’ and that past experience had taught them to 
avoid changing drug therapy in order to avoid a perceived higher risk of 
misadventure. Damestoy et al [157] reported that many of the physicians 
interviewed prescribed as they did because they didn’t often see side-effects. Spitz 
et al [162] used focus groups with prescribers to elucidate why opioids were 
underused in non-cancer pain in older people. They found that doctors were aware 
that opioids have a role in non-cancer pain, but felt the evidence base was 
insufficient to support this role. They also expressed their desire for evidence-based 
tools for calculating doses. Dickinson et al [161] showed that in relation to long 
term prescribing of antidepressants, GPs didn’t perceive a significant problem, as 
they hadn’t seen any evidence to indicate serious harm to older patient.  
2.3.1.4 Fear 
The final concept evident across the papers reviewed was fear. It manifested itself 
in a number of different ways but in each case it was clear that it was a contributing 
factor to PIP. For instance Agarwal et al [159] reported that doctors felt a sense of 
apprehension towards older patients in general due to their higher prevalence of 
frailty and co-morbidities. Consequently, they perceived more potential to do harm. 
They also observed a fear of the unknown amongst several GPs e.g. most admitted 
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to inexperience using insulin in older patients and found the prospect of initiating it 
anxiety-provoking, such that they would avoid prescribing it even if guidelines 
recommended it.  
Dickinson et al [161] also identified fear as a central theme amongst GPs in relation 
to PIP. Doctors described reluctance to discontinue a medication that has been 
taken for a long time by a patient in order to avoid worry, and spoke of not wishing 
to disrupt patients’ clinical stability. With this observation of fear of medication 
change and an apparent lack of fear of side effects, (also reported), these authors 
concluded that there was just no incentive for medication change. Fear of causing 
harm was the overwhelming barrier identified in the study by Spitz et al [162]. For 
example, prescribers described genuine fear of prescribing opioids for older 
patients, and worry regarding the possible serious side effects. Sometimes these 
fears arose from previous bad experiences with prescribing opioids in older 
patients. In other cases, this fear was more to do with avoidance of the guilt that 
would ensue if a patient was to have an adverse drug event due to the drug. 
Spinewine et al, observed a different kind of fear in their study looking at 
appropriateness of medicines in general in older patients [180]. Prescribers they 
interviewed described a fear of offending other doctors, including specialist doctors 
and GPs. If, for example, a doctor noticed something potentially inappropriate on a 
patient’s prescription, but if that patient was under the care of a specialist, they 
would be less likely to intervene. Similarly, when transferring information between 
levels of care, e.g. from hospital to primary care , it was noted that the amount of 
information could be limited due to fear of causing offence to patients’ GPs.
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Table 2.2: Excerpts supporting the four themes plus third order interpretations 
 Excerpts (first and second order constructs) Paper(s) Third order interpretations 
Desire to please the 
patient 
 
 
 
 
They [antidepressants] allow the doctor and the patient a feeling of doing something 
in the face of unsolvable problems. 
 
There appeared to be some sense of unease about prescribing a medical intervention 
for a social cause……the goal of both doctor and patient appears to be not to rock the 
boat. 
 
Prospects ranged from questioning the doctor’s authority and competence, to 
minimisation of negative side-effects, to finding another doctor who was willing to 
prescribe it. 
 
Many of the physicians thought patients would seek out another physician if they 
were not satisfied with their prescription, and they took this into account before 
prescribing. 
Dickinson et al 
[161] 
 
Dickinson et al 
[161]
 
 
 
Cook et al 
[158]
 
 
 
 
Damestoy et al 
[157]
 
The patient can have too much of a 
deciding role in their therapy at 
times. This sometimes hinders the 
doctor from making their decision 
based purely on what is the best 
course of action for this patient. 
Feeling forced to 
prescribe 
 
 
 
Some participants felt that certain homes coped better than others with problematic 
behaviours and one thought it depended on whether beds needed to be filled. 
 
GPs also described situations where their own experiences or knowledge of particular 
nursing homes or less-than-ideal care situations, hindered them from considering 
insulin treatment 
 
All participants felt strongly that there was a pressure to prescribe and that the 
availability of alternatives to medication influenced decisions. 
 
One frequently cited reason for the favouring of antidepressants was the inadequacy 
or unavailability of alternative treatments. 
 
They recognised that the inappropriate use of psychotropic medication for elderly 
patients was a public health problem, but they felt it was beyond the scope of the 
individual physician. 
Wood-Mitchell 
et al 
[160]
 
 
Agarwal et al 
[159]
 
 
 
Wood-Mitchell 
et al 
[160]
 
 
Dickinson et al 
[161]
 
 
Damestoy et al 
[157]
 
Due to a combination of intrinsic 
and extrinsic factors, and although 
they may realise it is not quite 
appropriate, doctors are 
sometimes left with no other 
choice but to prescribe, or not 
prescribe, in an inappropriate 
fashion. 
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GP=General practitioner
Experience Vs 
Guidelines 
 
 
 
 
In most cases, choice of medication was based on familiarity and past experience of a 
drug…..the influence of evidence base had a varying effect on the participants. 
 
Most GPs had little experience of treating older patients with insulin. This lack of 
experience made some apprehensive about initiating it. 
 
In the absence of evidence of specific adverse effects, there was little concern. 
Woods-Mitchell 
et al 
[160]
 
 
Agarwal et al 
[159]
 
 
Dickinson et al 
[161]
 
Past experience, or lack thereof, 
can sometimes over-ride guidelines 
or the appropriate decisions. 
Sometimes this may simply be 
necessary and actually be 
appropriate, however, the 
literature suggests it is also 
contributing to PIP.  
Prescriber fear  Two doctors acknowledged that information transferred to general practitioners 
could be limited by fear of offending them with comments on inappropriate 
prescribing. 
 
‘It’s scary to stop a medication that’s been going on a long time, because you think am 
I opening a can of worms here' 
 
‘I get frightened with 80+ year olds; how are they going to respond?’ 
Spinewine et 
al[177] 
 
 
Dickinson et al 
[161]
 
 
Spitz et al 
[162]
 
Fear is a multifactorial component 
of PIP. While not likely to be the 
major cause of inappropriate 
prescribing, it would seem to 
compound already existing factors, 
thereby contributing to the overall 
effect. 
Table 2.2 (continued) 
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2.3.2 Line of argument synthesis  
Looking at the four key concepts that emerged from the papers, it was concluded 
from the literature that, in many situations, prescribers suffer from ‘self-perceived 
restrictions’ leading to a sense of powerlessness to prescribe appropriately for older 
patients. This powerlessness in turn forces them to rely on what they know and 
have done before (previous habits/experience), which leads to the PIP that has 
been identified [11, 17, 41, 52, 165]. Figure 2.3 illustrates the line of argument 
synthesis. 
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Inability to 
implement 
guidelines 
Powerless to 
prescribe 
appropriately 
Previous 
habits/experience 
Potentially inappropriate prescribing 
Need to please 
the patient 
Forced to 
prescribe 
Experience VS 
guidelines 
Fear 
Figure 2.3: Line of argument synthesis 
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2.4 Discussion 
Although the published literature abounds with papers describing the prevalence of 
PIP in various clinical settings and the link between PIP and multi-
morbidity/polypharmacy in older people, there is a lack of detailed inquiry into the 
prescriber-based reasons that underpin PIP. This meta-synthesis has, for the first 
time, identified a cluster of reasons why physicians feel may perpetuate PIP in older 
people. The principal reasons include: 
(i) The need to please the patient 
(ii) Feeling forced to prescribe 
(iii) Tension between prescribing experience and prescribing  guidelines 
(iv) Prescriber fear.  
Ultimately, these factors in combination militate against safe and effective 
prescribing in older people.  
At the outset, this chapter aimed to achieve an understanding of why inappropriate 
prescribing occurs in older patients. This analysis, of course, involves all medication 
classes. It was unclear therefore, whether the selected papers would be suitable as 
six out of the seven focused on individual drug classes. Each paper was based on 
evidence that a certain amount of PIP was occurring within a certain class of drug. 
However, upon reading the papers and through reciprocal translation it became 
clear that although each study explored different areas of prescribing, and in 
significantly different settings, for the most part, similar themes were present 
amongst them all. This is encouraging since it suggests that measures taken to 
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address the issues highlighted here, will likely lead to improvements in all areas of 
prescribing, not just in one specific drug class. 
The line of argument synthesis suggested that doctors know the guidelines and for 
the most part, have no opposition them. They know that some of their prescribing 
is inappropriate, but feel powerless to do anything about it due to the pressures 
exerted on them in the key areas identified. This would suggest that future 
attempts to improve prescribing should not be focused on guidelines but rather on 
the issues that prevent these guidelines being implemented. Some of these issues 
can certainly be addressed and rectified, but others are more challenging. For 
example, patient education would very likely go a long way to helping prescribers 
when it comes to difficult decisions regarding patients’ prescriptions such as 
stopping, or reducing the dose of a drug.  
Looking at the concept of ‘please the patient’ identified from these studies, it is 
clear that resistance to change from the patient, previous bad experiences with 
patients and fear of losing patients to other doctors are significant contributing 
factors to a prescriber’s decision making process, and that can ultimately lead to 
inappropriate prescribing. It is interesting that prescribers are aware of this. Studies 
have shown that patient-centred educational programmes are effective, and 
significantly reduce inappropriate prescribing [181, 182]. If patients were better 
informed, prescribers may encounter less resistance to change, and be less worried 
about losing patients to other practises.  
One major factor contributing to prescribers’ feelings of being forced into decisions 
was the lack of resources available. On a large scale, this is difficult to rectify due 
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mainly to financial constraints. However, better use of the resources already 
available would be a start. For example, simple improvements in communication 
between different levels of care may address the feeling of isolation that doctors 
reported. It would also improve their confidence to prescribe outside their usual 
remits if the prescribing process has a greater multidisciplinary approach. This 
would also address the ‘fear of offending other physicians’ observed amongst 
prescribers. The concept of information sharing and feedback has already been 
shown to reduce inappropriate prescribing with respect to input from pharmacists, 
especially in secondary care [183, 184]. The other issues raised within the ‘fear’ 
domain were fear of doing harm and fear of the limitations of prescribers’ own 
capabilities. Prescriber education, although it certainly exists, probably needs to 
focus more on older patients. Greater input from geriatricians would be invaluable 
to GPs and others who regularly prescribe for this population.  
It is important to note that much of what prescribers expressed in these studies in 
terms of reasons for prescribing in the manner they do, is valid and may be 
perfectly appropriate in many cases. For example, few would argue with a doctor 
being more concerned with the quality of life of a patient rather than strict 
adherence to the guidelines. Equally, there are few objections to doctors 
prescribing drugs ‘off label’ if they are convinced that such prescriptions are of 
benefit to particular patients. However, as stated, PIP has been shown to be a 
significant problem leading to increased costs and adverse drug events. Some of the 
prescribing which would technically be labelled as ‘inappropriate’ may in reality be 
considered quite acceptable by some prescribe. However,  there is still a proportion 
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of prescriptions that are clearly inappropriate, and of which, prescribers are aware. 
It is clear from reviewing these studies that past experience of a drug or treatment 
regimen can have more influence on prescribers’ decisions than evidence base and 
guidelines. This reliance on ‘what they have done before’ feeds into a repetitive 
cycle that is more likely to result in PIP. 
To date, there is a lack of proven interventions that reliably counteract PIP in older 
patients. A recent review by O’Connor et al [52] points towards 4 potential areas of 
intervention to counteract PIP in this population, namely comprehensive geriatric 
assessment, medication use review, prescriber education/audit/feedback and 
computerized prescriber order entry with clinical decision support. However, the 
evidence to support routine implementation of any of these interventions to 
prevent PIP in multi-morbid older patients so far is weak. Prescriber education 
interventions to prevent PIP in particular drug classes have been shown to work, 
e.g. antibiotics, opioid analgesics and antipsychotics [52]. However, interventions to 
steer prescribers away from PIP in older patients in the broad sense are lacking. 
Rather surprisingly, researchers have given relatively little attention to prescriber 
decision-making as a prime target for attenuating PIP in the high-risk older multi-
morbid population.  
There may be other prescriber factors to consider other than the 4 prime reasons 
that predispose physicians to poor prescribing practices identified in this study. 
Nevertheless, these findings provide an evidence-based platform for design of more 
effective interventions as a means of PIP prevention in elderly populations. 
Whatever interventions are developed in the future, they should empower 
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physicians to prescribe in such a way as to improve adherence to guidelines, avoid 
feelings of being forced to prescribe inappropriately in order to please patients, and 
minimise fear of countermanding other physicians’ prescriptions.  
The global expansion of the frail older population demands an improved level of 
education in geriatric pharmacology at undergraduate and postgraduate level. 
Specifically, this will involve electronic education programmes that include self-
testing and feedback. Importantly, recent discourse on prescriber ‘non-technical 
skills’ has cast new light on a previously neglected aspect of prescriber behaviour 
[185]. These ‘non-technical skills’ encompass communication, team-
working/leadership, error awareness, risk assessment and situational awareness. 
This skill set must be incorporated into any prescriber education programme to 
enhance its efficacy. A model for the delivery of such an intervention has been 
suggested [185]. 
 
2.5 Limitations 
Although a systematic search was carried out for suitable papers, qualitative papers 
are often difficult to find due to ambiguous titles. 
Meta-ethnography, while a useful tool for this kind of research, is not an objective 
technique and is open to differing interpretations between different researchers. 
Therefore, while credibility, transferability and dependability are provided for by 
utilising well-established methods, the confirmability of the findings cannot be 
assured. 
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Four of the seven papers included in this review concerned the prescribing of 
psychiatric medications. Mediators of PIP may differ between psychiatry and other 
areas of medicine. Similarly, the mediators of the different forms of PIP (PIMs and 
PPOs) may differ. PIMs and PPOs were not separated for individual analysis in this 
paper.  
2.6 Conclusion 
PIP in older patients is a result of many factors, including patient-level, prescriber-
level and system-level barriers that result in prescribers feeling unable to prescribe 
in an appropriate manner. Possible remedies for this situation include better 
communication, more comprehensive education and system-level interventions to 
enable prescribers re-acquire this power. The problem is not a lack of prescribing 
guidelines, rather it is an abundance of barriers to implementing these guidelines, 
which need to be systematically removed. 
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3. Doctors’ perspectives on the barriers to 
appropriate prescribing in older 
hospitalised patients: A qualitative study 
 
Chapter description 
Given the lack of published qualitative research in the area of PIP in older patients 
highlighted in Chapter 2, it was decided to carry out an empirical qualitative study, 
both to add to the literature as well as guide and inform the next stages of research 
for this thesis. 
 
 
The work of this chapter has been published as Cullinan S, Fleming A, O'Mahony D, 
Ryan C, O'Sullivan D, Gallagher P, et al. Doctors' perspectives on the barriers to 
appropriate prescribing in older hospitalized patients: A qualitative study. British 
journal of clinical pharmacology. 2014. DOI: 10.1111/bcp.12555 (AppendixIV)
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3.1 Introduction 
As indicated in chapter 1, the population is ageing globally. Recent projections 
estimate  that    by  2018,  there  will  be  more  people  over  the  age  of  65 years,  
than  there  will children under 5 years worldwide [186]. By 2040, 1.3 billion people 
will be over 65 years of age, an increase from the current  7% of the worlds’ 
population  to 14% [186]. As well as economic progress globally, advances  in 
diagnostics, treatment, and in healthy-living initiatives, are largely responsible for 
this population growth [186]. The prescribing of multiple medications for multiple 
disease states, is common amongst older individuals, and these patients are 
therefore more vulnerable to medication related problems, including potentially 
inappropriate prescribing (PIP) [187, 188].  
Whilst it is acknowledged in the literature that PIP is an issue requiring significant 
attention, little qualitative research has been conducted into why PIP occurs. This 
was highlighted in Chapter 2. Indeed, studies investigating PIP have traditionally 
focused on the individual medicines or pharmacological class of medicines that are 
inappropriately prescribed [157, 159, 160, 162, 189, 190]. However, one study 
conducted by Spinewine et al. investigated contributory factors to PIP in general, 
and reported that reliance on acute general care, a passive attitude towards 
learning and a paternalistic relationship between doctor and patient all contributed 
to PIP [180].  
Behaviour change is key to any intervention requiring improvement in clinical 
practice. For example, Boscart et al demonstrated the benefits of applying 
psychological theory to inform a behaviour change intervention [191]. They 
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examined barriers and facilitators to hand hygiene practises in hospital, an area in 
which compliance is poor, in an effort to identify factors affecting nurses’ behaviour 
associated with hand hygiene [191]. They identified barriers both to current hand 
hygiene practise and to implementing a new electronic monitoring system for hand 
hygiene. Barriers included; a lack of commitment to improve practise, lack of focus 
on long-term consequences and a tendency to focus on their individual 
performances as opposed to creating a high-quality network. As a result of this 
exploration of nurses’ behaviours, implementation of this new system will now be 
an informed intervention with a higher chance of success.  
Similarly, in order to implement changes in current prescribing practise for older 
people, it is necessary to identify prescribers’ behaviour associated with the 
prescribing of inappropriate medicines. Further examination of the barriers and 
facilitators to these behaviours will allow for effective implementation of 
prescribing improvement interventions.  
Behaviour change interventions can be modelled on any number of evidence-based 
theories that exist within health psychology [192, 193]. However, with so many to 
choose from, there is always doubt as to whether the model chosen fully accounts 
for the behaviour under investigation. A solution has been presented to this 
problem. An overarching theoretical framework, combining 128 constructs from 33 
theories of behaviour change was  developed by Michie et al. [194]. The resultant 
framework, known as the “Theoretical Domains Framework” (TDF) consists of 12 
‘theoretical domains’ (See appendix V):  
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 Knowledge  Memory, Attention and Decision 
Processes 
 Skills  Environmental Context and 
Resources 
 Social/Professional Role and 
Identity 
 Social Influences 
 Beliefs about capabilities  Emotion 
 Beliefs about consequences  Behavioural Regulation 
 Motivation and goals  Nature of the Behaviours 
 
These domains serve as potential mediators of change. Using the TDF helps to 
define a behaviour and identify barriers and facilitators to that behaviour.  
The TDF has been employed in a wide range of healthcare related research. An 
Australian study by Pitt et al has looked at why doctors refer, or do not refer, 
people with osteoarthritis to self-management programmes [195]. They found 
barriers to referral to be lack of awareness amongst GPs of the existence of these 
programmes and uncertainty as to the clinical benefit of them. Enablers to referral 
were awareness amongst patients of the value and availability of these 
programmes, and positive GPs’ attitudes towards patient involvement [195]. In 
Finland, Amemori et al have studied why clinical guidelines recommending that 
dentists provide both tobacco abstinence and tobacco use cessation counselling to 
patients were not being implemented. They found that the environment in which 
the dentists work was inhibiting them from providing the counselling. They 
identified this as a potential target for interventions [196].  
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In the UK, the PROTECT study (PRescribing Outcomes for Trainee doctors Engaged 
in Clinical Training) investigated the prevalence and causes of prescribing errors 
made by junior doctors. As part of this study, Duncan et al used the TDF to explore 
the factors that influence junior doctors’ prescribing behaviour [197]. They found 
seven domains  to be likely mediators  of change and using previously  published  
methods [198], suggested several behaviour change techniques likely to be useful 
in an intervention study [197]. Similarily, in order to implement changes in current 
prescribing practice for older people, it is necessary to identify the processes 
leading to the prescribing of inappropriate medicines. Further  examination  of  the  
barriers  and  facilitators  to  these  processes  will  allow  for effective 
implementation of prescribing improvement interventions. 
The TDF was later expanded to 14 domains in 2012 by Cane et al [199]. Their study 
aimed to identify the optimal number of domains and domain labelling as well as to 
validate the contents of the domains and the TDF tool as a whole. In seeking the 
optimal structure for the TDF, they found that with their 14 domain version, 
explanatory and predictive power were increased making it a more useful tool for 
informing interventions.  To date, the TDF has not been used to study the 
behaviours associated with PIP.  
Once domains within the TDF are identified, they can be mapped to suitable 
intervention types using the ‘behaviour change wheel’, a previously published 
technique also developed by Michie et al [200] (See appendix VI). The behaviour 
change wheel consists of nine different intervention functions. The TDF domains 
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that are found to be relevant will determine which intervention functions would be 
suitable to change the behaviour in question. The intervention functions are;  
 Training 
 Restrictions 
 Persuasion 
 Incentivisation 
 Environmental restructuring 
 Education 
 Coercion 
 Enablement 
 Modelling.  
Each intervention function relates to several behaviour change techniques (BCTs) 
which are the specific activities needed to carry out the intervention [201].  
 
The aims of this study were; 
(1) To explore hospital doctors’ perceptions as to why PIP occurs using a 
phenomenological approach with a constructivist paradigm. 
(2) To identify the barriers to addressing the issues identified, thus identifying    
potential targets for intervention, and  
(3) To determine which intervention types would be best suited to minimizing PIP 
form a prescriber perspective. 
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3.2 Methods 
 
3.2.1 Sampling 
In Ireland, there are three types of hospitals; (1) public hospitals, owned and 
funded by the Health Service Executive (HSE), (2) voluntary hospitals, which are run 
by voluntary/private boards who receive money from the government  to provide 
health care services and (3) private  hospitals  which  receive  no  state  funding.  
Hospitals  were  purposively  selected  to ensure that  a  range  of  different hospital  
types  were  included  in  the  study-Large  HSE,  small  HSE,  large voluntary and 
small voluntary. Doctors were then purposively selected within each hospital. 
A sampling  matrix (Figure 3.1) was designed  to ensure  our participant  sample  
was representative  of doctors prescribing for older people in the hospital setting 
and represented doctors working in both geriatric medicine and in general internal 
medicine. The matrix ensured that an equal number of doctors of each grade, both 
from geriatrics and general medicine, and from each hospital were interviewed. 
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 Intern SHO Reg/SpR Consultant 
Large HSE 
Hospital (CUH) 
 
1 x General 
1xGeriatric 
1 x General 
1xGeriatric 
1 x General 
1xGeriatric 
1 x General 
1xGeriatric 
Small HSE 
Hospital 
(Mallow/Nenagh) 
1 x General 
1xGeriatric 
1 x General 
1xGeriatric 
1 x General 
1xGeriatric 
1 x General 
1xGeriatric 
Large Voluntary 
Hospital (MUH) 
 
1 x General 
1xGeriatric 
1 x General 
1xGeriatric 
1 x General 
1xGeriatric 
1 x General 
1xGeriatric 
Small Voluntary 
Hospital (St. 
John’s Limerick) 
1 x General 
1xGeriatric 
1 x General 
1xGeriatric 
1 x General 
1xGeriatric 
1 x General 
1xGeriatric 
HSE = Health Service Executive. CUH = Cork University Hospital. MUH = Mercy University 
Hospital Cork. Intern = 1st year qualified. SHO = Senior House Officer (next stage after 
intern). Reg/SpR = Registrar/Specialist Registrar. 
Figure 3.1 Sampling matrix 
The chosen hospitals, in the Munster region of Ireland, were contacted and asked if 
they would take part in the study. The chief hospital pharmacist was the point of 
contact in all hospitals, and approached hospital doctors to explain the study 
objectives. They were provided with a written description of the study’s 
background, aims and methods, and were asked to pass this information to hospital 
consultants. Consultants were asked if they would make themselves and their team 
available for a 25-30 minute one-on-one interview. This was then  followed  up  
with  an  email  within  one  week  of  the  initial  contact  with  the  chief 
pharmacist. Consultants willing to participate approached each member of their 
team informing them of the study and provided details of those team members 
who were willing to participate. Doctors were excluded if they were working in 
surgery, were involved in research related/similar to this study (currently or in the 
past), or had a pharmacy degree prior to undertaking their medical training. 
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3.2.2 Data collection 
A phenomenological approach with a constructivist paradigm was the methodology 
deemed suitable. The method of data collection was semi-structured interviews. 
Interview topic guides were formulated based on the TDF (see appendix VII). Using 
the TDF helps to define a behaviour and to identify barriers and facilitators to that 
behaviour. The original 12 domain TDF was used [194],  due to its proven  track 
record and use in similar studies [194-197]. The interview schedule was then 
evaluated by pilot study with  three  health-care  professionals  and amended 
accordingly. 
Semi-structured interviews were the preferred method of data collection as it is 
well established that semi-structured interviews penetrate sufficiently into the core 
of a subject and elicit more meaningful responses from participants [202]. 
The  purpose  of  the  topic  guide  was  to  explore  the  12  domains  of  the  TDF,  
while  also allowing participants to speak freely, unlimited by strict questions. It has 
been shown that interviews based on the TDF elicit responses from participants 
that would not otherwise be reported [203]. 
Participants were briefed about the study and reassured that all interviews would 
be anonymized. Demographic details were collected before the interview, 
including:  grade; gender; number of years working as a doctor; his/her current 
specialty; details of any specific  training  in  geriatric  medicine they may have 
received  and university attended. Interviews were audio-recorded and later 
transcribed verbatim. They were also asked some general questions regarding their 
knowledge and awareness of PIP. 
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Interview  locations  included  a private  hospital  office  used  for  various  research  
projects, consultants’ private offices, hospital canteens and doctors’ lounges. All 
locations were on hospital campuses to minimise disruption to participants. 
3.2.3 Data Analysis 
A similar approach adopted by Duncan et al [197] was followed for this study as a 
similar behaviour was being investigatetd i.e. prescribing. All transcripts were 
entered into QSR NVivo® Version 10 to facilitate analysis. Analysis was conducted in 
2 phases. Phase 1 was a familiarisation phase, where transcripts were read and re-
read to ensure that researchers were familiar with the entire  content  of  all 
transcripts  [204].  In phase  2,  conventional  content  analysis  [205]  was 
conducted,  independently  by two researchers. In conventional content analysis, 
the researchers identify themes within the transcripts, and code all subsequent 
texts to these themes as they arise. Findings were compared and differences 
resolved through further discussion, analysis and consensus [206]. 
 
Directed content analysis [205] was then employed to apply the TDF and identify 
relevant domains. In directed content analysis, unlike conventional analysis, texts 
are coded to a pre-defined list of domains or research findings. A  domain  was  
deemed  relevant  if  text  from  the  interview  transcripts  was frequently  coded 
into that domain  and participants  suggested  that constructs  within  the domain 
were an influencing  factor in PIP (see appendix VIII for screenshots of the process). 
Again, the domains identified as relevant were agreed upon by two researchers. 
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The behaviour change wheel [200] was then used to identify intervention types that 
would be suitable, given the domains identified. 
It was decided to use two forms of content analysis to ensure that all relevant 
themes were identified. For  the  purposes  of  the  study,  and  to identify domains  
to  be  targeted  in  a  future intervention,   the  directed  content  analysis  was  to  
be  the  primary  data  source.  The conventional content analysis was to be used to 
identify other, less critical areas of interest that may arise but which did not fit 
directly into the TDF. 
Ethics approval for this study was sought from and granted by the Clinical Research 
Ethics Committee in University College Cork, Republic of Ireland (see appendix IX).
 
3.3 Results 
All doctors approached to take part, did so and a total of 22 interviews were 
conducted. 
Four hospitals took part i.e two HSE and two voluntary (one large and one small of 
each), as well as all grades of doctor (Table 3.1). Thematic  saturation  was  reached  
after  18  interviews,  another  four  were  carried  out  to ensure no new themes 
were emerging, as per the Francis method [207]. 
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Table 3.1: Participant Characteristics 
Hospital Total No. of 
participants 
from each 
Grades of 
participants 
Total No. of 
participants 
working in 
geriatrics 
Sex 
Large HSE 6 
 
2 X Intern 
2 X SHO 
2 X Reg 
1 X Consultant 
2 3 X Male 
3 X Female 
Small HSE 5 
 
1 X Intern 
2 X SHO 
1 X Reg 
1 X Consultant 
3 3 X male 
2 X Female 
Large 
Voluntary 
6 
 
1 X Intern 
2 X SHO 
1 X Reg 
2 X Consultant 
3 4 X Male 
2 X Female 
Small 
Voluntary 
5 
 
1 X Intern 
1 X SHO 
1 X Reg 
1 X Consultant 
2 2 X Male 
3 X Female 
HSE= Health Service Executive. Intern= 1st year as qualified doctor. SHO= Senior House Officer 
(Next stage after Intern). Registrar (Reg)= Next stage after SHO 
 
As mentioned above, the topic guide used for the interviews was designed to 
explore the domains of the TDF. However it also included some questions designed 
to provide a cross- sectional picture of doctors’ awareness of PIP and prescribing in 
general for older patients. Some points of interest from these questions follow. 
(1) When asked to estimate what they thought the prevalence of PIP in hospitals 
was, the vast majority guessed above 50%. (2) When asked if they thought it was a 
problem that needs corrective action, all but one concurred (3) When asked where 
they thought PIP might be most prevalent i.e. in primary, secondary or tertiary care, 
14 doctors felt it was highest in primary care, (where  it  has  actually  been  shown  
to  be  lowest [11, 13, 17, 163, 164]). (4)  When asked to rate  their confidence in 
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prescribing for older patients on a scale of 1-10 (10 being the most confident), over 
half placed it at between 5 and 6. These were all interns (house officers) and senior 
house officers (SHOs). (5) When asked if they were aware of any screening tools to 
aid in prescribing for older patients, only the consultants were able to name the 
common ones. The other participants, for the most-part had heard of them but had 
no idea what they were.
Approximately half the doctors interviewed were, at time of interview, working in 
geriatric medicine (Table 3.1), with the remaining working in other medical 
specialties or in general internal medicine. The majority of doctors in geriatrics 
mentioned, without prompting or direct questioning on the matter, that prescribing 
within geriatrics was in general, far more appropriate than in other medical 
specialties they have experienced. There was a common trend within this group 
that more exposure to geriatricians would be of great benefit to prescribing in older 
patients, and this was also echoed by doctors not currently in geriatric medicine. 
 
3.3.1 Conventional content analysis 
Following  familiarisation,  and open coding, four over-arching  themes, contributing  
to PIP were identified.  They were; 
•   More education required in the area of geriatric pharmacotherapy. 
•   Prescribing environment is conducive to PIP, 
•   Poor information technology (IT) infrastructure, 
•   Lack of collaboration between levels of care. 
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3.3.2 Directed content analysis 
To identify relevant domains in the TDF that could be targeted in an intervention, 
directed content   analysis   was   employed.   In   all,   five   domains   were   
identified   as   relevant;  
(i) Environmental  context  and  resources 
(ii) Memory/attention  and  decision  processes 
(iii) Knowledge 
(iv) Skills   
(v) Social influences 
These same domains were identified from both the geriatricians’ interview 
transcripts and those not working in geriatric medicine. Behaviour regulation and 
beliefs about capabilities were also identified at an early stage. However, although 
purported to in some interviews, they were not indicated as being a significant 
contributory factor in PIP. How each of the five relevant domains were represented  
is presented  below. Knowledge and skills are presented together since participants 
made little distinction  between the two. More quotes supporting the different 
domains are presented in Table 3.2. 
 
3.3.3 Environmental context and resources 
The environment in which doctors prescribe was noted throughout the interviews, 
with interviewees   reporting   that   the   circumstances   in   which   they   prescribe   
are conducive to PIP. In particular, their workload, being interrupted while writing 
prescriptions and a lack of supportive IT infrastructure within their working 
environment, were considered conducive to PIP. They identified the 
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multidisciplinary team structure as a definite facilitator to appropriate prescribing, 
but indicated that its impact is attenuated by inefficient use of the resources within 
this team. 
“That’s a major problem. What you want to do when you’re writing out a drugs 
kardex [prescription chart], is to be on your own, to be left alone, for  five minutes 
while you just write out the thing. But it’s actually an ideal opportunity for anybody 
who wants a piece of you for advice or whatever, (…..) nobody respects that at all” 
Site 1, interview 6 (Intern) 
A theme evident throughout many of the interviews was that of limited resources 
available, with particular emphasis on the lack of IT infrastructure. Interviewees 
noted that improvements and developments in the IT infrastructure could lead to 
much safer and more appropriate prescribing. Many doctors emphasised that 
prioritising improvement initiatives around IT infrastructure could have the most 
significant impact on prescribing quality. 
“Part of the reason (for PIP) is there isn’t a very good interface between the 
electronic systems that they [General practitioners (GPs)] use and the electronic 
systems that we use. So in an ideal world the GPs should be able to electronically 
send in all up to date information.” Site 3, interview 2 (Consultant).
A further issue raised by the interviewees, was the team support within the hospital 
environment.  Particularly, the hospital pharmacist was considered a useful team 
member and a reliable resource. However, interviewees felt that the pharmacist’s 
input was not used to full effect, with many doctors not having regular pharmacist 
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input into the prescribing process.  Some interviewees also noted that the way in 
which advice from pharmacists was communicated to the prescribers was 
important, with interviewees favouring face-to-face communication rather than 
written communication. 
“…obviously it would be nice to think that every ward would have a pharmacist 
attached to it reviewing kardexes [prescription charts] and educating (….) but there 
is a feeling that the pharmacist comes and writes a note for you, but it’s not done 
face to face, and it actually is a bit  antagonistic  if anything  (….) having  ‘post-its’  
[notes]  stuck  on  things  saying  please review this, please review that. We all hate 
notes, everyone hates it, so I think that could be done  better.  So  more  pharmacy  
input,  but  more  integrated  pharmacy  input”  Site  3, interview 2 (Consultant) 
 
3.3.4 Memory/attention and decision processes 
Participants   referred   to  this   domain   in  two   contexts.   Firstly,   in conjunction 
with the high pressure environment in which they prescribe and their workload. 
This environment affects the attention they can give to each patient and their 
medicines. Their attention is not at the level it would otherwise be. 
“Particularly in A&E [accident and emergency] which is where you are doing the 
core prescribing, trying to determine what they should be on., making decisions 
about whether to hold things or not, and I mean there are four SHOs [senior house 
officers] trying to talk you, along with nurses and stuff” Site 1, interview 1 
(Registrar) 
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Secondly, several participants suggested doctors’ decision-making and the 
processes surrounding it as a cause of PIP. There was a feeling amongst these 
participants that there is
wide variation in practice amongst doctors, and that some do not go to the lengths 
required, or give sufficiently careful consideration to make an informed decision 
when prescribing. 
 
“…when they come in, and they don’t  have  a list of their medications,  some  
people  just inappropriately write down the dose that they think that they should be 
on or whatever, which often happens. Or a prescription of a patient that just came 
in on Sunday, had just the medications written with no doses at all (….) so if you’re 
not going to write a dose you probably shouldn’t write anything.” Site 1, interview 1 
(Registrar) 
 
3.3.5 Knowledge/Skills 
Although separated into two domains in the TDF, participants for the most part 
alluded to constructs  within  these  domains  as  a single  domain,  and  therefore 
these domains are reported together. Participants noted a lack of specific education 
and training in geriatric pharmacotherapy,  and also a lack of communication of 
clinically relevant information with regards to older patients, such as which drugs to 
avoid. Interviewees noted that experiential   learning   is  how  their  prescribing   
skills  and  knowledge   of  issues  around prescribing in older people progress. 
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However they felt that this was not sufficient and that further structured training 
was required. 
“I’d say if there was a monthly, or periodic review of the literature (…) to put  out  a  
newsletter   or  something,   for  medications   that  are  found  to  be  obsolete, 
medications that are found to be harmful, because we see a lot of people on 
medication that were used ten or twenty years ago and are no longer in the 
guidelines and no longer the current practice (…) I think that would be a good idea.” 
Site 2, interview 2 (Registrar) 
“I don’t think there is enough training for prescribing in older patients. There is no 
distinction between older patients  and the general adult population  in the training.  
You just learn it from practice.” Site 4, interview 2 (Registrar) 
Patient education was also considered important. 
“And even when they [the patients] bring a list, their knowledge of those meds is 
not good. And the patient education of their own drug therapies is fairly poor. 
Community wise, nationwide, there is a
big  area  that  needs  to  be  addressed  in terms  of  patient  education”  Site  2,  
interview  1 (Consultant) 
 
3.3.6 Social influences 
Participants   were   specifically   asked   about   outside   influences   that   may   
affect   their prescribing and  perhaps  increase  the  risk  of PIP.  The majority of 
doctors  admitted  that patients and patients’ families  can influence  their 
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prescribing,  to the point where the doctor may prescribe a drug he/she is not 
completely comfortable with. 
“As  a  doctor  sometimes,  you  feel  that  you  have  to  do  something,  you  get 
pressurized by either nursing staff, relatives or patients. You have to give them 
something. So you end up giving something that you are not 100% happy with. “Site 
2, interview 2 (Registrar) 
Most interviewees did say however that they didn’t think these choices were 
putting their patients at any risk due to these choices after weighing the risks and 
benefits and that the quality of life was a major deciding factor. 
“I would like to think that we never prescribe something that we know is wrong or 
don’t prescribe something that we know is right, even if the family has concerns, I 
do think we can stand our ground and document  their concerns  and  do it (…) I 
think we are always  just thinking about the patient’s quality of life (…) but there’s 
no doubt it sways you where it’s a grey area” Site 3, interview 2 (Consultant)
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Table 3.2: Supporting quotes from interviews 
TDF Domain and intervention 
types identified as suitable by the 
behavior change wheel 
 
 
 
Supporting quotes 
 
Environmental context and 
resources 
 
Behaviour change wheel 
interventions identified: 
 
-Environmental re-structuring 
-Persuasion 
-Incentivisation 
 
 
 
 
 
 
 
 
 
 
“I do think though, it’s a tough job, it really is very tough, you’re just flat 
out busy all the time, I think a lot of times you’re just transcribing things 
you just go into auto pilot and you transcribe things that have already 
been prescribed and you don’t question it.” Site 3, interview 1 (Intern) 
“We should have open access computers on every ward for resources 
including BNFs and other sorts of policy documents, antimicrobial policy 
and other things you use all the time. And these are all barriers, if you’re 
unsure about checking the medication, these are all barriers that will put 
a lazy person off am, checking it. I think it’s really important that we 
have  better  access  to  IT  on  every  ward.  It’s  really  terrible  at  the 
moment.” Site 1, interview 6 (Intern) 
“I  think  it  [improved IT  inifrastructure] is  a  resource  that  would  be 
potentially brilliant for drug and prescribing management, in general. 
How could I give you a better example of that now..….I think let’s say in 
community, in retail pharmacy, there are platforms available which off 
the bat [straight away], will flag drug-drug interactions, as you fill a 
script, and it’s up to the pharmacist to look at it. We don’t have anything 
like that, and it would be so easy.” Site 1, interview 6 (Intern) 
“In New Zealand we had a pharmacist for every team in the hospital who 
used to go around and check all the meds and they were very much part 
of the medical team and we took a lot of advice from them because they 
had more time to go through them [the medicines prescribed]. I know 
like the culture here is kind of, that we [prescribers] are in charge of 
meds, but that was one thing that was brill, and it wasn’t just a green 
thing on the front of the chart, they would go through every admission, 
which was a big job, but they would go through every patient and go on 
the ward round, and they would have a medical idea of why the patient 
was in and recommend changes to the medications. I thought that was 
very good. The team didn’t have to take the advice. Pharmacists are 
better at that kind of thing so I think that would be a really good idea” 
Site 1, interview 1 (Registrar) 
“I think that actually, I do think pharmacists have helped me an awful lot 
this year. Like things like pointing out drug interactions that you mightn’t 
have noticed (….) definitely find the pharmacist really helpful so I don’t 
mind them ringing me and their notes are great on the kardexes 
[prescription chart] and stuff. And it’s especially helpful if there’s 
something the patient can’t remember”. Site 4, interview 6 (Intern) 
“Well we don’t have clinical pharmacy involvement here, which hopefully 
it’s going to start and that’s a great thing you know it improves our 
prescribing overall.” Site 4, interview 3 (Consultant) 
 
 
 
  
 
 
 
Memory/attention and 
decision processes 
 
Behaviour change wheel 
interventions identtified: 
-Enablement 
-Modelling 
“You  know  sometimes you’re  writing  three  or  four  pages  of  a  drug 
kardex, and to look at every possible interaction, you know you’d see the 
common things but the less common things get overlooked all the time.” Site 
2, interview 3 (SHO) 
“….some people just believe everything the patient says at face value     without 
ever really investigating whether or not they actually know what   they are 
talking about” Site 4, interview 1 (SHO) 
“I think you have to be more thoughtful prescribing for elderly patients and I 
think a lot of people just do it without taking enough care and stuff like that, 
you know you have to know what you’re prescribing and you do have to be 
aware of any interactions.” Site 3, interview 2 (Consultant) 
Knowledge and skills 
 
Behaviour change wheel 
interventions identified: 
-Enablement  
-Modelling 
“It’s a different knowledge set. And it’s difficult you know because there isn’t 
a huge amount of data out there, or its not communicated to us very well, 
I mean we all hear about the randomised controlled trials when new drugs 
come out, we get info [information] about that but we don’t really hear much 
like, on grand rounds you know, what meds are good or bad in elderly people” 
Site 1, interview 5 (Registrar) 
“….as an undergrad, students don’t have a tenth of the teaching that they 
should have, all doctors of all levels will openly put their hand up and say, as an 
undergrad, they didn’t have the teaching so most definitely they should be an 
increase in what they are teaching in clinical pharmacy, they should have a 
huge amount more time at undergraduate level for that because it’s such a 
dangerous occupation you know, prescribing, something has to be done about 
it” Site 3, interview 1 (Intern) 
“I think we do need a lot more patient education, I think we do need the 
patients, not only going home, not only having a prescription, but they have a 
detailed patient education leaflet, documenting all the drugs they are on, and 
their purpose, frequency and duration.” Site 2, interview 1 (Consultant) 
Social influences 
 
Behaviour change wheel 
interventions identified: 
-Restrictions 
-Persuasion 
“There is no doubt that we would come under pressure to prescribe anti-
depressants or sleeping tablets from the family members, not just the person 
and you have to resist that if you think it is inappropriate but you know, the 
fact that you have to resist it means that sometimes you probably are swayed 
by it. And similarly there may be a medication that you may be thinking of 
prescribing and the family say absolutely no, or have huge concerns about it 
you know if you are iffy about it, that might be enough to dissuade you.” Site 
3, interview 2 (Consultant) 
 
“I’d start with education actually, but its educating patients as well you know. 
There’s a notion out there you know that you go to the doctor, and the 
outcome of any consultation should be a prescription.” Site 4, interview 4 
(Consultant) 
Table 3.2 Contd 
 3.3.7 Barriers to behaviour change 
From the above analysis, it can be seen that the main barriers to appropriate 
prescribing are: 
•   An environment which is conducive to sub-optimal prescribing 
-Interruptions, lack of IT infrastructure, distracting environment, all combine 
to make it difficult for the prescriber to give the extra thought required to 
ensure the older patient’s prescription is appropriate.  
•   Strained resources 
-Lack of targeted pharmacy input on the wards, poor collaboration between 
different levels of care due to busy schedules, and again lack of IT 
infrastructure.   
•   Lack of specific training 
-Not enough geriatric pharmacotherapy training, particularly for 
undergraduates. Prescribers feel ill-equipped to prescribe appropriately for 
older patients with multi-morbidities and associated polypharmacy.  
•   Poor patient education 
-Patients’ knowledge of their own medicines is generally poor and they can 
often be reluctant to change long-term prescriptions. This can make 
adjusting medications difficult for the prescriber. 
 
 3.3.8 Behaviour change wheel 
Having identified the domains within the TDF [194] that are relevant to PIP, the 
behaviour  change  wheel  [200] was then used to  identify  intervention  types  that  
would  be  suitable  to address   these   domains.   According   to   the   behaviour   
change   wheel,   the   types   of interventions that would be beneficial in the area of 
PIP are; training, environmental restructuring,    restrictions,    persuasion,    
incentivisation,    modelling    and    enablement.
 
3.4 Discussion 
This is the first study to use a theoretical approach to investigate issues associated 
with potentially inappropriate prescribing in older patients. 
The responses to the general questions at the start of the interviews paint a clear 
picture. Doctors  are  aware  that  PIP  is  problematic  in  this  age  group.  Their 
estimations of its prevalence were quite accurate. However they feel ill-equipped to 
deal with it and are poorly informed  about  the  measures  that  already  exist  to  
deal  with  it,  as illustrated  by  their widespread  lack  of  awareness  of  the  
common  screening  tools  for  prescribing  in  older patients. 
The consensus amongst all doctors (not just those in geriatrics) that increased 
exposure to geriatricians would be of great benefit is an important point. It is logical 
that guidance from experienced geriatricians would improve prescribing in older 
patients, but to hear it from practicing doctors, who have experienced prescribing 
within multiple specialties emphasizes this point. It is also of interest that the same 
TDF domains were identified from the transcripts of doctors working in geriatric 
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medicine as well as in other specialties. This is not surprising since doctors from all 
medical specialties are caring for more and more older patients currently, so the  
challenges these patients present are common to all who prescribe for them. 
The domains in the TDF identified as relevant provide the details to the overall 
situation described above. It is well recognised that a doctor’s workplace can be 
chaotic [208, 209], and so the emergence of ‘environmental context and resources’ 
was not unexpected.  Improving the environment in which doctors prescribe is not 
an easy task.  However, areas have been highlighted throughout these interviews 
that could be good starting points. For example, making better use of the resources 
available. In particular, the hospital pharmacist. Perhaps interventions designed to 
restrict interruptions to doctors while writing prescriptions.  In addition, improved 
IT infrastructure would likely improve prescribing in older patients generally. 
The domain of “memory/attention and decision processes” was clearly intertwined 
with the domain “environmental   context  and  resources”.   Even  with  a  calm 
prescribing environment free of distractions, prescribing is still a challenging 
exercise. The complexity of prescribing for multi-morbid older patients is well 
recognised.  Aronson has identified the need for a wide range of skills and judgment   
when prescribing, and  the  increased   challenges   when  dealing   with  a 
vulnerable population [210-212]. With the extra stresses the work environment 
brings the exercise of prescribing and correct therapeutic decision making becomes 
significantly more difficult. Doctors’ indications that decision making processes,   
particularly   when   writing   prescriptions,   vary   quite   significantly   between 
individuals is an important point to consider, and a possible target for intervention. 
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Providing an environment more conducive to appropriate  prescribing will address 
this issue to some extent. However, the interviews  also  suggest  that  greater 
efforts are needed  to standardize  doctors’ prescribing practices. 
‘Knowledge’ and ‘skills’ were two clear areas that participants felt could be 
targeted, although for the most part they referred to these domains as one entity.  
The majority of interviewees expressed a desire for further training; those who did 
not were the most senior doctors i.e. hospital consultants.  Most interviewees felt 
they did not receive adequate specific geriatric pharmacotherapy    training   as   
medical   undergraduates. In addition, there   was   a   perceived   lack   of 
communication of the salient therapeutic points from the research literature once 
they qualify. This is an area with significant potential for intervention in terms of 
feasibility. Pharmacists and clinical pharmacologists are ideally placed to address 
this issue and equip doctors with the necessary tools to prescribe for older patients. 
Restructuring the undergraduate medical curriculum is also required, with more 
emphasis on geriatric pharmacotherapy. It should be noted that while participants 
mostly referred to ‘knowledge’ and ‘skills’ as one and the same, they are in fact 
fundamentally different behavioural determinants and as such, require different 
interventional approaches. ‘Knowledge’ can be enhanced through increased 
education, whereas addressing ‘skills’ may require non-technical training, as 
reported by Gordon et al [185]. 
 
An  unexpected  result  of  the  study  was  the  emergence  of  the  domain  ‘social 
influences’. Over half the participants, including the majority of consultants, said 
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that they would be, and/or have been influenced by the patient or their family to 
prescribe in a manner that could be deemed inappropriate, with several doctors 
using the term “forced to prescribe”. Although most interviewees added that they 
still felt they weren’t putting the patient at risk, the notion of a doctor feeling 
forced into a prescribing decision is worrying. Many interviewees referred to 
patient education as a solution to this. Dealing with patients’ and families’ 
demands, and being able to resist demands, is likely an important component of 
educational interventions going forward. Implementation of the model for delivery 
of this type of training in ‘non-technical skills’ proposed by Gordon et al [185] is 
warranted given the findings of this study.  
The findings correlate well with the meta-synthesis in chapter 2, which found that 
some doctors feel restricted in terms of their abilities to prescribe appropriately 
due to a combination of factors such as pressure to please the patients, and fear of 
doing harm by changing a patient’s medications [156]. Shared decision making with 
patients [213] should also be explored as a means to address this issue that doctors 
have identified as problematic. This would also counter-act the traditional 
paternalistic approach to prescribing which has previously been identified as 
problematic and contributory to PIP [180].  
It should be noted that while doctors admitted to sometimes knowingly prescribing 
inappropriately, in certain circumstances, they were conscious of paying more heed 
to the patient’s quality of life rather than the appropriateness of their prescriptions. 
This is an important consideration as these patients’ therapeutic targets are often 
very different from those of younger adults. 
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This study has highlighted the specific barriers to change that exist in the area of 
PIP. The intervention functions identified through use of the behaviour change 
wheel correlate well with these barriers, in that, interventions based on 
environmental restructuring and training would  certainly  seem  logical  given  that  
three  of  the  four  barriers  identified  fall  under ‘environment’ or ‘training’. We 
can be confident therefore, that an intervention informed by these techniques 
would likely be justified and beneficial. 
To date, interventions that reliably counteract PIP in older patients are lacking. 
O’Connor et al [52] recently conducted a review which suggests 4 areas of 
intervention to counteract PIP in this population, namely comprehensive geriatric 
assessment, medication use review, prescriber education/audit/feedback and 
computerized prescriber order entry with clinical decision support. The evidence to 
support any of these interventions to prevent PIP in older patients is however 
weak. Prescriber education interventions to prevent PIP in particular drug classes 
have been shown to work, e.g. antibiotics, opioid analgesics and antipsychotics [52]. 
Whether prescriber education can minimize PIP in older patients in general is 
unknown. 
Although the TDF domains were examined and presented individually, there is 
significant cross over between them. The environmental context has an impact on 
doctors’ memory/attention and decision processes, as well as their ability to carry 
out basic skills. Similarly, doctors’ particular skill sets may determine whether or not 
they are prone to social influences and  whether  they  allow  such  pressures  to 
affect their  prescribing. Bearing in mind these cross overs between domains, it is 
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highly probable that an intervention to address PIP will have to be multi-faceted.  
One of the intervention types identified by the behaviour change wheel is unlikely 
to result in a significant improvement if implemented in isolation. A combination of 
intervention types however would be justified and would likely have a higher 
chance of success. 
3.5 Limitations 
Much of the responsibility for recruitment of participants for this study laid with a 
third party i.e the hospital pharmacist. While it was useful to have a person known 
to the medical staff to introduce the project, it is preferable that the researcher(s) 
claim responsibility for recruitment when using qualitative methodologies. 
Whilst the sampling matrix was used to ensure inclusivity within the hospital 
setting, this study therefore reflects the barriers encountered by hospital doctors, 
and is not generalizable to primary care. 
The sample size of 22, although acceptable for qualitative research, is small, and as 
with all qualitative research, is not generalisable.  
3.6 Conclusion 
Doctors are aware that PIP in older patients is a real problem that needs solutions. 
The current study indicates that the causes are a combination of environmental and 
social factors, compounded by doctors’ lack of specific training and education in 
geriatric pharmacotherapy. This study has identified   key   areas   for targeting   of  
intervention   studies   in  the  future,   as  well   as intervention  types that should 
be used.
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4. Use of an e-learning educational module to 
better equip doctors to prescribe for older 
patients - A randomised controlled trial 
 
Chapter description 
Amongst the findings from Chapter 3, it was reported that doctors feel they do not 
receive enough specific geriatric pharmacotherpay education as undergraduates. 
They expressed a desire for this teaching to be delivered in such a way as it could be 
completed in their own time. Therefore, an educational intervention was developed 
which delivered on this and the impact of it on prescribers’ knowledge and 
confidence with regards to prescribing for older patients was explored by 
randomised controlled trial. 
 
 
The work of this chapter is currently under review for publication in the British 
Journal of Clincal Pharmacology. 
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4.1 Introduction 
Earlier chapters of this thesis have highlighted the negative impact PIP in older 
patients is having on healthcare systems both in Ireland and abroad [11, 12, 15, 17, 
214]. Older patients’ susceptibility to PIP has also been described [187, 188]. The 
difficulty with prescribing for older patients stems from a lack of evidence of the 
effectiveness of medicines in the multi-morbid older patient [52], as well as altered 
pharmacokinetic and pharmacodynamic properties of some drugs when consumed 
by older patients [53]. Hence, the older patient population is significantly different 
from the younger adult population with regards to dose selection for a wide variety 
of drugs.  
Recent investigation of prescribing attitudes and behaviour indicate that doctors 
feel there is insufficient distinction made between the two adult populations i.e 
younger and older adults during their undergraduate education, and that doctors 
do not receive enough education and training in geriatric pharmacotherapy either 
at undergraduate or postgraduate levels [215], as highlighted in Chapter 3. As a 
result, doctors may lack the confidence to make decisions as to the appropriateness 
of pharmacotherapy when dealing with older patients [216, 217]. Recently 
published research also indicates that recently graduated doctors  feel that 
supplementary training, delivered in a  way that would allow them to complete it in 
an on-line format and in their own time would be of benefit [215].  
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The qualitative research described in Chapter 3 exploring doctors’ beliefs about the 
causes of PIP, indicates several possible areas for intervention [215]. Not 
surprisingly, online educational interventions and supplementary training are 
among them. Educational interventions have had moderate success in various 
clinical disciplines in the past, and randomised controlled trials have shown that 
such interventions significantly reduce the amount of inappropriate prescribing 
[107, 108]. The overall evidence as regards efficacy of educational interventions has 
been somewhat mixed [52, 103, 104]. However, many of the previous studies in the 
past have not been well informed by prior qualitative research or have not utilised 
technology to make  educational tools and resources more convenient to the 
participants  with a view to enhancing  efficacy [110-112]. Also, most of the 
previous studies have focused only on single drug classes, rather than prescribing in 
general in the target population [106-108]. 
Previous studies indicate that online educational, ‘or ‘E-learning’, interventions are 
at least as effective as standard  educational techniques [218-220], and have shown 
promise in the area of paediatric prescribing [221]. As stated in the literature, it is 
unlikely that any one form of education will ever suffice, and a  combination of 
complementary techniques will  very likely be required for maximum efficacy [218].  
The aim of this study is to determine if an online educational module, focused on 
geriatric pharmacotherapy improves doctors’ prescribing knowledge, as well as 
prescribing confidence as applied to older patients. 
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4.2   Methods 
4.2.1 Study design 
The impact of the intervention on doctors’ knowledge and confidence with regards 
to prescribing for older patients was measured using a non-blinded randomised 
controlled trial. 
4.2.2 Intervention 
For the online module, a licence to use the ‘Standard Computerised Revalidation 
Instrument for Prescribing and Therapeutics (SCRIPT)’ tool developed by NHS 
Health Education West Midlands, University of Birmingham and OCB Media in the 
UK was obtained. This is a comprehensive doctor training tool utilised in the UK 
which covers all aspects of prescribing, including a specific module for prescribing in 
older patients (See appendix X for screenshots of the module). Areas covered in the 
older person prescribing module include drug-drug interactions, pharmacokinetics, 
pharmacodynamics, adverse drug reactions and appropriateness of prescribing. 
This interactive module is designed to be completed in 1-2 hours and has been 
peer-reviewed by experts in geriatric pharmacotherapy. No comparable 
educational tool is currently available to doctors in the Republic of Ireland. 
Three assessments were created and marking schemes agreed upon by a consultant 
physician in geriatric medicine and 2 clinical pharmacists (Appendix XI). Each 
assessment consisted of 10 multiple choice questions (MCQ) (20 marks) followed by 
5 case studies (30 marks). The case studies in each assessment tested participants’ 
knowledge of prescribing appropriateness in older patients, requiring them to 
identify specific issues with regard to the patient’s prescription. At the end of each 
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assessment, the participants were asked some questions about their confidence 
levels when prescribing for older patients, their opinions of the training they had 
received so far, their knowledge of tools to aid in prescribing for older patients and 
their opinions of PIP in older patients.  
At baseline, both groups (control and intervention) completed the first assessment.  
Participants in the intervention group were then given access to the Script module 
for 4 weeks. After this time, both groups completed the second assessment. The 
third and final assessment was completed by both groups after 12 weeks.  
4.2.3 Recruitment 
Non-consultant hospital doctors (NCHDs) of all grades i.e house officers (interns), 
senior house officers (SHOs) and registrars were recruited from 6 public hospitals 
within the Health Service Executive (HSE) Southern Region in Ireland between 
January and April 2015. Exclusion criteria were: having a pharmacy degree; history 
of working in the pharmaceutical industry; working as a consultant doctor. It was 
calculated that a sample of 78 participants was required to provide 90% power to 
detect a 20% difference in mean test scores post-intervention. To allow for an 
expected 35-45% attrition rate from baseline to 12 weeks, a sample of 146 was 
obtained. 
Sample size calculation for a continuous endpoint 
Standardised difference = Difference to detect / anticipated standard deviation                             
= 10 marks (20%) / 13.5 (SD reported from similar study) [221] 
=0.74 
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Table 4.1: Sample size table for continuous variables showing number of patients 
required per arm 
 
Power 
Standardised difference 
0.55 0.6 0.65 0.7 0.75 0.8 0.85 0.9 0.95 
0.8 53 45 39 33 29 26 23 21 19 
0.9 71 60 51 44 39 34 31 27 25 
 
With a standardised difference of 0.74, and requiring 90% power, 39 patients are 
required per arm, 78 in total. To allow for a max of 45% attrition, (78 / 55) X 100 
= 140 participants required in total. 
A computerised random number generator was used to allocate participants to 
control or intervention groups. Stratified randomisation was used to ensure even 
distribution of hospitals, grade of doctor (intern, SHO and registrar) and area of 
practice (medical, surgical and geriatrics) within each group.  
4.2.4 Data analysis 
The primary outcome measure was prescribing skill measured by the total correct 
responses in each assessment. Each assessment was marked out of 50, with 20 
marks available for the multiple choice questions, and 30 marks for the case 
studies. Secondary outcomes were doctors’ confidence levels with regards to 
prescribing for older patients as well as their opinions on the training they had 
received to date, their knowledge with regard to common screening tools for PIP 
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and their opinions as to what should be done to address the issue. The latter was 
treated as qualitative survey data and analysed accordingly through content 
analysis. 
The researcher marking the assessments and performing the analysis was blinded 
to the allocation group of the participants during this process. To analyse test 
scores, the Student’s t test was used. Data were analysed using IBM SPSS Statistics 
(version 22). 
The Consolidated Standards of Reporting Trials (CONSORT) guidelines were applied 
during design, implementation and reporting of the trial [222] (Appendix XII). 
Ethics approval was sought from and granted by the Clinical Research Ethics 
Committee, University College Cork (Appendix XIII). The trial was registered with 
the United States National Institutes of Health (NCT02405975) 
https://clinicaltrials.gov/show/NCT02405975 
 
4.3 Results 
As per the CONSORT guidelines, Figure 4.1 shows the flow of participants through 
the trial. Seventy participants were randomised to the control group, of which 39 
completed the 12 weeks. Seventy six were allocated to the intervention group, of 
which 41 completed the 12 weeks. 
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Figure 4.1: Flow diagram of participants through the trial 
Assessed for eligibility (n=150) 
Excluded (n=4) 
 Consultant doctor (n=2) 
 Worked as pharmacist 
previously (n=2) 
Randomised (n=146) 
Allocated to intervention group (n=76) 
 Returned 1
st
 assessment (n=67) 
 Did not return 1
st
 assessment (n=9) 
-Only partially completed (n=4) 
-Lost to follow-up (n=5) 
 
 
 
 
Allocated to control group (n=70) 
 Returned 1
st
 assessment (n=63) 
 Did not return 1st assessment (n=7) 
-Only partially completed (n=2) 
-Lost to follow up (n=5) 
 
 Completed intervention (n=64) 
 Lost to follow-up (n=3) 
No intervention (n=63) 
 Returned 2
nd
 assessment (n=56) 
 Did not return 2
nd
 assessment (n=8) 
-Only partially completed (n=1) 
-Lost to follow-up (n=7) 
 
 Returned 2
nd
 assessment (n=42) 
 Did not return 2
nd
 assessment 
(n=21) 
-Only partially completed (n=2) 
-Lost to follow-up (n=19) 
 Returned 3
rd
 assessment (n=41) 
 Did not return 3
rd
 assessment (n=15) 
-Only partially completed (n=2) 
-Lost to follow-up (n=13) 
 Returned 3
rd
 assessment (n=39) 
 Did not return 3
rd
 assessment (n=3) 
-Only partially completed (n=1) 
-Lost to follow-up (n=2) 
 
Baseline assessment 
Intervention 
4 weeks 
12 weeks 
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Table 4.2 shows the participant characteristics of each group. Stratified 
randomisation with a random number generator ensured even distribution of 
hospital, grades of doctor and specialist areas in each group. 
Table 4.2: Participant characteristics of control and intervention groups 
Control 
Hospital Grade Area Total 
1 Intern (n=12) 
SHO (n=7) 
Reg (n=9) 
Medicine (n=11) 
Geriatrics (n=10) 
Surgery (n=7) 
28 
2 Intern (n=2) 
SHO (n=2) 
 
Medicine (n=2) 
Geriatrics (n=2) 
4 
3 Intern (n=5) 
SHO (n=7) 
Reg (n=3) 
Medicine (n=4) 
Geriatrics (n=6) 
Surgery (n=5) 
15 
4 Intern (n=1) 
SHO (n=2) 
Reg (n=2) 
Medicine (n=2) 
Geriatrics (n=2) 
Surgery (n=1) 
5 
5 Intern (n=2) 
SHO (n=2) 
Reg (n=2) 
Medicine (n=3) 
Surgery (n=3) 
6 
6 Intern (n=3) 
SHO (n=4) 
Reg (n=5) 
Medicine (n=5) 
Geriatrics (n=4) 
Surgery (n=3) 
12 
Total 70 
Intervention 
Hospital Grade Area Total 
1 Intern (n=10) 
SHO (n=12) 
Reg (n=11) 
Medicine (n=12) 
Geriatrics (n=10) 
Surgery (n=11) 
33 
2 Intern (n=1) 
SHO (n=3) 
Reg (n=2) 
Medicine (n=3) 
Surgery (n=3) 
6 
3 Intern (n=5) 
SHO (n=6) 
Reg (n=1) 
Medicine (n=4) 
Geriatrics (n=3) 
Surgery (n=5) 
12 
4 Intern (n=2) 
SHO (n=1) 
 
Medicine (n=1) 
Surgery (n=2) 
3 
5 Intern (n=2) 
SHO (n=1) 
 
Medicine (n=2) 
Geriatrics (n=1) 
 
3 
6 Intern (n=6) 
SHO (n=5) 
Reg (n=8) 
Medicine (n=7) 
Geriatrics (n=5) 
Surgery (n=7) 
19 
Total 76 
91 
 
There was no significant difference between control and intervention group scores 
at baseline (p=0.071) and the data across both groups was normally distributed 
with minimal skewness (skewness = 0.087), see Figure 4.2.  
 
Figure 4.2: Distribution of test scores across both groups 
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Table 4.3 shows the baseline and post-intervention total scores for the 
assessments. A significant difference was seen between the groups at 4 weeks post-
intervention, with the intervention group scoring an average of 11 marks higher 
than the control group, which equates to a 22% difference (p<0.0001), and a 24% 
improvement from their own baseline score (p<0.0001 using paired t-test for within 
group analysis). This significance was maintained at 12 weeks. There was no 
significant difference in scores within the control group between baseline and the 
12 week assessment. There was no significant difference in scores at any time-point 
between interns, SHOs and registrars, or between doctors working in internal 
medicine, geriatric medicine or surgery. Interns improved the most between 
baseline and 4 week post-intervention with a mean difference of 7.2 marks, 
however this was not significantly better compared to SHOs and registrars (interns 
versus SHOs p=0.804, interns versus registrars p=0.874 using paired t-tests for 
within group analysis). 
Table 4.3: Scores from control and intervention groups for each assessment  
Assessment Control group Intervention 
group 
p value 
(independent 
two-tailed t test) 
95% Confidence 
intervals of the 
difference 
Baseline 
Mean marks out of 50 
(SD±) 
 
23.74 (5.88) 21.82 (6.1) 0.071 (-4.00 , 0.17) 
4 weeks post- 
intervention 
Mean marks out of 50 
(SD±) 
 
23.12 (5.93) 33.67 (5.99) <0.0001 (8.13 , 12.97) 
12 weeks post-
intervention 
Mean marks out of 50 
(SD±) 
 
22.88 (4.48) 32.63 (4.59) <0.0001 (7.72 , 11.76) 
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Table 4.4 shows the breakdown of scores for the multiple choice questions and the 
case studies in each assessment. There was no significant difference between 
control and intervention groups at baseline in the multiple choice questions or case 
studies (p=0.60 and 0.11 respectively). A significant difference was detected 
between the groups at 4 weeks post-intervention for both sets of questions, with 
the intervention group scoring an average of 4.65 marks higher than the control 
group in the MCQs, i.e a 23% difference (p<0.0001), and a 25% improvement from 
their own baseline score (p<0.0001 using paired t-test for within group analysis). 
This significance was maintained at 12 weeks. In the case studies, the intervention 
groups scored an average of 5.71 marks higher than the control group i.e a 19% 
difference (p<0.0001) and a 23% improvement from their own baseline score 
(p<0.0001 using paired t-test for within group analysis). There was no significant 
difference in scores within the control group between baseline and the 12 week 
assessments. 
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Table 4.4: Breakdown of scores for multiple choice questions and case studies  
Assessment Control group Intervention 
group 
p value 
(independent 
two-tailed t test) 
95% Confidence 
intervals of the 
difference 
MCQs 
Baseline MCQ 
Mean marks out 
of 20 (SD±) 
 
10.76 (3.26) 10.46 (3.19) 0.60 (-1.42 , 0.82) 
4 week MCQ  
Mean marks out 
of 20 (SD±) 
 
10.71 (3.02) 15.36 (2.91) <0.0001 (3.44 , 5.84) 
12 week MCQ 
Mean marks out 
of 20 (SD±) 
 
10.92 (3.52) 14.93 (3.33) <0.0001 (2.48 , 5.53) 
Case Studies 
Baseline Case 
Studies 
Mean marks out 
of 30 (SD±) 
12.98 (5.43) 11.36 (5.86) 0.11 (-3.58 , 0.35) 
4 week Case 
Studies 
Mean marks out 
of 30 (SD±) 
12.60 (5.68) 18.31 (5.64) <0.0001 (3.42 , 8.01) 
12 week Case 
Studies 
Mean marks out 
of 30 (SD±) 
11.96 (5.25) 17.70 (5.50) <0.0001 (3.34 , 8.13) 
 
At baseline, when asked to choose a statement best describing their confidence 
with regards to prescribing for older patients, 40% of participants in the 
intervention group, and 45% of participants in the control group chose ‘not 
confident at all’, with only 3% and 9% respectively choosing ‘confident’. When 
asked the same question at 4 weeks post-intervention, only 16% of participants in 
the intervention group rated themselves as ‘not confident at all’ with 34% choosing 
‘confident’. Figures in the control group remained much the same as baseline (‘not 
confident at all’=42%, ‘confident’=12%). When asked for their opinions on the 
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geriatric pharmacotherapy training they had received prior to this study, 50% 
reported ‘I did not receive sufficient training in geriatrics. I acquired, or am 
acquiring the necessary skills through practice, but feel there needs to be 
supplementary training also’. Participants were asked if they ever use tools such as 
the Beers criteria [63, 64, 66] or STOPP/START criteria [69, 70] to aid with 
prescribing optimisation in older patients. 60% were unaware of the Beers criteria 
and 55% were unaware of the STOPP/START criteria. Finally, participants were 
asked for their own opinions as to what specifically would benefit prescribing in 
older patients and would address PIP in older patients. Content analysis of the 
answers revealed three over-arching themes:  
(i) Supplementary training in Geriatric Medicine with more pronounced 
distinction made between older patients and the general adult 
population 
(ii) Improved IT support in terms of transfer between levels of care 
(iii) Increased communication between the levels of care i.e GPs, hospitals, 
pharmacies and nursing homes.  
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4.4 Discussion  
This study has shown that a short e-learning module can significantly improve 
doctors’ prescribing skills and prescribing confidence with regards to older patients. 
Furthermore, this is a sustainable improvement as shown by the scores after 12 
weeks. The low scores in both groups at baseline, and low scores of the control 
group at each time-point, indicate that prescribing for older patients is indeed a  
challenging task for NCHDs. This is not just true for interns, who have been the 
focus of some recent sub-optimal prescribing studies [209, 223, 224], but for all 
NCHDs, in all areas of practice. With more and more doctors from every specialist 
area  treating older patients on a day-to-day basis, these results illustrate the extent 
of NCHDs’ limitations with regard to geriatric pharmacotherapy.  Despite this, it is 
encouraging that an easy-to implement intervention such as this can significantly 
alter junior doctors’ level of knowledge of geriatric prescribing for the better in a 
relatively short period of time.  
Historically, studies such as this have not been followed up with research 
demonstrating a translation of these improved skills into actual improved patient 
outcomes [225]. While this study did not aim to demonstrate this, it is encouraging 
to note the significant improvement in participants’ scores in the case studies. 
These cases were taken from real-life patient records and are therefore a good  
representation of the doctors’ prescribing  skill  in actual clinical cases.  Our data 
show that the intervention not only enhanced the participants’ knowledge base, 
but also their decision making and overall prescribing skills.  
97 
 
The present study also shows an improvement in the participants’ self-reported 
confidence levels with regards to prescribing for older patients after the 
intervention.  Thirty four percent of doctors who completed the e-learning module 
reported feeling confident in their skills, compared to just 3% before the 
intervention. The low test scores  in both groups at baseline correlate well with the 
finding that half of all participants felt they did not receive enough training in 
geriatric pharmacotherapy  as undergraduates. This is compounded by the fact that 
over half of participants had never heard of the Beers criteria or the STOPP/START 
criteria, two well established tools for detecting potentially inappropriate  
prescribing in older patients.  Participants’ desire for supplementary training, 
improved IT support and increased communication between the levels of care 
further highlight the deficiencies that currently exist in the training and practice of 
doctors in relation to geriatric pharmacotherapy.  
Given the multiple factors that  contribute to PIP in older patients, future strategies 
to minimize PIP will  require a multi-faceted approach. This study  shows  that well-
structured, accessible prescriber education interventions such as this have a 
significant role in tackling PIP as an increasing clinical and public health problem. 
While further study is required to determine how improved prescribing skills 
translate into everyday practice and their effect on patient outcomes, it is a logical 
and reasonable assumption that non-complex, e-learning interventions will benefit 
doctors and older patients alike.  
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4.5 Limitations 
Participants in this trial were volunteers which presents an initial bias. There was a 
45% drop-out rate from recruitment to the final assessment at 12 weeks. Both 
these factors potentially reduce the reliability of the findings. Drop-out data was 
not included in the analysis. One possible method of handling the missing data 
would be to employ the ‘last observation carried forward (LOCF)’ method. This 
involves simply imputing values for participants who have dropped out based on 
their last recorded results. However, in a recent advisory report, the National 
Academy of Sciences recommended against the use of methods like LOCF due to 
the risk of underestimating the treatment effect [226]. Finally, as mentioned above, 
this study did not explore if the intervention resulted in improved patient 
outcomes. 
 
4.6 Conclusion 
PIP is a widespread problem across multiple grades of doctors in multiple areas of 
practice. Doctors often lack confidence in their skills as prescribers for older 
patients and feel poorly equipped to manage the complexities associated with older 
people, particularly frailer older people with multi-morbidity and associated 
complex polypharmacy. A short e-learning module focused on geriatric 
pharmacotherapy can significantly improve doctors’ prescribing skills and 
confidence with regards to older patients. Whether this results in actual 
improvements in appropriateness of prescribing for these patients remains to be 
seen. 
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5. Use of a frailty index to identify potentially 
inappropriate prescribing and adverse 
drug reaction risks in older patients 
 
Chapter description 
Chapters 2 and 3, clearly highlighted that doctors working lives, and working 
environments are chaotic and inconducive to appropriate prescribing. They simply 
do not have the time to review and assess every patients’ chart for 
appropriateness. Chapter 3 also showed that interventions based on ‘enablement’ 
would be potentially beneficial in addressing PIP. Therfore, it was decided to 
explore the potential of an intervention based on highlighting patients at increased 
risk of PIP/ADRs to doctors by way of a simple indicator on the front of their chart 
or in their medical notes. 
 
 
 
The work of this chapter has been accepted for publishing in Age and Ageing and is 
currently in press. 
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5.1 Introduction 
 
Much quantitative research has taken place in recent times to identify the 
prevalence and severity of PIP. Interest is currently focused on identifying the 
causal factors surrounding this phenomenon in an effort to minimise and prevent 
PIP and its effects. Chapters 2, 3 and 4 identified several areas for such intervention 
[156, 215]. It has been shown that doctors often possess an inherent fear of 
changing a patient’s prescription, even when they know it may not be appropriate 
for that patient [156]. For other prescribers, checking for appropriateness of 
medications is a low priority [156]. Doctors are quite aware that PIP is a significant 
problem, but busy working environments, lack of time for prescription surveillance 
and lack of specific geriatric pharmacotherapy training all serve as barriers to 
optimal prescribing for older patients in their minds [215]. Considering these issues, 
one can hypothesise that, if doctors were given a single indicator of PIP and 
consequent ADR risk on a patient’s prescription, it might stimulate them to review 
the medicines on that prescription, with a view to minimising PIP. It was suggested 
that a frailty index (FI) score may be such a suitable indicator.  
Frailty is defined as a clinical state in older vulnerable adults arising from age-
associated decline in physiological functions across multiple organ systems, 
resulting in a diminished ability to respond to physiological stressors [227-230]. In 
recent years, the importance of frailty and its identification in older patients has 
been recognised and the literature has seen a rise in studies exploring the link 
between frailty and several adverse health outcomes related to cardiovascular 
health, cognitive performance, depression, quality of life, falls, post-op recovery, 
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altered pharmacokinetics of medications, hospitalisations and mortality [91, 231-
238].  
The pathogenesis of frailty has also been extensively researched and a number of 
key pathophysiological processes have been reported as instrumental in the 
development of frailty. Underlying chronic inflammation and immune system 
activation have been shown to be possibly the most significant contributory factor 
to frailty [239-254]. Loss of muscle mass and strength, also known as sarcopenia, 
has also been shown to be a likely contributor to frailty and research into same is 
regarded as a potential intervention area for frailty [255, 256]. Age-related declines 
in hormones such as oestrogen, testosterone, cortisol and vitamin D have also been 
linked to frailty [257-259], as well as mid-life obesity [260-263]. 
While frailty itself is a syndrome which requires therapy such as exercise and 
comprehensive geriatric assessments [227, 264-267], it is also considered a useful 
clinical tool for identification of adverse outcome risk in older patients [91, 229, 
261, 268]. However, although there has been considerable efforts to reach 
international consensus on frailty [269], there has been much debate as to how 
best to define, measure and utilise frailty identification for this purpose. Several 
tools have been developed to identify and measure frailty such as FRAIL (Fatigue, 
Resistance, Ambulation, Illnesses, Loss of weight) (International Academy of 
Nutrition and Aging) [270], Frailty Instrument for Primary Care of the Survey of 
Health, Ageing and Retirement in Europe (SHARE-FI) [271], and the Groningen 
Frailty Indicator [272]. However two in particular have dominated the literature.  
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Firstly, the frailty phenotype, developed by Fried et al. diagnoses frailty if a patient 
meets three or more of five criteria:  
(i) Weakness as measured by low grip strength 
(ii) Slowness by slowed walking speed 
(iii) Low level of physical activity 
(iv) Low energy or self-reported exhaustion 
(v) Unintentional weight loss [229].  
 
The second, is the frailty index (FI) [273]. The FI is based on a comprehensive 
geriatric assessment by counting the number of deficits accumulated, including 
diseases, physical and cognitive impairments, psychosocial risk factors, and 
common geriatric syndromes. The number of variables included in an FI typically 
ranges from 30-70 [274] and each variable must meet 5 criteria to be included:  
(i) The variables must be deficits associated with health status 
(ii) A deficit's prevalence must generally increase with age 
(iii) Similarly, the chosen deficits must not saturate too early 
(iv) When considering the candidate deficits as a group, the deficits that 
make up an FI must cover a range of systems 
(v) If a single FI is to be used on a sample of patients, the items that make 
up the FI need to be the same from one iteration to the next. The 
requirement to use the same items need not apply to comparisons 
between samples – i.e. samples that use difference FIs appear to yield 
103 
 
similar results [268, 275]. This is useful as the same information 
regarding deficits is not always available in different sites.  
The number of deficits a patient has is then summated and the result is divided by 
the number of variables to yield an FI score of between 0 and 1. 
The FI was originally developed as a means of assessing individual aging [276]. 
While age alone is an important determinant of health and survival, the older a 
population becomes, the more variance is observed in health [277] i.e individuals of 
the same age can differ greatly from each other in terms of general health, hence 
the need for a more accurate measurement of health status. Since the FI was 
developed, it has been extensively researched and assessed with regards to its 
relevance and generalizability [268, 278-282]. Interestingly, results from multiple 
different studies, all using different combinations of deficits have been consistent 
[275]. As reported by Searle et al: “this indicates that frailty can be measured in 
many ways, and therefore can be studied in many existing datasets that might not 
have set out to measure frailty per se” [275]. 
Recently, Cesari et al. showed that, although the frailty phenotype and frailty index 
are often thought of as alternatives to each other, they are different instruments, 
with different purposes, and should therefore be seen as complementary to one 
another [283].  
There has been much debate as to how best to operationalise frailty assessment 
scales and utilise them effectively in everyday practise [284, 285]. The majority of 
studies exploring frailty and it’s significance focus on the correlation between it and 
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mortality or adverse outcomes such as hospitalisation, self-reported quality of life, 
intensity of treatment, nursing home admission, after-hours GP visit or social 
vulnerability [286]. No published studies have explored the link between frailty and 
increased risk of potentially inappropriate prescribing (PIP) and adverse drug 
reactions (ADRs). 
If a positive relationship between these entities exists, then an FI score above a 
certain threshold could be used as an indicator to prescribers that a patient’s 
medications should be reviewed for instances of PIP/potential ADRs. Whether this 
approach is superior to, for example, just using the number of medications a 
patient takes to identify risk of PIP/ADRs is unknown. 
The aim of this chapter is to determine whether such a relationship between a 
patient’s frailty, the appropriateness of their medications and their likelihood of 
developing ADRs exists, and whether this is a more useful approach than just using 
the number of medications alone to identify patients for review. 
5.2 Methods 
An FI was constructed using methods outlined by Searle et al. [275], and applied to 
a database of comprehensive geriatric assessments for 737 hospital in-patients. 
Details of the construction of the FI are outlined below. An FI was chosen over a 
frailty phenotype as the frailty phenotype is typically more suitable when applied at 
first contact with the patient [283]. Also, the frailty phenotype may lose some of its 
clinical relevance when applied to older patients already experiencing disability 
[283], which it was felt would be the case in a high proportion of patients in the 
database.  
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The FI was then used to assign each patient an FI score. The correlation between 
this score and the number of instances of PIP on a patient’s prescription, as well as 
patients’ likelihood of developing ADRs was then explored and compared to just 
using the number of medications taken by the patient.  
 
5.2.1 Construction of patient database 
 
The database used for this study was previously compiled as part of a randomised 
controlled trial assessing the impact of a structured pharmacist intervention on the 
appropriateness of in-patients’ medications [287]. In all, 737 patients underwent a 
comprehensive geriatric assessment on admission to hospital. Information relating 
to their physical and mental well-being was collected and these details were 
entered directly into an electronic database (Microsoft Access™). 
5.2.2 Construction of frailty index 
 
All the variables collected to form the database were assessed for suitability for 
inclusion in the FI using the criteria suggested by Searle et al [275]. Although it has 
been reported that frailty indices comprising a minimum of 50 variables are robust 
[283], shorter versions (as low as 20) have been utilised and shown to be 
sufficiently accurate for predicting adverse outcomes [278]. 
All binary variables were coded as 1 or 0 (1 indicating presence of the deficit, 0 
indicating absence of the deficit). To code continuous variables, an interim index, 
consisting of only binary variables was established. The purpose of this interim 
index was to provide cut-off points for the continuous variables. These variables 
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were correlated with the interim index and the mean value corresponding to 0.2 on 
the interim index was used as that variable’s cut-off point. An FI score of 0.2 is 
recognised by multiple frailty measures as approaching a frail state [229, 279, 280]. 
Using the completed index, each patient was then given an FI score by summating 
all the deficits present for that patient and dividing by the total number of 
variables.  
5.2.3 Statistical analysis 
 
To explore the relationship between frailty and appropriateness of patients’ 
medications, each patient’s FI score was correlated with the number of breaches of 
STOPP criteria (version 1) (Appendix XIV) [69] identified within that patient’s 
prescription. Version 1 was used as this was the version originally applied to the 
database. STOPP criteria identify more common instances of PIP. The median 
number of breaches of the STOPP criteria was then determined for each point of 
the frailty score scale. Pearson correlation tests and linear regression using 95% 
confidence intervals were performed to quantify the relationship. The mean FI 
score above which patients were found to have at least one instance of PIP present 
on their prescription was then determined to identify an FI threshold that could be 
used to identify frailer older patients at risk of PIP/ADRs, and therefore needing 
medication review. A similar threshold was obtained for ‘number of medications’ so 
this could be compared to the FI to see which performed better in terms of 
identifying patients at risk of PIP/ADRs. 
ADR ascertainment in the original RCT was based on the WHO ADR definiton, i.e. “a 
response to a drug which is noxious and unintended and which occurs at doses 
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normally used in man for the prophylaxis, diagnosis, or therapy of disease or for the 
modification of physiological function”.  The research pharmacist performed ADR 
ascertainment, facilitated by the use of a pre-defined ADR trigger list consisting of 
the ten most common clinical manifestations of proven ADRs, derived from a 
combined database of two recent studies of 600 [24] and 513 [38]  elderly 
hospitalized patients. For each ADR, the primary researcher recorded details of the 
suspect medication(s), i.e. dose, formulation and duration, as well as a description 
of the ADR and any actions taken to resolve it. A physician trained in Geriatric 
Medicine and experienced in Geriatric Pharmacology/Therapeutics reviewed and 
verified all ADRs identified by the primary researcher.  
The number of patients experiencing at least one instance of PIP/ADR within 7 days 
of their hospital stay, on both sides of this threshold was then compared. The 
extent to which an instance of PIP/ADR was dependent on frailty was quantified by 
a chi-square test, and the risk associated with being in either group was determined 
by calculating odds ratios.  
This same procedure was applied using the ‘number of medications’ threshold.  
Ethical approval for this study was sought from and granted by the Clinical Research 
Ethics Committee, University College Cork (Appendix XV). 
5.3 Results 
 
From all the variables in the database, 34 were deemed suitable for inclusion in the 
FI as per the methods proposed by Searle et al [275]. 711 patients in the database 
had the information required for inclusion. Mean age of participants was 74. Of the 
108 
 
34 variables, 32 were binary and 2 were continuous (number of medications and 
abbreviated mental test score (AMTS)). The variables and their cut off points (for 
the continuous variables) are displayed in Table 5.1. These were determined by 
correlating the continuous variables with the interim index consisting only of binary 
variables, and identifying the values corresponding to a frailty score of 0.2 on the 
interim index. 
Table 5.1: Variables and cut-off points used for frailty index 
 Variable Cut-off point 
1. Needs help grooming Yes=1   No=0 
2. Needs help using toilet Yes=1   No=0  
3. Needs help feeding Yes=1   No=0 
4. Needs help with transfer Yes=1   No=0 
5. Needs help mobilising Yes=1   No=0 
6. Needs help dressing Yes=1   No=0 
7. Needs help with stairs Yes=1   No=0 
8. Needs help bathing Yes=1   No=0 
9. Dementia/cognitive impairment Yes=1   No=0 
10. On-going constipation Yes=1   No=0 
11. Fall in the last 3 months Yes=1   No=0 
12. Difficulty swallowing Yes=1   No=0 
13. Trouble sleeping Yes=1   No=0 
14. Previous myocardial infarction Yes=1   No=0 
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15. Hypertension Yes=1   No=0 
16. Congestive cardiac failure Yes=1   No=0 
17. Peripheral vascular disease Yes=1   No=0 
18. Cerebrovascular disease Yes=1   No=0 
19. Chronic pulmonary disease Yes=1   No=0 
20. Rheumatological disease Yes=1   No=0 
21. Peptic ulcer disease Yes=1   No=0 
22. Mild or moderate liver disease Yes=1   No=0 
23. Diabetes Yes=1   No=0 
24. Diabetes with complications Yes=1   No=0 
25. Hemiplegia or paraplegia Yes=1   No=0 
26. Renal disease Yes=1   No=0 
27. Any malignancy Yes=1   No=0 
28. Moderate or severe liver disease Yes=1   No=0 
29. Metastatic solid tumour Yes=1   No=0 
30. Incontinence (bowels) Yes=1   No=0 
31. Incontinence (bladder) Yes=1   No=0 
32. Self-reported depression Yes=1   No=0 
33. Number of medications >=6=1   <6=0 
34. AMTS (Abbreviated Mental Test Score) <=8=1     >8=0 
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FI scores among the 711 patients ranged from 0 to 0.51, with a mean of 0.15 
(±0.09). Data was normally distributed with a slight positive skew (skewness = 
1.137), see Figure 5.1. 
 
 
 
Figure 5.1: Distribution of Frailty Index (FI) scores 
 
 
403 patients experienced at least one instance of PIP, defined by a breach of the 
STOPP guidelines, within seven days of their hospital stay. In these 403 patients, 
there were a total of 733 instances of PIP. 
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Figure 5.2 shows the frailty scores plotted against the median number of breaches 
of the STOPP criteria for each observed point on the FI scale. A significant 
correlation between FI score and median number of STOPP breaches was observed 
(R=0.92). Median was chosen as although the number of breaches of the STOPP 
criteria was also normally distributed, the skewness was greater (skewness = 
2.011). 
 
Frailty index (FI) score 
Figure 5.2: Frailty index score plotted against Median number of breaches of the STOPP 
criteria 
Table 5.2 summarises the results of the Pearson correlation and linear regression 
tests. The Pearson coefficient of 0.92 is significant (p < 0.0001). The R squared value 
of 0.837 illustrates that 83.7% of the variance within the number of instances of PIP 
experienced by patients can be accounted for by their FI scores. The 
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unstandardized beta coefficient of 0.488 suggests that for each 0.1 rise in FI score, 
the number of instances of PIP rises by 0.488. The intercept value of 0.04 is the 
number of instances of PIP that can be expected when FI score is equalled to zero. 
 
Table 5.2: Results of Pearson correlation and linear regression 
 Value P value 95% confidence 
intervals 
Pearson 
correlation (R) 
0.915 < 0.0001 N/A 
R squared 0.837 N/A N/A 
Unstandardised 
Beta coefficient 
0.488 N/A 0.4062 , 0.5698 
Intercept 0.04 N/A -0.187 , 0.267 
 
 
To determine the threshold above which a patient should be brought to the 
attention of the prescriber, the mean FI score at which the median number of 
STOPP breaches was equal to one i.e the FI score at which patients had at least one 
instance of PIP on their prescription was calculated. This was shown to be 0.16. 
Figure 5.3 shows how this threshold was determined.  
 
As the ‘number of medications’ is a continuous variable in the FI the threshold for 
this was determined as described above, by identifying the mean number of 
medications taken by patients with a FI score of 0.2 on the interim index. This was 
found to be 6. 
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FI score 
Figure 5.3: The mean FI score, above which patients had at least one instance of PIP 
present on their prescription is 0.16 
 
In order to determine if adverse outcomes such as PIP and ADRs are actually 
dependent on frailty status/number of medications, chi square tests were 
performed using the following cross-tabulations, Tables 5.3 and 5.4. The results are 
summarised in Table 5.5.  
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Table 5.3: The differences in PIP/ADR occurrence on both sides of frailty index threshold 
(expressed as number of patients experiencing/not experiencing at least 1 instance of 
PIP/ADR) 
 Patients with PIP Patients with 
No PIP 
Total 
Frailty index 
score < 0.16 
155 192 347 
Frailty index 
score ≥ to 0.16 
248 116 364 
Total 403 308 711 
 
 Patients with 
ADRs 
Patients with 
No ADRs 
Total 
Frailty index 
score < 0.16 
57 290 347 
Frailty index ≥ 
to 0.16 
107 257 364 
Total 164 547 711 
 
 
Table 5.3 shows the number of patients that experienced at least 1 instance of PIP, 
as well as the number of patients who experienced no PIP, both above and below 
the FI threshold of 0.16. 68.1% of patients with an FI score of greater than or equal 
to 0.16 experienced at least one instance of PIP compared to just 44.7% of patients 
with score of less than 0.16. Also displayed in Table 5.3 is the number of patients 
that experienced at least 1 ADR, as well as the number of patients who experienced 
no ADRs, both above and below the FI threshold. 29.4% of patients with an FI score 
greater than or equal to 0.16 experienced at least on ADR compared to just 16.4% 
of patients with score of less than 0.16. 
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Table 5.4: The differences in PIP/ADR occurrence on both sides of the number of 
medications threshold (expressed as number of patients experiencing/not experiencing 
at least 1 instance of PIP/ADR) 
 Patients with PIP Patients with 
No PIP 
Total 
< 6 medicines 
 
77 128 205 
≥ 6 medicines 
 
326 180 506 
Total 403 308 711 
 
 Patients with 
ADRs 
Patients with 
No ADRs 
Total 
< 6 medicines 
 
55 150 205 
≥ 6 medicines 
 
109 397 506 
Total 164 547 711 
 
 
Table 5.4 shows number of patients that experienced at least 1 instance of PIP, as 
well as the number of patients who experienced no PIP, both above and below the 
‘number of medications’ threshold of 6. 64.4% of patients taking 6 or more 
medications experienced at least one instance of PIP compared to just 37.6% of 
patients with less than 6 medications.  
Also displayed in Table 5.4 is the number of patients that experienced at least 1 
ADR, as well as the number of patients who experienced no ADRs, both above and 
below the ‘number of medications’ threshold. 21.5% of patients with 6 or more 
medications experienced at least one ADR compared to just 26.8% of patients with 
less than 6 medications.  
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Table 5.5 compares the FI with just using ‘number of medications’ by way of 
association with PIP and ADR occurrence. 
Table 5.5: Association between frailty index score, number of medication, PIP occurrence 
and ADR occurrence 
 
 
 
 
 
Patients with FI 
score ≥ to 0.16 
% Experiencing at least 
1 ADR 
Odds ratio and 
95% CI 
Chi-
square 
p value 
29.4% 
 
(Compared to 16.7% of 
patients with FI < 0.16) 
 
2.1 (1.474, 3.044) 16.030 <0.0001 
% Experiencing at least 
1 instance of PIP 
Odds ratio and 
95% CIC 
Chi-
square 
p value 
68.1% 
 
(Compared to 44.7% of 
patients with FI < 0.16) 
 
2.6 (2.0, 3.6) 39.831 <0.0001 
Patients taking 
more than 6 
medications 
% Experiencing  at least 
1 ADR 
Odds ratio and 
95% CI 
Chi-
square 
p Value 
21.5% 
 
(Compared to 26.8% of 
patients with less than 6 
medicines) 
0.75 (0.515 , 1.089) 2.299 0.129 
% Experiencing at least 
1 instance of PIP 
Odds ratio and 
95% CIC 
Chi-
square 
p value 
64.4% 
 
(Compared to 37.6% of 
patients with less than 6 
medicines) 
3.01 (2.15 , 4.21) 42.887 <0.0001 
 
Patients with an FI score greater than or equal to 0.16 were twice as likely to 
experience at least one instance of PIP, and twice as likely to experience at least 
one ADR during the index hospitalisation. 
Instances of PIP and instances of ADRs were found to be significantly dependent on 
frailty scores (p < 0.0001 for both.) 
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Patients taking more than 6 medications were not statistically more likely to 
experience an ADR, however, were 3 times more likely to experience at least one 
instance of PIP. 
PIP was found to be highly dependent on number of medications taken (p<0.0001). 
ADR occurrence was not significantly dependent on number of medications 
(P=0.129) 
5.4 Discussion 
 
5.4.1 Implications for clinical practice 
The principal novel findings in this study are:  
(i) A significant positive relationship between a patient’s frailty status and the 
appropriateness of their medications exists. This is a clinically relevant finding as 
frailty is relatively easily quantified using an FI, when compared to medication 
appropriateness, which is not as easily determined, and is often not acted upon 
when PIP is identified [156]. These findings show that an FI score greater than 0.16 
would be a suitable prompt for prescribers to review a patient’s medications, with a 
view to minimising PIP.  
(ii) As mentioned, an FI score of 0.2 has traditionally been accepted as ‘approaching 
frailty’ [229, 279, 280]. It appears logical therefore to use this as the threshold, 
above which a patient’s prescription would be highlighted to a prescriber for 
review. However, the present study shows that at a frailty score of 0.16 and above, 
most patients will have at least one instance of PIP on their prescription list. This 
difference of 0.04 in the FI score equates to 1 less deficit a patient would need to be 
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considered ‘at risk’ (using a 34 variable FI such as the one presented here). This 
becomes significant when we consider that 95% of the patients in the database had 
less than 10 of the deficits in the frailty index.  
(iii) The results of the statistical analysis strengthen the argument for using an FI 
score as a means of identifying patients at risk of PIP and associated ADRs. Almost 
84% of the variance within the number of instances of PIP was accounted for by 
patients’ FI scores. Highly significant p values and odds ratios greater than 2.0, all 
indicate that patients with an FI score ≥ 0.16 are at significantly increased risk of PIP 
and ADRs. Furthermore, when the FI is compared to just using ‘number of 
medications’, we see that while both ADR and PIP occurrence are significantly 
dependent on FI scores, only PIP is significantly dependent on ‘number of 
medications’. In fact, patients taking more than 6 medications were 3 times more 
likely to experience PIP. Therefore, while this suggests an FI is superior in terms of 
identifying patients at risk of both ADRs and PIP, utilisation of both a frailty index 
threshold and a ‘number of medications’ threshold would seem to be the optimum 
i.e patients with FI score ≥ 0.16 and taking more than 6 medications are at high risk 
for PIP and ADRs.  
FI scores and PIP criteria may not secure the attention of some prescribers. 
However, most physicians are aware of ADRs and accept that they are an area of 
concern in frailer older patients [288]. Therefore, if a patient is highlighted to a 
doctor on the basis of a frailty score above a threshold that indicates a heightened 
risk of that patient experiencing an ADR, it is likely to carry more significance to the 
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doctor than simply indicating that the patient is taking a potentially inappropriate 
medication (PIM).  
5.4.2 Implications for future research 
Implementation of this initiative to determine if it successfully reduces PIP rates 
and ADR rates in a clinical setting is the next logical step in terms of research. This 
idea of intervention based on the concept of enablement has recently been 
suggested as an area that should be targeted to reduce PIP [215]. Historically, the 
quality of interventions aimed at reducing PIP has been questionable [289]. 
However, it is only in recent times that qualitative research methodologies have 
been utilised to inform such interventions. If these methodologies are implemented 
correctly, the result could be more targeted interventions with quantifiably better 
clinical outcomes. 
It should also be considered, that while older patients are often under the care of 
multiple doctors, their primary care physician is in the best position to oversee the 
management of their care. Previous studies have shown that a FI can be 
operationalised in primary care using routinely gathered data [290, 291]. Future 
research in primary care settings, identifying cut-off points for continuous variables 
and implementing systems to identify frailty could potentially lead to improved care 
for these patients.  
While it has been shown that an intervention based upon highlighting patients with 
an FI score above a certain threshold to prescribers for careful medication review 
would be justified, nevertheless, educational interventions focused on specific 
aspects of geriatric pharmacotherapy are still required to enable doctors make 
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clinically sound decisions in frailer, older, multi-morbid patients with polypharmacy. 
This need for tailored training has been raised in several studies to date and has 
also been shown to be effective in preventing PIP [52, 215].  
 
5.5 Limitations 
The dataset used for this study was limited to 711 patients.  
A prospective study to validate the FI would be of benefit. 
The health economic impact of the tool and its implications would be warranted. 
While much of the patient data used to create the FI is routinely available, 
collecting all the data required may be somewhat complex in secondary care and 
may negatively impact the feasibility of such an initiative being implemented. 
The dataset used for this study utilised STOPP/START version 1. The STOPP/START 
guidelines have since been updated and now contain 22 new STOPP rules and 12 
new START rules as well as new categories in each [70] (Appendix XIII). Given that 
this study used breaches of STOPP/START criteria to determine appropriateness of 
patients’ medications, the methodologies should be repeated using the updated 
guidelines.  
The max FI score in this study was 0.51. This is considerably lower than the 
commonly reported 99% limit to deficit accumulation seen in secondary care (0.69) 
[292]. This limits the generalisability of these results and warrants further research. 
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5.6 Conclusion 
 
A significant positive relationship exists between a patient’s frailty status, the 
appropriateness of their medications and their likelihood of developing an ADR. At 
an FI score of 0.16 and higher, patients are twice as likely to have at least one PIM 
prescribed. Also, patients above this threshold are twice as likely to experience an 
ADR compared to those below the threshold. While ADR occurrence is not 
significantly dependent on the number of medications a patient takes, PIP is. 
Therefore the use of both a FI as well as ‘number of medications’ seems the best 
approach to identify patients at risk.
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6. Application of a frailty index threshold to 
identify older patients at risk of 
potentially inappropriate prescribing and 
adverse drug reactions: A prospective 
observational study 
 
Chapter description 
In this chapter, the findings from chapter 5 were applied to a different patient 
group using a modified version of the frailty index to validate and reinforce the 
conclusions in the previous chapter. 
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6.1 Introduction 
In chapter 5, it was shown that there is significant correlation between a patient’s 
frailty status (as measured by the frailty index (FI)), and their propensity to 
experience PIP and ADRs (R=0.92). It was found that at an FI score of 0.16 and 
above, patients were twice as likely to experience both PIP and ADRs (p<0.0001). 
This approach was compared to using the number of medications a patient took as 
an indicator of PIP/ADR risk. This revealed that while the FI threshold of 0.16 
identified patients at risk of both PIP and ADRs, just using a ‘number of medications’ 
threshold of 6 (identified by correlating number of medications to an interim FI), 
was only useful in identifying patients at risk of PIP, albeit PIP was found to be 
highly dependent on the number of medications. Patients above this threshold 
were three times more likely to experience PIP (p<0.0001). It was concluded 
therefore, that using both an FI and number of medications as tools to identify 
patients at risk of PIP/ADRs was superior to using either method in isolation i.e 
patients with an FI score ≥ 0.16 and taking 6 or more medications are at high risk of 
PIP/ADRs. 
The aims of this chapter were:  
(i) To apply the FI threshold of 0.16 to a new set of patients’ data to 
determine if the results seen in Chapter 5 are reproducible, and in doing 
this, validate those results,  
(ii) To compare the use of an FI in isolation to using the number of 
medications a patient takes to identify those at risk of PIP/ADRs. 
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6.2 Methods 
An FI was constructed using methods outlined by Searle et al. [275], and applied to 
comprehensive geriatric assessments for 545 hospital in-patients. Details of the 
construction of the FI are outlined below.  
The FI was then used to assign each patient an FI score. Patients above and below 
the threshold of 0.16 were identified and the relationship between their frailty 
status and instances of PIP (as defined by the STOPP guidelines [69]) and ADRs was 
then explored to determine if this threshold identifies patients at risk. This was 
compared to simply using the number of medications threshold of 6, as in Chapter 
5.  
6.2.1 Patient group 
This study was carried out as a sub-study of an ongoing, larger randomised 
controlled trial (Development and clinical trials of a new Software ENgine for the 
Assessment & optimization of drug and non-drug Therapy in Older peRsons-
SENATOR) in six hospitals across Europe. The sites include:  
(i) Cork University Hospital, Ireland 
(ii) Ghent University Hospital, Belgium 
(iii) Hospital Universitario Ramón y Cajal, Spain 
(iv) Landspitali University Hospital Reykjavik, Iceland 
(v) Aberdeen Royal Infirmary, Scotland  
(vi) Ospidale Riuniti, Ancona, Italy.  
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As per the SENATOR trial protocol, patients over the age of 65 presenting to the 
emergency department with an acute illness requiring admission, ≥ 3 chronic 
medical disorders and being under the care of a specialist other than a geriatrician, 
palliative medicine physician, haematologist, oncologist or clinical pharmacologist 
were included in the study within 72 hours of arrival. Exclusion criteria included: 
elective hospitalisation, direct admission to intensive care unit and documented 
plan for consultation with geriatric medicine. All patients signed a consent form 
after they were informed of the study. In the case of cognitive impairment, a care-
giver signed consent by proxy. 
6.2.2 Construction of the frailty index 
All the variables collected as part of the SENATOR trial were assessed for suitability 
for inclusion in the frailty index using the criteria suggested by Searle et al [275].  
All binary variables were coded as 1 or 0 (1 indicating presence of the deficit, 0 
indicating absence of the deficit). To code continuous variables, an interim index, 
consisting of only binary variables was established. The purpose of this interim 
index was to provide cut-off points for the continuous variables. These variables 
were correlated with the interim index and the mean value corresponding to 0.2 on 
the interim index was used as that variable’s cut-off point. An FI score of 0.2 is 
recognised by multiple frailty measures as approaching a frail state [229, 279, 280]. 
Using the completed index, each patient was then given an FI score by summating 
all the deficits present for that patient and dividing by the total number of 
variables.  
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6.2.3 Statistical analysis 
The numbers of patients experiencing at least one instance of PIP/ADR within 7 
days of their hospital stay, on both sides of the FI threshold were then compared. 
The extent to which an instance of PIP/ADR was dependent on frailty was 
quantified by a chi-square test, and the risk associated with being in either group 
was determined by calculating odds ratios.  
This same procedure was applied using the ‘number of medications’ threshold.  
Ethical approval for this study was sought from and granted by the Clinical Research 
Ethics Committee, University College Cork as part of the SENATOR study (see 
appendix XVI). 
 
6.3 Results 
From all the deficits measured as part of the SENATOR trial, 34 were deemed 
suitable for inclusion in the FI as per the methods proposed by Searle et al. [275]. 
Twenty of these were identical to those used in chapter 5. The full list of 34 
variables is presented in Table 6.1. While not identical to those in Chapter 5, these 
variables still cover the same array of physiological systems and deficits. 518 
patients had the information required for inclusion as of July 2015. Mean age of 
participants was 82 (±7 years). Of the 34 variables, 32 were binary and 2 were 
continuous (number of medications and Mini Mental State Examination (MMSE) 
score). The variables and their cut off points (for the continuous variables) are 
displayed in Table 6.1. These were determined by correlating the continuous 
127 
 
variables with the interim index consisting only of binary variables, and identifying 
the values corresponding to a frailty score of 0.2 on the interim index. 
Table 6.1: Variables and cut-off points used for frailty index. Variables marked with * did 
not appear in Chapter 5 
 Variable Cut-off point 
1. Needs help grooming Yes=1   No=0 
2. Needs help using toilet Yes=1   No=0  
3. Needs help feeding Yes=1   No=0 
4. Needs help with transfer Yes=1   No=0 
5. Needs help mobilising Yes=1   No=0 
6. Needs help dressing Yes=1   No=0 
7. Needs help with stairs Yes=1   No=0 
8. Needs help bathing Yes=1   No=0 
9. Dementia/cognitive impairment Yes=1   No=0 
10. Respiratory disease (other than COPD)* Yes=1   No=0 
11. Fall in the last 3 months Yes=1   No=0 
12. Upper GI disease* Yes=1   No=0 
13. Lower GI disease* Yes=1   No=0 
14. Chronic Pain/discomfort* Yes=1   No=0 
15. Hypertension Yes=1   No=0 
16. Congestive cardiac failure Yes=1   No=0 
17. Previous ADR* Yes=1   No=0 
18. Cerebrovascular disease Yes=1   No=0 
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19. Delirium* Yes=1   No=0 
20. Arthritis* Yes=1   No=0 
21. COPD* Yes=1   No=0 
22. Mild or moderate liver disease Yes=1   No=0 
23. Diabetes Yes=1   No=0 
24. Vision impairment* Yes=1   No=0 
25. Hearing impairment* Yes=1   No=0 
26. Renal disease Yes=1   No=0 
27. Stroke* Yes=1   No=0 
28. Osteoporosis* Yes=1   No=0 
29. Malnutrition* Yes=1   No=0 
30. Incontinence (bowels) Yes=1   No=0 
31. Incontinence (bladder) Yes=1   No=0 
32. Self-reported depression Yes=1   No=0 
33. Number of medications ≥ 6=1   < 6=0 
34. Mini Mental State Examination (MMSE)* ≤ 25=1     >25=0 
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FI scores among the 518 patients ranged from 0.06 to 0.85, with a mean of 0.36 
(±0.16). Data was normally distributed with a slight positive skewness (skewness = 
0.419), see Figure 6.1. 
 
Figure 6.1: Distribution of frailty index scores 
 
351 patients experienced at least one instance of PIP, defined by a breach of the 
STOPP guidelines, within seven days of their hospital stay. 253 patients experienced 
at least 1 ADR. 
In order to determine if adverse outcomes such as PIP and ADRs are actually 
dependent on frailty status/number of medications, chi square tests were 
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performed using the following cross-tabulations, Tables 6.2 and 6.3. The results are 
summarised in Table 6.4.  
 
Table 6.2: The differences in PIP/ADR occurrence on both sides of frailty index threshold 
(expressed as number of patients experiencing/not experiencing at least 1 instance of 
PIP) 
 Patients with 
PIP 
Patients 
with No PIP 
Total 
Frailty index score 
< 0.16 
31 21 52 
Frailty index score 
≥ to 0.16 
320 146 466 
Total 351 167 518 
 
 Patients with 
ADRs 
Patients 
with No 
ADRs 
Total 
Frailty index score 
< 0.16 
14 38 52 
Frailty index score 
≥ to 0.16 
239 227 466 
Total 253 265 518 
 
 
Table 6.2 shows the number of patients that experienced at least 1 instance of PIP, 
as well as the number of patients who experienced no PIP, both above and below 
the FI threshold of 0.16. 68.7% of patients with an FI score of greater than or equal 
to 0.16 experienced at least one instance of PIP compared to 59.6% of patients with 
score of less than 0.16. Also displayed in Table 6.2 is the number of patients that 
experienced at least 1 ADR, as well as the number of patients who experienced no 
ADRs, both above and below the FI threshold of 0.16. 51.3% of patients with an FI 
score greater than or equal to 0.16 experienced at least on ADR compared to just 
26.9% of patients with score of less than 0.16. 
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Table 6.3: The differences in PIP/ADR occurrence on both sides of the number of 
medications threshold (expressed as number of patients experiencing/not experiencing 
at least 1 instance of PIP) 
 Patients with 
PIP 
Patients with 
No PIP 
Total 
Number of meds 
< 6 
108 87 195 
Number of meds 
≥ to 6 
243 80 323 
Total 351 167 518 
 
 Patients with 
ADRs 
Patients with 
No ADRs 
Total 
Number of meds 
< 6 
88 107 195 
Number of meds 
≥ to 6 
165 158 323 
Total 253 265 518 
 
 
Table 6.3 shows number of patients that experienced at least 1 instance of PIP, as 
well as the number of patients who experienced no PIP, both above and below the 
‘number of medications’ threshold of 6. 75.2% of patients taking 6 or more 
medications experienced at least one instance of PIP compared to 55.4% of patients 
with less than 6 medications.  
Also displayed in Table 6.3 is the number of patients that experienced at least 1 
ADR, as well as the number of patients who experienced no ADRs, both above and 
below the ‘number of medications’ threshold. 51.1% of patients with 6 or more 
medications experienced at least one ADR compared to 45.1% of patients with less 
than 6 medications.  
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Table 6.4 compares the FI with just using ‘number of medications’ by way of 
association with PIP and ADR occurrence. 
Table 6.4: Association between frailty index score, number of medications, PIP 
occurrence and ADR occurrence 
 
 
 
 
 
Patients with 
FI score ≥ to 
0.16 
% Experiencing at least 
1 ADR 
Odds ratio and 
95% CI 
Chi-
square 
p value 
51.3% 
 
(Compared to 26.9% of 
patients with FI < 0.16) 
 
2.86 (1.51, 5.42) 11.114 0.001 
% Experiencing at least 
1 instance of PIP 
Odds ratio and 
95% CIC 
Chi-
square 
p value 
68.7% 
 
(Compared to 59.6% of 
patients with FI < 0.16) 
 
1.49 (0.83, 2.67) 1.755 0.185 
Patients taking 
more than 6 
medications 
% Experiencing  at least 
1 ADR 
Odds ratio and 
95% CI 
Chi-
square 
p Value 
51.1% 
 
(Compared to 45.1% of 
patients with less than 6 
medications) 
1.27 (0.89 , 1.81) 1.726 0.189 
% Experiencing at least 
1 instance of PIP 
Odds ratio and 
95% CIC 
Chi-
square 
p value 
75.2% 
 
(Compared to 55.4% of 
patients with less than 6 
medications) 
2.45 (1.68 , 3.57) 21. 926 <0.0001 
 
 
Patients with an FI score greater than or equal to 0.16 were 2.86 times more likely 
to experience at least one ADR, and 1.49 times more likely to experience at least 
one instance of PIP within 7 days of admission compared to patients with FI scores 
less than 0.16. 
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Instances of ADRs were found to be significantly dependent on frailty scores (p = 
0.001). However, were instances of PIP were not significantly dependent on frailty 
(p = 0.185). 
Patients taking more than 6 medications were 1.27 times more likely to experience 
an ADR, and 2.45 times more likely to experience at least one instance of PIP. 
In direct contrast to the FI results, PIP was found to be highly dependent on number 
of medications taken (p<0.0001), whereas ADR occurrence was not significantly 
dependent on number of medications (p=0.189) 
 
6.4 Discussion 
The findings of this study reflect the findings in Chapter 5 while also uncovering 
some differences. In Chapter 5, both ADRs and PIP were found to be significantly 
dependent on patients’ frailty status (whether they were above or below the 
threshold of 0.16) with odds ratios greater than 2 and p<0.0001 for both. This study 
however has shown just ADRs to be significantly dependent on frailty status (ADRs: 
OR = 2.86, p = 0.001 Vs PIP: OR = 1.49, p = 0.185). In Chapter 5, PIP was found to be 
highly dependent on the number of medications a patient took (whether they were 
above or below the threshold of 6) with an odds ratio of 3.01 and p<0.0001. ADRs 
were not significantly dependent on the number of medications a patient took (OR 
= 0.75, p = 0.129). This study has reproduced this finding. Patients taking 6 or more 
medications were twice as likely to experience PIP (p<0.0001) but ADRs were not 
significantly dependent on the number of medications taken (OR = 1.27, p = 0.189).  
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So although there were some minor differences between the studies, namely the 
significance of the relationship between frailty status and PIP, the overall message 
from Chapter 5 remains true here i.e use of an FI threshold of 0.16 successfully 
identifies patients at risk of ADRs, and use of a ‘number of medications’ threshold 
of 6 successfully identifies patients at risk of PIP. Therefore, utilisation of both 
methods of detection is the optimum for identifying patients at risk of PIP/ADRs.  
The FIs used in Chapter 5 and in the present study differed in terms of the variables 
used. This study utilised data collected from 5 different hospitals in 5 different 
countries. Therefore all the identical deficit information used in Chapter 5 was not 
available in each site. It has previously been reported that FIs using different 
variables yield similar results when comparing different patient groups [275]. The 
range of FI scores and the mean FI score in this study differ from Chapter 5, and are 
more in-line with reported FI scores, in secondary care [292]. This might appear to 
conflict with the above statement. However, the overall findings remained constant 
across the studies, suggesting that FIs which are customised to include deficit 
information available in specific sites can be compared effectively. The higher mean 
FI score and higher max value in this study may be explained by the higher mean 
age of 82 compared to 74 in chapter 5. This was simply an older, frailer population. 
Therefore, the differences in reported FI scores are not necessarily a reflection of 
inconsistencies between the FIs, but rather are a reflection of the differences in 
patient populations. 
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6.5 Limitations 
This study was limited to 518 patients. Larger studies would be beneficial to further 
validate the results.                                                                                                                                                           
For sites with electronic prescribing and electronic medical records the collation of 
data for the FI would be relatively swift. However, where this is not the case, as in 
the Republic of Ireland, data collection may be somewhat laborious.                                                                                                      
Also, while much of the data included in the FI is routinely gathered information on 
admission which is readily available, some of it is not so accessible and may be 
limited to the researchers capabilities and amount of time available for data 
collection eg malnutrition, MMSE, previous ADRs.  
 
6.6 Conclusion 
The findings from Chapter 5 and this study suggest that using an FI threshold, as 
well as the number of medications a patient takes, as indicators to identify patients 
at risk of PIP and ADRs could potentially be a beneficial initiative to aid physicians in 
optimising prescribing for older patients. Time restraints, chaotic working 
environments and lack of training in geriatric medicine have all been suggested by 
prescribers as barriers to prescription reviews [156, 215]. Therefore a simple 
indication on the patient’s case notes, such as a ticked box to indicate a patient 
above the thresholds, would seem a logical and useful activity. Whether this results 
in reduced instances of PIP and ADRs in routine clinical practice requires further 
research. 
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7. Could the Structured HIstory taking of 
Medication use (SHiM) tool optimise 
prescribing for older patients and reduce 
adverse events? 
 
Chapter description 
In an effort to identify more ways to optimise prescribing in older patients, and 
again, target ‘enablement’ as an intervention type, the SHiM tool was assessed on 
its potential ability to prevent adverse events in older patients.  
 
 
The work of this chapter is currently under review for publication in the 
International Journal of Clinical Pharmacy 
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7.1 Introduction 
It has been shown that on admission to hospital, almost 60% of older patients’ 
medication lists contain at least one discrepancy compared to what they actually 
take at home [102, 293-295]. Discrepancy rates as high as 83% have been reported 
[296]. Medication history errors can result in adverse drug events (ADEs), patient 
harm and increased costs [296, 297]. In the studies carried out to date, 22-59% of 
medication history errors have had potential to cause harm based on propensity for 
harm criteria [296, 298-300]. Older patients, due to polypharmacy, co-morbidities 
and frequent exposure to  multiple prescribing doctors are particularly susceptible 
to medication history errors [301, 302]. 
Medication reconciliation at the point of admission to hospital can reduce 
medication discrepancies and ADEs [303-306]. A number of definitions for 
medication reconciliation have been proposed in the past [307-310]. Essentially, 
medication reconciliation is the process of comparing a patient’s medication list at 
the point of assessment, with what the patient actually takes at home, while noting 
any discrepancies and changes [311]. In 2007, the World Health Organisation 
expanded this definition by suggesting that medication reconciliation should also 
include a review of the appropriateness of patients’ medications [312]. 
Until recently, there had been no structured format to the medication 
reconciliation process. Multiple sources had typically been used to determine 
patients’ medication lists, such as community pharmacy records, general 
practitioner records, patients’ own medication lists as well as their actual medicines 
brought into hospital. None of these sources on their own has been shown to be 
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completely accurate [313] and none has been used in a structured fashion [303, 
314, 315].  
In 2011, Drenth-van Maanen et al. developed a questionnaire, the Structured 
HIstory taking of Medication use (SHiM), to provide a structure for taking a detailed 
medication history in older people [300]. SHiM is based on multiple sources [309, 
316] and consists of 21 questions exploring patients’ current and recent medication 
use, practical problems concerning their medications, medication knowledge, 
beliefs about medicine and drug allergies/intolerances.  
In a prospective study in which SHiM was applied to 100 older patients on 
admission to hospital in Utrecht, Netherlands, and compared to standard care, 
Drenth-van Maanen et al. found that SHiM revealed discrepancies with the 
medication lists obtained by the physician in 92% of patients [300]. Seventy-two 
percent of these discrepancies were judged to be potentially clinically relevant, 
while retrospective analysis of actual clinical events revealed that 21% of patients 
experienced actual clinical consequences arising from medication history 
discrepancies [300]. This study was, however, small scale - it only comprised 100 
patients. Beyond this initial study, there has been very little research with regards 
to SHiM and its application to older patients. In addition, there was potential over-
estimation of results in the above study due to recall bias [300]. Therefore, we 
cannot be certain as to the true impact of SHiM on older patients’ prescriptions. 
The aim of this chapter was to determine whether application of SHiM could 
optimise older patients’ prescriptions on admission to hospital, and in-turn reduce 
ADEs, compared to standard care. 
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7.2 Methods 
7.2.1 Setting and study population 
A prospective observational study was carried out between March 2014 and 
November 2014, as a forerunner to a, larger randomised controlled trial 
(Development and clinical trials of a new Software ENgine for the Assessment & 
optimization of drug and non-drug Therapy in Older peRsons-SENATOR 
www.senator-project.eu) in six hospitals across Europe. The sites included:  
(i) Cork University Hospital, Ireland 
(ii) Ghent University Hospital, Belgium 
(iii) Hospital Universitario Ramón y Cajal, Spain 
(iv)  Landspitali University Hospital Reykjavik, Iceland 
(iv) Aberdeen Royal Infirmary, Scotland 
(vi)  Ospidale Riuniti, Ancona, Italy 
As per the SENATOR trial protocol, patients over the age of 65 presenting to the 
emergency department with an acute illness, ≥ 3 chronic medical disorders and not 
under the care of a geriatrician were eligible for inclusion in the study within 72 
hours of presentation to the emergency department. Exclusion criteria included, 
elective hospitalisation, direct admission to intensive care unit and documented 
plan for consultation with geriatric medicine. All patients signed a consent form 
after they were informed and appraised of the study and its aims. In the case of 
patients with cognitive impairment, proxy consent from their next of kin was 
sought. 
140 
 
7.2.2 Application of SHiM 
As part of the SENATOR trial, a case report form (CRF) was completed for each 
recruited patient. The CRF systematically collected data on patients’ demographics, 
living arrangements, medical history, medications history, as well as several tests 
assessing their overall health. SHiM was one component of the CRF.  
A modified version of SHiM consisting of 18 questions was used to obtain accurate 
drug histories for patients in phase 1 of the trial, an observational only phase. Table 
7.1 lists the questions asked. Researchers conducted a structured interview with 
patients within 72 hours of arrival to the emergency department, or in the case of 
cognitive impairment, this interview was conducted with a reliable care-giver. SHiM 
was applied after the attending physician had obtained a medication history via the 
standard methods i.e patient reports, patients’ own medications brought to 
hospital, general practitioner records and/or community pharmacy records. As this 
was part of an observational phase of the SENAOTR trial, the findings from SHiM 
were not relayed to the medical team. 
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Table 7.1: Modified Structured History taking of Medication use (SHiM) questionnaire 
General questions 
1. Are you using your medication as prescribed (dosage, dose, frequency, dosage form)? 
2. Are you experiencing any side effects? 
3. What is the reason for deviating from the dosage, frequency, dosage form or for not taking 
the medicine at all? 
4. Are you using any other prescription drugs that are not mentioned on this list? 
5. Are you using non-prescription drugs? 
6. Are you using homeopathic drugs or herbal medicines (especially St. John’s wort)? 
7. Are you using drugs that belong to family members or friends? 
8. Are you using any “as needed” drugs? 
9. Are you using drugs that are no longer prescribed? 
Questions concerning the use of medicines 
10. Are you taking your medication independently 
11. Are you using a dosage system? 
12. Are you experiencing problems taking your medication? 
Difficulties with medications 
13. In case of inhalation therapy: What kind on inhalation system are you using? 
14. Are you experiencing any problems using this system? 
15.  In case of eye drops: Are you experiencing any difficulties using the eye drops? 
16. Do you ever forget to take your medication? If yes, which medication? Why? What do you 
do? 
Other 
17. Do you have any drug allergies? If yes, specify the drugs/drug classes and symptoms of the 
allergy. 
18. Do you have any drug intolerances? If yes, specify which drugs/drug classes and symptoms 
of the intolerance. 
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7.2.3 Outcomes 
Discrepancies (any difference between the medication list obtained by the 
physician via standard methods and SHiM) were classified into omission 
discrepancies (drugs identified by SHiM but did not appear on the prescription), 
commission discrepancies (drugs added to the prescription but not used by the 
patient, as revealed by SHiM), dose/frequency discrepancies and substitution 
discrepancies (a drug changed to another drug in that class). Both prescription and 
non-prescription drugs were included. 
Two clinical pharmacists separately classified the potential clinical relevance of the 
discrepancies using the classification system put forward by Cornish et al. [298] and 
used by Drenth-van Maanen et al. in their study [300].  
 Class 1 discrepancies were unlikely to cause patient discomfort or clinical 
deterioration, such as omission of non-prescription vitamins.  
 Class 2 discrepancies had the potential to cause moderate discomfort or 
clinical deterioration, such as diarrhoea, nausea, or moderate pain (solved 
by paracetamol).  
 Class 3 discrepancies had the potential to result in severe discomfort or 
clinical deterioration, such as gastro-intestinal bleeding, sedation, 
anaphylactic shock, or severe pain (not solved by paracetamol).  
Cases of disagreement were resolved by discussion until consensus was reached. 
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All potential ADEs experienced by patients during their hospital stay were 
thoroughly documented, as per the SENATOR trial protocol. The reports of these 
events were used to determine if discrepancies in patients’ medication histories, as 
revealed by SHiM, resulted in actual clinical consequences. 
7.2.4 Data analysis 
Statistical analyses were performed in IBM SPSS Statistics version 22. Descriptive 
statistics were applied to summarise the baseline characteristics, and to describe 
the number and type of discrepancies. 
Ethics approval for this study was sought from and granted by the Clinical Research 
Ethics Committee, University College Cork as part of the SENATOR trial (Appendix 
XVII).  
 
7.3 Results 
SHiM was applied to 123 patients from 5 of the 6 sites. One of the sites (Ancona) 
had not begun recruiting at the time of this study. The mean age of the participants 
was 78 (±6 years). 73 (59%) were male. The median number of medications per 
patient was 11 (IQR=10.0-14.0). Table 7.2 summarises the participant 
characteristics. 
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Table 7.2: Characteristics of the patients (N=123) 
Character Value 
Age (±SD) 78 (±6) 
Number of men (%) 73 (59) 
Number of women (%) 50 (41) 
Median number of medications per patient (IQR) 11 (10.0 – 14.0) 
Median number of prescription medications per 
patient (IQR) 
10 (8.0 – 13.0) 
Median number of non-prescription medications 
per patient (IQR) 
1 (0.0 – 2.0) 
Number of patients from:  
Ireland 68 
Iceland 13 
Spain 18 
UK 21 
Belgium 3 
IQR = Interquartile range 
 
200 discrepancies between the medication list obtained by the attending hospital 
doctors and the list obtained by the researcher using SHiM were discovered. Ninety 
patients (73%) had at least one discrepancy with a median of 1.0 discrepancies per 
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patient (IQR=0.00-2.25). Of the 200 discrepancies, 132 (66%) related to non-
prescription drugs (mostly over-the-counter analgesia, laxatives and antacids) while 
68 (34%) related to prescription-only drugs (mostly inhaled bronchodilators, 
methylcellulose-based eye drops, anti-hypertensives and anti-depressants). 
Omissions were the most common discrepancy with a total of 131 (65.5%). Table 
7.3 summarises the findings of SHiM. 
Table 7.3: Number and type of discrepancies revealed by SHiM 
 Total 
Number of patients with ≥ 1 discrepancy (%) 
 
90 (73%) 
Median number of discrepancies per patient (IQR) 
 
1 (0.0 – 2.25) 
Total number of discrepancies 200 (131 prescription only 
drugs and 68 non-prescription 
drugs) 
Number of omission discrepancies (%) 
 
131 (65.5) 
Number of commission discrepancies (%) 
 
28 (14) 
Number of dose/frequency discrepancies (%) 
 
32 (16) 
Number of substitution discrepancies (%) 
 
9 (4.5) 
IQR – Interquartile range 
 
The 200 discrepancies were classified into 3 different categories, as per Cornish et 
al. [298]. Fifty-three (26.5%) were classified as class 1 (unlikely to cause patient 
discomfort or clinical deterioration), 145 (72.5%) as class 2 (potential to cause 
moderate discomfort or clinical deterioration), and 2 (1%) as class 3 (potential to 
cause severe discomfort or clinical deterioration). 
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Adverse events experienced by patients were examined to determine if they 
resulted from medication history discrepancies. Of the 123 patients, 19 experienced 
a total of 33 ADEs. Of these ADEs, 2 were judged to have been a direct result of 
discrepancies as revealed by SHiM. Both ADEs related to development of marked 
constipation. One was due to omission of a laxative for a patient taking an opioid 
analgesic. The second was due to alverine being prescribed three times daily, when 
the patient only took it periodically when required at home. 
7.4 Discussion 
The principle findings from this study are as follows:  
(i) At least one discrepancy between the medication list obtained by the 
physician and that obtained by the researcher using SHiM was found in 
almost three quarters of patients’ prescriptions (73%) 
(ii) Two thirds of these discrepancies were due to non-prescription drugs, 
and the majority were omission discrepancies. 
(iii) The majority (72.5%) of discrepancies were judged to have potential to 
cause moderate discomfort or clinical deterioration 
(iv) Only 2 (1%) discrepancies resulted in actual clinical consequences. 
These findings in part correlate with the limited amount of data in the literature, 
while also generating novel discussion points. Discrepancies were found in the 
majority of patients’ prescriptions as per previously reported findings [293, 294, 
296, 301, 313], although the median number of discrepancies per patient in this 
study was lower (1.0 compared to 3.0 [300]). The majority of discrepancies were 
omissions, and had potential to cause moderate discomfort or clinical 
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deterioration, similar to previous findings [300, 313]. Most studies to date have not 
explored the link between medication history discrepancies and actual adverse 
events [313]. Also, many have not included non-prescription medicines [300]. 
Drenth-van Maanen et al. did account for these and reported that 21% of patients 
experienced actual clinical consequences as a result of medication history 
discrepancies. Thirty-four percent of discrepancies in that single centre study were 
due to non-prescription medicines [300]. However, in the present study, less than 
2% of patients experienced clinical consequences as a result of discrepancies, while 
non-prescription medicines accounted for 66% of all discrepancies.  
The large difference in proportions of patients experiencing consequences as a 
result of discrepancies is curious. It could possibly relate to the proportion of 
discrepancies caused by non-prescription medicines. It is possible that over-the-
counter medicines are less likely to cause symptomatic adverse events within a 
short period of time. This would explain the small numbers of patients developing 
ADEs in the present study given that the majority of discrepancies were related to 
non-prescription medicines. By contrast, in the study by Drenth-van Maanen et al. 
the vast majority of discrepancies were caused by prescription-only medicines. 
However, even though most patients in the present study did not experience 
discrepancy-related ADEs, most discrepancies were judged to be clinically relevant 
with potential to cause harm. This demonstrates the importance of accurately 
recording non-prescription as well as prescription drugs in a medications 
reconciliation. 
148 
 
The results clearly reinforce the message proposed by previous studies that a 
structured history taking optimises the medication reconciliation process and elicits 
more information than standard methods. However, they do not suggest that SHiM 
could actually prevent avoidable ADEs to a large extent. Ninety-nine percent of the 
ADEs which patients experienced would not have been prevented by the 
application of SHiM. However the fact that almost 75% of discrepancies had the 
potential to cause moderate discomfort or clinical deterioration indicates that SHiM 
does have a place in optimising prescribing for older patients. Applying structure to 
the medications reconciliation process is undoubtedly logical and beneficial, as 
illustrated in this study and similar studies in the literature [300, 313, 317, 318]. 
Typically, medication histories taken by different health care professional vary in 
terms of quality and thoroughness [313, 319]. However with a structure for 
medication reconciliation in place, not only is the resultant medication list more 
accurate, but the medications reconciliation can be completed to the same 
standard by doctors, nurses and pharmacists [300].  
While SHiM revealed discrepancies in patients’ prescriptions, it must be 
remembered that it is unlikely that all these were unintentional. Doctors often 
initiate/discontinue medications, adjust doses or substitute medications on 
admission to hospital based on their clinical assessment of the patient. The 200 
discrepancies identified in this study therefore may not be a true reflection of how 
many unintentional discrepancies were present. As with previous studies, the small 
sample size in this study limits the generalizability of the results, although the range 
of countries involved is a strength of the study. 
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The overall evidence for using SHiM is mixed and further research is needed, with 
larger cohorts, to clarify the role of SHiM in the optimisation of older patients’ 
prescriptions. First and foremost, SHiM is a tool to optimise medications 
reconciliation. The results presented here and elsewhere indicate that SHiM 
achieves this aim. Whether it can serve as an ADE preventative is less certain. 
7.5 Limitations 
This study was limited to 123 patients. While this is a larger sample size than 
previous studies examining SHiM [300], it is still small and studies using larger 
cohorts are required. 
One of the sites involved in the SENATOR project had not begun recruiting at the 
time of this study therefore no data was available.  
While it is useful to collect data from several international sites, it also introduces a 
problem in terms of variability. Each site had researchers of different professions 
and backgrounds collecting the data which may lead to differing interpretations of 
data. There was also much variation in the numbers of patients recruited from each 
site, making direct comparisons between countries impossible.  
Since much of the SHiM tool involves researchers’ own interviewing skills, the 
validity and reliability of the total data set is questionable given the broad range of 
experience amongst the researchers. 
7.6 Conclusion 
The use of SHiM to obtain medical histories for 123 patients revealed 200 
discrepancies from the list obtained by the attending physician. The majority of 
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these discrepancies were due to non-prescription drugs, and most were omissions 
discrepancies. However, only two of these discrepancies resulted in actual adverse 
drug events. The results indicate that SHiM is an effective medications 
reconciliation tool. However, further research applying SHiM in larger populations 
of older people in a variety of clinical settings is required to assess its ability to 
contribute to ADE prevention. 
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8. A meta-synthesis of potentially 
inappropriate prescribing in older 
patients: An update 
 
Chapter description 
The meta-synthesis described in chapter 2 analysed studies published up to and 
including April 2013. It was timely therefore to perform another search of the 
literature and update the findings. 
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8.1 Introduction 
In chapter 2, qualitative studies exploring the causative factors of PIP were 
synthesised using meta-ethnographic methodology [171]. This meta-synthesis 
identified four key concepts that reflected the findings in the chosen papers as 
being contributory factors to PIP in older patients, namely:  
(1) Desire to please the patient  
(2) Feeling of being forced to prescribe 
(3) Tension between experience and guidelines and  
(4) Prescriber fear 
It was concluded that, in many situations, prescribers suffer from ‘self-perceived 
restrictions’ leading to a sense of powerlessness to prescribe appropriately for older 
patients. This forces them to rely on what they know and have done before, leading 
to the PIP that has been identified [11, 17, 41, 52, 165]. 
The meta-synthesis in chapter 2 included papers up to and including April 2013. The 
aim of this chapter therefore, is to update the search using papers published since 
then, and adjust the findings accordingly.  
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8.2 Methods 
As in chapter 2, the meta-ethnographic process, as described by Noblit and Hare 
[171] was utilised to synthesise suitable papers. This process is described in detail in 
chapter 2 and was implemented in identical fashion for this chapter. Figure 8.1 
illustrates the process. 
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Figure 8.1: Flow diagram of meta-ethnography process 
Common concepts representing 
the entire data set are identified. 
Where are these concepts 
evident in each paper? List 
illustrative excerpts. Are the 
papers actually saying the same 
thing but in different 
ways/contexts? 
Explain these illustrative 
excerpts in a one-line 
summation that applies across 
all the studies. 
Re-interpret the third order 
constructs to create a coherent 
argument explaining what all the 
studies have reported in one 
holistic theme. 
Reciprocal translation 
Create third order constructs 
Line of argument synthesis 
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8.3 Results 
 
The search of the electronic databases identified 151 papers, leaving 58 after 
duplicates were removed (Figure 8.2). After title and abstract review, a further 50 
were removed: 41 did not use qualitative methods, 4 did not involve PIP, 3 did not 
deal with patients over 65 and 2 had no abstracts available. Eight full papers were 
retrieved for review. Of these, 5 were eliminated. Three did not use qualitative 
methods and 2 did not explore causative factors of PIP. This left 3 papers for 
inclusion in final synthesis (Table 8.1). 
All 3 papers were of high quality when assessed using the CASP criteria; each of the 
papers met most of the criteria for inclusion in the analysis. Common weaknesses 
were: 
(1) Discussion around the contribution of the findings to current knowledge. 
(2)  ‘Reflexivity’ (the awareness of the researcher's own contribution to the 
construction of meanings throughout the research process). 
(3) Examination of the relationship between the researcher and the 
participants. 
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Figure 8.2: PRISMA flow diagram of literature review process
PubMed, Embase, CINAHL and Web of Knowledge searched using following 
terms: Qualitative AND (Inappropriate* OR Appropriat* OR Safe) AND (Elderly 
OR Aged OR Geriatric* OR Old) AND Prescri*. Reference lists of papers also 
searched. 
151 Papers 
58 Papers 
8 Papers 
3 Papers 
Duplicates removed 
Title/abstract review 
Full article review 
157 
 
Table 8.1: Characteristics of papers identified 
 Paper title (year of publication) 
 
Authors Country Sample size Methods 
1 Factors influencing prescribing of fall-
risk-increasing drugs to the 
elderly: A qualitative study (2015) 
Bell et al. [320] Norway 13 GPs Systematic text 
condensation . Semi-
structured focus 
groups.  
 
2 Doctors’ perspectives on the barriers 
to appropriate prescribing in older 
hospitalised patients: A qualitative 
study (2014) 
 
Cullinan et al.[215] Ireland 22 Hospital doctors Framework analysis. 
Semi-structured 
interviews 
3 GPs, medications and older people: A 
qualitative study of 
general practitioners' approaches to 
potentially inappropriate 
medications in older people (2015) 
Magin et al. [321] Australia 22 GPs Thematic analysis. 
Semi-structured 
interviews 
GP=General practitioner 
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8.3.1 Reciprocal translation 
Four key concepts that reflected the findings in the 3 papers were identified from 
the meta-synthesis as being contributory factors to PIP:  
(1) Patient influences 
(2) Quality of life versus prescribing guidelines influencing decision making 
(3) Working environment 
(4) Lack of prescriber knowledge 
The reciprocal translation and final synthesis are presented below. Each of these 
thematic concepts are described in greater detail. Excerpts consisting of original 
quotes from participants (first order constructs) as well as authors’ findings (second 
order constructs), from the original papers are presented in table 8.2 along with 
third order interpretations to illustrate how the four themes were identified. 
Patient influences 
As in Chapter 2, there was a clear theme of wanting to please the patient amongst 
the three papers identified in this search. While prescribers were aware that their 
prescriptions were often potentially inappropriate, patients demands and 
preferences often led to potentially inappropriate medications (PIMs) being 
prescribed anyway. Magin et al. described the difficulty in stopping 
benzodiazepines.  
“Each time you try and broach it with them [benzodiazepine cessation] you do the 
same dance and end up back at the same spot”. (Respondent 6) [321] 
159 
 
Bell et al. reported that prescribers find it ‘unpleasant to say no’ when asked ny 
patients to renew their sleeping pills prescription. Their study found that doctors 
tired of saying no even though they knew the potential adverse effects of these 
drugs. 
“Many patients are very fond of their drugs and are very reluctant to end the 
treatment. Then my threshold to let them continue is often low”. (Female GP, 11 
years of practice) [320] 
Cullinan et al. [215] echoed these sentiments describing the pressure prescribers 
feel to prescribe something they know is not appropriate.  
“As a doctor sometimes you feel that you have to do something, you get pressurised 
by relatives or patients. You have to give them something. So you end up giving 
something that you are not 100% happy with”. (Site 2, interview 2, registrar). [215] 
Quality of life versus prescribing guidelines influencing decision making 
Each of the 3 papers highlighted the conflict that exists between common 
prescribing guidelines and prescribers’ decision making processes. One common 
theme was that the guidelines are not suitable for older patients as this population 
react so differently to drugs. Therefore what the guidelines deem ‘inappropriate’ 
may be true for one patient but not for the next. Prescribers reported treating 
patients on a case-by-case basis and if they thought stopping a medication 
according to the guidelines would impact on the patient’s quality of life, they would 
more often than not continue with the current treatment.  
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“All trials are a sort of pooled data situation, and there will be individuals for whom 
a particular medication works well and may still be appropriate. I think we deal with 
an individual and a person sitting in front of us and try and juggle things…I don’t 
think they [guidelines like the Beers criteria] should ever be rigid ones because that 
doesn’t fit reality”. (Respondent 1) [321] 
Bell et al. reported that prescribers feel guidelines ‘do not reflect the complexity in 
primary care’ and that ‘elderly people with polypharmacy and multiple diseases are 
very different from the population the guidelines are based upon’. This leads to GPs 
continuing to prescribe medications that technically may be classified as 
inappropriate. ‘The GPs would continue to prescribe fall risk increasing drugs 
(FRIDs) if they perceived that termination of that medication would negatively 
impact the patient’s quality of life’ [320]. 
Quality of life compared to prescribing guidelines also emerged as a causative 
factor of PIP in the study by Cullinan et al. ‘Doctors did however say that they did 
not think their choices were putting their patients at risk after weighing the risks 
and benefits and that quality of life was a major deciding factor’ [215]. 
Working environment 
The environment in which doctors prescribe was reported as a contributory factor 
to PIP is some manner in all 3 papers. It was referred to in terms of doctors’ 
workloads, resources available, demands on their time from multiple sources and 
interactions, or lack thereof, between the different levels of care. All were said to 
lead to the prescribing of PIMs. 
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For example, Bell et al. described how GPs felt that older patients often present 
with multiple issues therefore reducing the amount of time available to review their 
medications. This often resulted in prescriptions just being renewed without a 
critical assessment of appropriateness. 
“If he struggles with his sleep that is only one of many problems. I do not arrange a 
new appointment to just talk about his drugs. That will be a complication for both 
him and me”. (Male GP, 9 years in practice) [320] 
The same study also highlighted the availability of electronic prescribing systems to 
prescribers as beneficial in terms of ‘improving the possibility of gaining an 
overview of the patient’s drug use and also of preventing over-prescribing and 
misuse’. 
Cullinan et al. showed that the busy environment in which hospital doctors work 
was a probable contributing factor to PIP in older patients.  
“That’s a major problem. What you want to do when writing out a drug kardex 
[prescription chart] is to be on your own, to be left alone for 5 minutes…..But it’s 
actually an ideal opportunity for anybody who wants a piece of you for advice or 
whatever…nobody respects that at all and nursing staff will use it as an opportunity 
to unload multiple other problems”. (Site 1, Interview 6, Intern) [215] 
In the same study, lack of information technology (IT) infrastructure was reported 
as a further contributory factor to PIP. ‘Interviewees noted that improvements in 
the IT infrastructure could lead to much safer and more appropriate prescribing, 
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with many doctors emphasising that prioritising improvement initiatives around IT 
could have the most significant effect on appropriateness of prescribing’. [215] 
Magin et al. described the lack of communication between levels of care as being a 
contributory factor to PIP. Specifically, if a medication is started by a specialist, 
there is a reluctance by the patient’s GP to change it, or even to contact the 
specialist to discuss it. As a result, the GP renews a prescription for something that 
he/she may feel is not appropriate [321].  
“Potentially inappropriate medications may be prescribed by a specialist….it’s a bit 
difficult….being a GP to then say ‘well, I don’t think I want that’”. (Respondent 11) 
[321] 
Lack of prescriber knowledge 
All 3 papers reported prescribers’ lack of geriatric pharmacotherapy as a potential 
cause of PIP in older patients. Most participants recognised the older population as 
being very different to the general adult population and acknowledged the extra 
demands their care requires. However, not all had the knowledge base to prescribe 
appropriately for older patients. Magin et al. showed that ‘the anticholinergic 
effects on cognition of some PIMs were not universally appreciated’ [321].  
“I know it [propantheline] can cause dry mouth and things like that…..and the 
constipation but I was unaware of cognitive effects in a patient with dementia”. 
(Respondent 8) [321] 
Magin et al. also reported that none of the participants were aware of the Beers 
criteria [321].  
163 
 
Cullinan et al. showed that doctors often feel they are not well equipped to 
prescribe appropriately for older patients due to ‘a lack of specific education and 
training in geriatric pharmacotherapy, and also a lack of communication of clinically 
relevant information with regards to older patients’ [215]. 
“I don’t think there is enough training for prescribing in older patients. There is no 
distinction between older patients and the general adult population in the training”. 
(Site 4, Interview 2, Registrar) [215] 
Again, none of the participants in this study (except consultants) were aware of any 
screening tools for PIP in older patients such as Beers Criteria [63] or STOPP/START 
criteria [69, 70]. 
Bell et al. described how GPs did not associate increased risk of falls with certain 
inappropriate medications [320].  
“To be honest I believe it is the sum of many factors like alcohol, domestic traps, 
multiple diagnoses and bad quality of life that makes them fall”. (Male GP, 10 years 
of practice) [320] 
The authors described how ‘GPs did not consider drug use to be an important 
enough risk factor for falls in general to let it affect their habit of renewing 
prescription of ‘fall risk inducing drugs’ (FRIDs) without performing regular drug 
reviews’ [320]. They indicated that this is in contrast to research findings which 
suggest that use of FRIDs is in fact associated with increased risk of falls. They 
concluded that ‘GPs need to be reminded of this connection and that the patient’s 
drug list needs to be assessed for such instances [320].
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Table 8.2: Excerpts supporting the four themes plus third order interpretations 
 Excerpts (first and second order constructs. First 
order constructs in italics) 
Paper(s) Third order interpretations 
Patient influences  “It might be our bad consciences that make it easier to write 
a prescription. Most patients are more satisfied if they get 
one” 
 
The majority of doctors admitted that patients and/or their 
families can influence their prescribing to the point where 
they prescribe something they are not totally happy with. 
 
“I would like to think we never prescribe something we know 
is wrong but there’s no doubt it sways you where it’s a grey 
area” 
 
“Each time you try and broach it with them [benzodiazepine 
cessation] you do the same dance and end u[p back at the 
same spot” 
 
“When people first come, I don’t usually go OK well we need 
to stop this, this and this. I mean, you’ve got to gain some 
sort of confidence that you know what you are doing”.  
Bell et al. 
[320]
 
 
 
 
Cullinan et al.
[215]
 
 
 
 
Cullinan et al.
[215]
 
 
 
 
Magin et al.
[321]
 
 
 
 
Magin et al.
[321]
 
Doctors are aware that sometimes they 
prescribe medications which are 
potentially inappropriate. However, 
there is a sense of fighting a losing battle 
at times with patient demands and 
patient satisfaction guiding prescribing 
rather than prescribing guidelines 
Quality of life versus prescribing 
guidelines influencing decision 
making 
The GPs would continue to prescribe FRIDs if they perceived 
that termination of that medication would negatively affect 
the patient’s quality of life 
 
Doctors did say they did not think they were putting their 
patients at risk and that quality of life was always a major 
deciding factor. 
 
Initiation or continued prescription in any individual scenario 
Bell et al. 
[320]
 
 
 
 
Cullinan et al.
[215]
 
 
 
 
Magin et al.
[321]
 
Guidelines cannot be applied 
unequivocally across the board in older 
patients. An individualised approach 
must be taken which can at times result 
in medications which would technically 
be classified as inappropriate being 
prescribed, 
165 
 
was found to be a result of a reasoned weighing of harms 
and benefits. 
 
“You’ve got a description from the patient, an idea of how big 
the problem is, we don’t expect the drugs to bee completely 
safe, we’re trying yo weigh up whether the risks are justified 
by the size of the benefit we’re looking for”. 
 
 
 
 
Magin et al.
[321]
 
Working environment A pull factor that could initiate change in prescribing of FRIDs 
and other drugs was the electronic prescription system. 
 
The GPs said that time set aside for consultations affected 
prescribing. 
 
“I do think though, it’s a tough job. It really is very tough, 
you’re just flat out busy all the time. I think a lot of times 
you’re just transcribing things. You go into auto pilot and you 
don’t question it”. 
 
Another frequent scenario was of PIMs initiated by 
specialists. GPs felt that these were very difficult for them to 
cease. 
Bell et al.
[320]
 
 
 
Bell et al.
[320]
 
 
 
Cullinan et al.
[215]
 
 
 
 
 
Magin et al.
[321]
 
Several factors in a doctor’s working 
environment contribute to PIP. Heavy 
workloads, lack of time, lack of 
resources and lack of communication 
between levels of care all create an 
environment conducive to PIP. 
Lack of prescriber knowledge “I find it easier to remove antihypertensive medications 
compared to psychotropic drugs since I better understand the 
pharmacological correlation between the effect of the drug 
and the symptom of dizziness” 
 
Participants noted a lack of specific geriatric 
pharmacotherapy training and a lack of communication of 
clinically relevant information. 
 
 
 
Bell et al.
[320]
 
 
 
 
 
Cullinan et al.
[215]
 
 
 
 
 
 
Lack of specific geriatric 
pharmacotherapy training results in 
doctors being unequipped to prescribe 
appropriately for older patients. 
Table 8.2 Contd 
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“It’s a different knowledge set. And it’s difficult you know 
because there isn’t a huge amount of data out there, or its 
not communicated to us very well” 
 
GPs were generally unaware of the Beers criteria. 
 
The anticholinergic effects on cognition of some PIMs were 
not universally appreciated.  
 
Few respondents identified additive anticholinergic effects of 
different medications as being something that they 
considered in prescribing in older perrsons. 
 
 
 
 
Magin et al.
[321]
 
 
Magin et al.
[321]
 
 
 
Magin et al.
[321]
 
 
 
 
Table 8.2 Contd 
167 
 
8.3.2 Line of argument synthesis 
 
In Chapter 2, a line of argument synthesis was proposed, stating that in many 
situations, prescribers suffer from ‘self-perceived restrictions’ leading to a sense of 
powerlessness to prescribe appropriately for older patients. This forces prescribers 
to rely on what they know and have done before, which leads to the high 
prevalence rate of PIP that has been identified [11, 17, 41, 52, 165]. Examining the 
concepts identified in this updated search, the same line of argument synthesis 
appears to hold true. Patient demands, perceived lack of appropriate guidelines, 
working environments conducive to inappropriate prescribing and lack of geriatric 
pharmacotherapy knowledge all serve to render the prescriber powerless to 
prescribe appropriately and diminish any incentive for change. 
8.4 Discussion 
 
While presented differently at times, all 4 concepts identified in Chapter 2 were 
present in this updated search of the literature. ‘Desire to please the patient’ was 
directly related to ‘patient influences’, as was ‘feeling of being forced to prescribe’. 
‘Tension between experience and guidelines’ was directly related to ‘quality of life 
versus prescribing guidelines influencing decision making’. The theme of ‘prescriber 
fear’ was evident in several places. For example, in ‘patient influences’ there was a 
fear of disrupting a patient’s care by stopping a medication when they had been 
taking it for a long time. In ‘lack of prescriber knowledge’ there was fear of stopping 
a patient’s medications due to lack of understanding of pharmacological correlation 
between the effect of the drug and the potential for adverse effects. 
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A new concept arising out of this search was that of the working environments of 
doctors being a contributory factor to PIP. Although not evident in chapter 2, this 
factor seems likely given the generally large workloads of doctors today, and 
therefore is a logical addition to the findings of this research.  
As a result, while the various strategies suggested in chapter 2 to empower 
physicians to prescribe appropriately still hold true, this update has highlighted that 
changes to the environment in which doctors work are also required. This includes 
making the necessary resources available, allowing doctors sufficient time to review 
patients’ medications and improving communication between levels of care. 
Another point of note arising from this update is the dissatisfaction with current 
guidelines with regard to prescribing for older patients. In chapter 2, participants 
expressed frustration arising from inability to implement the guidelines due to 
external pressures. However, the participants in this updated search argue 
convincingly that most prescribing guidelines are not designed specifically for older 
patients and therefore cannot be applied effectively to this population. However, in 
all 3 papers in this review, very few of the participants were aware of Beer’s 
criteria, one of the primary tools available for assessing older patients’ prescription 
for appropriateness. Therefore, while their arguments may hold true with respect 
to generic prescribing guidelines, the question must be asked why they are not 
aware of the tools available that are in fact designed for use in older patients. This 
points towards another clear area for future intervention. 
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8.5 Limitations 
 
Although suitable papers were systematically searched for, qualitative papers are 
often difficult to find due to ambiguous titles. 
Meta-ethnography, while a useful tool for this kind of research, is not an objective 
technique and is open to differing interpretations between different researchers. 
I was the one of the researchers who read all the papers. Given that one of the 
papers included was my own publication, it introduces an element of bias, which 
potentially affects the reliability of the findings. 
 
8.6 Conclusion 
 
The concepts identified in Chapter 2 remain relevant after this updated search. 
However, an additional concept has beeen identifed. Doctors’ working 
environments currently contribute to PIP due to lack of resources, strains on 
doctors’ time and lack of communication between levels of care. These issues, as 
well as others raised here and in chapter 2 will need to be addressed in future 
interventions to address PIP.  
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9. Thesis Discussion 
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9.1 Summary of findings 
The first novel outcome of this thesis, leading to two publications in peer-reviewed 
journals, was the exploration of the causative factors of PIP and related outcomes 
through qualitative research. The first step in this process was a systematic review 
of existing qualitative literature (meta-synthesis) exploring PIP (Chapter 2) [156]. 
There is debate as to the appropriateness of combining qualitative studies in a 
formal synthesis like this and whether different types of qualitative studies using 
different methodologies should be combined [322]. Recent investigation suggested 
that it is difficult to draw firm boundaries around what is, and is not, a particular 
type of qualitative research as many authors fail to clearly define their 
methodologies [322]. Despite this, the same investigation also found that it is 
possible to synthesise across different traditions such that some researchers 
consider the combining of data from multiple theoretical and methodological 
traditions a strength of the review [323].  
The meta-synthesis identified four key concepts as being contributory factors to 
PIP. They were:  
(i) Desire to please the patient. In the majority of papers, there was a clear 
underlying theme of ‘wanting to please the patient’. This usually meant 
prescribing outside common guidelines. Doctors recognised the problem 
of prescribing PIMs, however, due to some patients’ resistance to 
alternative therapies, they proceeded with prescribing the medication 
anyway (Chapter 2, p38). 
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(ii) Feeling of being forced to prescribe. One consequence of this need to 
please the patient was that prescribers often felt they were forced into 
prescribing, or not prescribing medications, in a manner they knew did 
not adhere to guidelines. However there were other factors leading to 
prescribers feeling forced to prescribe e.g. poor quality of treatment 
resources and lack of alternative therapies (Chapter 2, p40). 
(iii) Tension between experience and guidelines. Physicians perceived a 
significant problem with implementing prescribing guidelines in day-to-
day practice. The end result was reversion to previous practises, and 
what they were familiar with. Lack of evidence supporting some 
guidelines also influenced prescribers in favour of his/her own 
experiential evidence (Chapter 2, p41). 
(iv) Prescriber fear. Doctors felt a sense of fear towards older patients in 
general due to their frailty and co-morbidities. Consequently, they 
perceived more potential to do harm. They also observed a fear of the 
unknown amongst several GPs (Chapter 2, p42). 
 
The update of the search, presented in Chapter 8, identified one further theme i.e. 
the working environment of prescribers being conducive to PIP. This included 
factors such as time constraints, lack of resources for non-drug therapies and lack 
of communication between levels of care (Chapter 8, p161). 
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These findings correlate well with another recent meta-synthesis exploring 
causative factors of PIP from the prescribers’ perspective [324]. In this study, 
Anderson et al. identified 4 analytical themes contributing to PIP, namely: 
(i) Problem awareness. Poor insight into PIP was observed throughout the 
papers selected for the meta-synthesis. 
(ii) Inertia. Inertia is defined as the failure to act, despite awareness that 
prescribing is potentially inappropriate, because discontinuing PIMs is 
perceived to be a lower value proposition then continuing PIMs. Factors 
such as fear of unknown/negative consequences of change, downplaying 
risk of harm and delegating responsibility to another party (another 
prescriber) all contributed to this theme.  
(iii) Self-efficacy. This theme refers to factors that influence a prescriber’s 
belief and confidence in his/her own ability to address PIM use. 
Knowledge or skill deficits, including difficulty in balancing the benefits 
and harms of therapy, recognising adverse drug effects and establishing 
clear-cut diagnoses/indications for medicines, were challenges 
prescribers faced in identifying and managing PIMs.  
(iv) Feasability. This refers to factors, external to the prescriber, which 
determine the ease or likelihood of change. The most frequently 
expressed barrier to PIM avoidance was patients’ ambivalence or 
resistance to change and their poor acceptance of alternative therapies. 
The limited time and effort to review and discontinue medications was 
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another common constraint as was the limited availability of effective 
non-drug treatment options. 
Although labelled differently, all the above themes from Anderson et al’s. study are 
identified to some extent in the meta-synthesis presented in Chapters 2 and 8 of 
this thesis. The similarity between the findings strengthens the argument for both 
studies’ conclusions i.e PIP is a result of both external and internal factors affecting 
prescribers’ decision making. A multi-faceted approach to minimising PIP is clearly 
needed. This includes more comprehensive education with greater emphasis on de-
prescribing and system-level interventions that empower physicians to prescribe 
appropriately is required to address each area identified by this research. 
To further explore the causative factors of PIP, and given the lack of qualitative 
research in the field highlighted in Chapter 2, an empirical qualitative study was 
carried out and is presented in Chapter 3. Analysis of 22 semi-structured interviews 
with hospital doctors of varying grades using the TDF (Appendix V) identified 5 
domains as relevant to minimising PIP (Chapter 3, p67). They were: 
(i) Environmental  context  and  resources, 
(ii) Memory/attention  and  decision  processes, 
(iii) Knowledge, 
(iv) Skills,   
(v) Social influences. 
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These findings largely concur with the findings of the literature review i.e a mixture 
of external factors (working environment, patient influences and lack of resources) 
and internal factors (lack of knowledge and confidence with regards to geriatric 
pharmacotherapy) combine and ultimately result in PIP. Of particular note in this 
study, more so than in the literature review, was participants’ dissatisfaction and 
frustration with current IT infrastructure in Irish hospitals, especially with regards to 
patient transition between levels of care. Improved IT resources was commonly 
suggested as factor likely to improve prescribing in older patients.  
Lack of specific geriatric pharmacotherapy training was also seen as a contributory 
factor to PIP. Doctors indicated that they often feel ill-equipped to prescribe 
appropriately for older patients. This deficiency was not only their technical 
knowledge, but also, it would seem, in their interactions with these patients and 
their families. Doctors reported being frequently influenced in their decision making 
by patient demands/preferences. This usually meant prescribing drugs they knew to 
be potentially inappropriate. This would suggest that doctors’ training should 
incorporate some level of guidance on dealing with patients’ and families’ 
treatment demands, and being able to resist these demands when necessary and in 
patients’ best interests. Recently, Gordon et al. recognised this need and has 
proposed a template for such pragmatic training [185, 325].  
The findings from Chapter 3 shed new light on the causative factors of PIP. In 2005, 
Spinewine et al. explored the processes leading to PIP in older inpatients using 
qualitative methods [180]. They identified transition between levels of care as a 
contributing factor to PIP. In addition, lack of disparity between prescribing trends 
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for older adults and the younger adult population and lack of time to prioritise 
medication appropriateness were also contributory factors to PIP. However, their 
findings with regards to the attitudes of prescribers differ significantly from those 
presented in Chapter 3. They reported that prescribers adopted a passive attitude 
towards learning, expressing a view that it would take too long to find the 
information they needed about medicines. They also described a lack of self-
directed learning amongst the doctors they interviewed [180].  
In contrast, some of the study findings described in Chapter 3 were the converse of 
those of Spinewine et al. i.e doctors were very interested in learning more because 
they felt they hadn’t been taught enough as undergraduates and welcomed any 
opportunity to enhance their knowledge base. Spinewine et al. also described the 
relationship between the prescriber and the patient as a paternalistic one, with the 
prescriber making the decisions without due consideration of the patient’s wishes. 
This, they found, contributed to PIP [180]. Once again, the study presented in 
Chapter 3 had opposite findings with doctors allowing themselves to be influenced 
by patients’ demands often resulting in PIP. It is likely that elements of both studies 
combine to cause PIP. The profile of the participants in both studies must also be 
considered. Spinewine et al. interviewed nurses and pharmacists as well as doctors. 
Chapter 3 only involved interviews with doctors thereby applying a narrow focus. 
However the difference in attitudes, identified by this thesis, between Ireland and 
mainland Europe may be an area for future research. 
The second novel outcome of this thesis was, using the findings of the qualitative 
research, the identification of the types of interventions that would be suitable for 
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the purpose of preventing PIP and related adverse outcomes. At the end of Chapter 
3, the domains identified in the TDF were mapped to the behaviour change wheel 
(Appendix VI) for this purpose (Chapter 3, p76). The intervention types found to be 
suitable were:  
(i) Training,  
(ii) Environmental restructuring,  
(iii) Restrictions,     
(iv) Persuasion,  
(v) Incentivisation,  
(vi) Modelling,  
(vii) Enablement 
These findings provide a roadmap for future research in the field of PIP prevention 
in secondary care. A similar investigation into suitable intervention types for PIP 
prevention in primary care has recently been published [326]. Although not based 
on any theoretical model,  Clyne et al. did use qualitative methods to inform an 
intervention aimed at preventing PIP. They reported that academic detailing, with a 
medicines usage review conducted by a pharmacist and patient information leaflets 
had the potential to reduce PIP in patients under the care of primary care 
physicians [326]. This intervention, guided by the United Kingdom Medical Research 
Council (MRC) Framework on developing complex interventions [327] is currently 
being evaluated in a randomised controlled trial [328].  
Of the intervention types identified by their study, two directly overlap with those 
identified in Chapter 3 of this thesis i.e. academic detailing (training) and medicines 
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usage review by a pharmacist (environmental restructuring). Patient information 
leaflets do not fall under any of the intervention types identified in this thesis. 
However, this is not surprising as the TDF and behaviour change wheel were 
employed to identify areas for intervention at the prescriber level. Nevertheless, 
patient education was mentioned by participants in the interviews described in 
Chapter 3 as a potential enabler to appropriate prescribing in older patients. 
Therefore it would seem that interventions to address PIP will be similar in both 
primary and secondary care.  The fact that the meta-synthesis in Chapter 2 
(involving primary and secondary care physicians) and the qualitative study in 
Chapter 3 (involving secondary care physicians only) produced similar findings 
supports this view point. 
The third novel goal of this thesis was to develop and conduct an intervention 
informed by the qualitative research, based upon the intervention types deemed 
suitable by mapping the qualitative research to the behaviour change wheel and 
suitable for the purpose of countermanding PIP. There was general dissatisfaction 
among NCHDs with the lack of geriatric pharmacotherapy training they had 
received as undergraduates. Consequently, there was general agreement among 
them that improving pharmacotherapy knowledge would be a vital step in 
countermanding PIP. Therefore, an educational intervention was decided upon 
(Chapter 4). Specifically, an online module providing geriatric pharmacotherapy and 
prescribing training. Doctors expressed a general desire for more training, and a 
view point that it should be delivered in a fashion in which they could complete it in 
their own time. Given these expressed views, and the fact that ‘training’ was one of 
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the intervention types identified by the behaviour change wheel, this intervention 
seemed appropriate.  
The results raise several points of interest. Firstly, the low knowledge scores 
achieved at baseline are in agreement with doctors’ reports of being unequipped to 
prescribe for older patients due to insufficient training in this area (Chapter 4, Table 
4.3, p92). Secondly, the marked improvement in scores post-intervention 
demonstrates the benefit of a tool like this. Gordon et al. have reported similar 
findings using an online training tool for doctors designed to improve prescribing in 
children in the UK [221].  
As mentioned in the introduction to this thesis, specific educational interventions 
are often promoted as essential for helping doctors to prescribe appropriately in 
specific patient groups [52]. Interactive style interventions, such as that described 
in this thesis, are usually the preferred choice [106-108]. The results from the RCT in 
Chapter 4 corroborate previous findings as to the value of such interventions. In 
addition, the data make a strong case for changing the focus of these interventions 
from single drug classes to prescribing for older people in general with particular 
emphasis on the physiological changes that occur as patients age. The basics of 
geriatric pharmacotherapy must be mastered first and this research strongly 
suggests that these basics are being overlooked in medical education. The reality is 
that physicians are often prescribing for a patient population for which they have 
not been adequately trained. Therefore, they often prescribe as they would for a 
younger adult. Tools like the one used in this thesis could have a central role in the  
future in preparing doctors for the challenges of geriatric pharmacotherapy, 
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Especially in Ireland, and other countries, where these educational tools are not 
routinely available. 
The suggestions from the RCT participants put forward for preventing PIP are also 
noteworthy (Chapter 4, p95). Interestingly, after content analysis of all suggestions, 
the 3 overarching themes were: 
(i) Supplementary training in Geriatric Medicine with more emphasis on the 
differences between older patients and the general adult population in 
relation to drug choice and dose selection, 
(ii) Improved IT support in terms of transfer between levels of care, 
(iii) Improved and more systematic communication between the levels of 
care i.e GPs, hospitals, pharmacies and nursing homes.  
The findings echo those of Chapter 3 and underline what prescribers feel is required 
to address PIP. The issue of insufficient and inadequate IT support in Ireland, and 
it’s association with PIP is a novel and important finding of this thesis. Research to 
date investigating the role of IT in prescribing has mainly focused on medication 
adherence, prescribing accuracy, reducing medication errors and improving 
efficiency of transition of care [329-332]. A review of studies examining the use of 
IT in prescribing also described research aimed at using IT to improve overall 
appropriateness of prescribing in patients with heart failure [330]. The message 
from this research is similar throughout. Agrawal et al. reported that use of 
electronic systems for prescribing and collating patients’ medical records reduces 
errors, increases overall safety and improves efficiency of transition of care [330].  
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There are some concerns surrounding these systems however e.g. cost. IT systems 
are of little clinical value unless all healthcare facilities have the capacity to interact 
with them. Widespread implementation such as this places a large burden on any 
institution or organisation [330-332]. The user interface is another commonly 
reported barrier. There is a danger that prescribers would become frustrated with 
an electronic system constantly interrupting their workflow [330]. Therefore 
streamlining of these systems is required to encourage their use. 
Several of these IT systems exist abroad in some form, and are showing potential in 
improving prescribing. In Ireland, the great majority of health records, prescribing 
and interactions between levels of care are still paper-based. The present research 
has highlighted prescribers’ frustration with this status quo. Something which has 
not received much attention to date but clearly needs to in the future. Recent large 
scale European studies involving Ireland, such as the EU FP7 funded SENATOR 
project and the Horizon 2020 funded project- OPERAM, both focusing on 
developing software to aid physicians to optimise their prescribing for older 
patients, are therefore a timely and welcome development (www.senator-
project.eu). 
The final novel outcome of this thesis, leading to publication in a peer-reviewed 
journal, was the assessment of other possible intervention types identified in the 
thesis for suitability and applicability with regards to preventing PIP and related 
outcomes such as ADRs. This thesis has shown that doctors are not adequately 
trained in geriatric pharmacotherapy to identify instances of PIP to a sufficiently 
high level. In addition, doctors are under increasing time pressures and 
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appropriateness of prescribing is not always a priority. One of the intervention 
types identified by the behaviour change wheel was ‘enablement’. In other words, 
if one could enable doctors to readily identify patients with instances of PIP, or at 
least with an increased risk of PIP and related outcomes, it could potentially have a 
positive effect on PIP/ADR rates.  
Given the need for succinct interventions due to the already complex environment 
doctors work in, it was hypothesised that a single indicator of PIP/ADR risk on the 
patient’s drug chart or medical notes would be beneficial. To do this, a frailty index 
(FI) was developed and tested, and frailty scores assigned to patient databases in 
Chapters 5 and 6. Significant correlation between the FI scores and appropriateness 
of patients’ medications indicated that FI scores did have potential to form the 
basis of such an indicator for physicians to review a patient’s medications (Chapter 
5, Figure 5.2, p111). Further analysis identified an FI threshold above which patients 
were statistically more likely to experience PIP/ADRs raising the possibility that such 
an intervention could be delivered by simply ticking a box if a patient is above this 
threshold (Chapter 5, Figure 5.3, p113). The findings from Chapter 5 were tested on 
a different patient set in Chapter 6 and generated strikingly similar results (Chapter 
6, Tables 6.2, 6.3 and 6.4, p130-132) thereby adding weight to their significance.  
This research has identified a novel use for the FI, a tool which has often generated 
debate as to how best to utilise it [229, 279, 283]. The study indicates that this is 
one potential way for patients at high risk of PIP/ADRs to be highlighted to doctors 
who otherwise may go unnoticed due to the barriers already identified in this 
thesis. Educational interventions would still be required however so that once a 
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patient is highlighted as being at high risk, the prescriber can amend their 
prescription appropriately.  
Finally, the SHiM tool was assessed with regard to its potential for optimising 
prescribing in older patients and preventing ADEs. Designed purely as a medications 
reconciliation tool, Chapter 7 showed that it undoubtedly optimises this process 
and elicits a more accurate medication list than that obtained by the attending 
physician. However the findings suggest it has little value for preventing ADEs 
(Chapter 7, Table 7.3, p145). While the majority of discrepancies identified by SHiM 
did have the potential to cause harm, suggesting it does hold some value, in terms 
of ADE prevention tools, this research suggests that time and resources would be 
better spent exploring other avenues. 
 
9.2 Future work 
The research described in this thesis provides a robust platform for further research 
aimed at combating PIP in older patients. Future research should focus on the 
following areas: 
(i) Investigation of the translation of the improved prescribing skills 
observed in Chapter 4 into actual improvements in patient outcomes 
and prescribing appropriateness. 
(ii) Implementation of the FI threshold system in a clinical setting to 
determine if this results in lower PIP and ADR incidence and prevalence. 
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A qualitative aspect to this research would also be useful to describe 
how doctors perceive such an intervention. 
(iii) Improving the IT infrastructure for supporting prescribing for older 
patients in all levels of care in Ireland. Given the progress made in this 
area in other countries, there is a clear need to investigate in detail the 
impact of IT-supported electronic prescribing for older people in Ireland.  
(iv) As stated in the literature and several times throughout this thesis, 
educational interventions will continue to be a vital aspect of addressing 
PIP in older patients. Any research driven systems or procedures put in 
place to aid prescribers are unlikely to achieve their full potential unless 
those prescribers have the fundamental skills required to make decisions 
with regards to older patients’ pharmacotherapy. The undergraduate 
curriculum for medical students should also be a target for future policy 
makers. 
 
9.3 Conclusions 
PIP and related adverse outcomes in older patients are not attributable to one 
easily identifiable cause. Similarly, PIP in older patients cannot be corrected with 
any one easily-implemented solution. Several complex factors combine to cause 
suboptimal prescribing, or non-prescribing, of medications in older patients. Lack of 
geriatric pharmacotherapy training, dissatisfaction with prescribing guidelines, 
working environments conducive to PIP, patient influences and poor IT 
infrastructure all contribute to PIP and all must be addressed thoroughly to 
minimise PIP and its negative consequences. Educational interventions such as that 
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presented in this thesis have an important role in the continuing strive for improved 
prescribing for older patients. Education must be consolidated by more targeted 
interventions such as enabling initiatives like an FI score. Given the complex 
aetiology of PIP in older patients, it is likely that a multi-faceted approach is 
required to address this problem in a systematic way. In Ireland the lack of 
electronic prescribing systems is a clear barrier to minimising PIP in older patients. 
There is therefore, an urgent need to drastically improve the IT infrastructure in this 
country. Particularly in light of the rapidly growing population of older people with 
complex multi-morbidity and associated polypharmacy. 
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11.1 Appendix I: A meta-synthesis of potentially inappropriate 
prescribing in older patients 
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11.2 Appendix II: CASP checklist for qualitative studies 
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11.3 Appendix III: PRISMA checklist for systematic reviews 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.   
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.   
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
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Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).   
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I
2
) for each meta-analysis.  
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11.4 Appendix IV: Doctors’ perspectives on the barriers to 
appropriate prescribing in older hospitalised patients: A 
qualitative study 
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11.5 Appendix V: Theoretical domains framework 
(Reproduced with permission, September 2015, Prof. Susan Michie)  
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11.6 Appendix VI: Behaviour change wheel 
(Reproduced with permission, September 2015, Prof. Susan Michie) 
 
The domains of the TDF are presented in yellow here. Depending on which domains 
are identified, they can be mapped to the suitable intervention types, shown here 
in red. 
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11.7 Appendix VII: Interview Topic Guide 
 
“Before we start I just want to check that you’re still happy for this interview to be 
recorded and that you know we can stop at any time?  
I’d like to thank you for agreeing to participate in this interview and stress that 
everything said here today is completely confidential. Your name will not appear on 
any documents or recording discs and I personally will anonymise the transcript 
from this interview, and will ensure that no one else will be identifiable either. 
There won’t be any consequences to what you tell me and there will be no blame 
attributed to you or anyone else.  
These interviews are part of my PhD which is looking at inappropriate prescribing in 
older patients and the processes that surround it. Inappropriate Prescribing for 
older people, and by older I mean over the age of 65, is an important cause of 
adverse events in hospitals and by investigating how this happens, we hope we can 
develop further studies aimed at improving prescribing for older people.    
There are no right or no wrong answers to these questions, just give as much detail 
as you can. It will probably last about 30 minutes.  
Does all that sound ok? Are you happy for me to record the interview? 
Demographic Questions: 
 Physicians’ Grade: 
 Gender: 
 How many years have you worked as a doctor? 
 Are you currently working in any particular speciality? 
o What specialities have you experienced?                              
 Do you have any specific training in geriatric medicine? 
o Undergrad/postgrad?  
 Where did you complete your undergraduate training? 
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(Prompts are in red) 
1. Could you tell me what you understand by the term “ INAPPROPRIATE 
PRESCRIBING”? 
 Can you give an example? 
 Drug with wrong/no indication? 
 Drug with high risk of ADR 
 Drug that is unnecessarily expensive? 
 Prescribed for too short or too long a period? 
 Failure to prescribe a drug for irrational or ageist reasons? 
 
A number of studies have looked at prescribing in older patients, and have tried to 
estimate how much of it is inappropriate. 
2. What proportion of OLDER PEOPLE i.e. ≥65 years, would you say are 
prescribed at least one inappropriate medicine? 
 
A. Upon admission 
B. During their stay in hospital 
C. On discharge 
 
Do you think the level of inappropriate prescribing is a problem in 
amongst older patients? 
 
 Primary care? 
 Secondary care? 
 Tertiary care? 
 
 
3. What do you think contributes to inappropriate prescribing in older people? 
Age, major polypharmacy, comorbidities (eg heart failure, renal impairment, 
hepatic impairment), multiple doctors, hx of falls? 
 
4. Do you think there is anything in particular you should know more about 
when you are prescribing for older people? 
Clinical knowledge 
Procedural knowledge 
 
5. Could you tell me what you understand by the term adverse drug reaction? 
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What classes of drug would you say are likely to be problematic in older 
patients? 
What percentage of older patients would you say experience an adverse 
drug reaction? 
 
6. On a scale of 1 to 10, how would you rate your confidence in prescribing for 
older people, 1 being not confident at all and 10 being very confident? 
 
Compared to prescribing for the general adult population? 
Is it a different skill? 
What parts of the prescribing process would you be least confident about? 
Deciding on the drug, appropriateness of drug, dose, duration? 
 
7. What would you say the potential consequences of inappropriate 
prescribing are? 
For: Patient, you, job, colleagues, patient’s family, etc 
 
 
8. Do you think the possibility of prescribing an inappropriate medicine is 
something that is on doctors’ minds on a day to day basis? 
 
 
9. As a (grade and speciality of doctor here) doctor, how would you describe 
your own role in ensuring medicines prescribed for older people are 
appropriate? 
 
Directly involved? 
Not much input? 
Reviewing charts. 
 
 
10. Would you feel comfortable changing an inappropriate prescription if it was 
highlighted to you, if not, why not? 
 
If you had prescribed something and it was highlighted to you? 
If you noticed something else someone had prescribed? 
Have you done it in the past?  
What would warrant you changing a prescription? 
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11. From your experience would you say environmental context impact a 
doctors’ prescribing? And does this increase the chance of inappropriate 
prescribing? 
 
Time constraints. 
Other tasks. 
 Are the necessary resources available? 
 
 
 
12. To what extent do the views/actions of your colleagues affect your 
prescribing? 
Same for patients and patients’ families? 
 
13. Do you think your emotions ever impact on prescribing? And does this 
increase the chance of inappropriate prescribing? 
 
 
14.  Do you think there is a particular way of working or steps that could be 
taken to encourage appropriate prescribing in older patients? 
Are any of these routinely done at the moment? 
 
15.  If something could be done tomorrow to address inappropriate prescribing, 
what do you think would need to be done differently and who would need 
to do it? 
 
Do you think this can be easily achieved? 
What barriers do you see to implementing this? 
 
 
16. What role do you think screening tools play in prescribing for older patients? 
 
Are you aware of the tools? BEERS, STOPP/START. 
Do you refer to them?  
 
17. Is there anything else you would like to add? 
Thank you for your time. 
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11.8 Appendix VIII: NVivo screen shots of coding process 
 
 
Creation of case nodes 
1st round open coding 
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2nd round coding, creation of hierarchies.  
 
 
 
Directed content analysis to theoretical domains framework 
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11.9 Appendix IX: Ethics approval for Chapter 3 research 
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11.10 Appendix X: Screen shots of SCRIPT module 
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11.11 Appendix XI: Assessments and Marking Schemes for RCT 
Baseline assessment 
MCQs (20 marks in total) 
 
1. The excretion of which of the following drugs is NOT likely to be reduced in an older 
patient (>65 years of age)? 
Atenolol 
Diazepam 
Metformin 
Digoxin 
2. With increasing age comes….. 
A decrease in lean body mass, and body fat in relation to total body weight, as well as, an 
increase in body water. 
A decrease in lean body mass, and body water, as well as, an increase in body fat in relation 
to total body weight. 
An increase in lean body mass, and body water, as well as, a decrease in body fat in relation 
to total body weight. 
An increase in total body fat in relation to total body weight, and body water, as well as, a 
decrease in lean body mass. 
3. In older patients, decreased liver blood flow often leads to.... 
Increased first pass metabolism of water–soluble drugs resulting in lower absorption rates 
of these drugs. 
Decreased first pass metabolism of water-soluble drugs resulting in higher absorption of 
these drugs. 
Increased first pass metabolism of lipid-soluble drugs resulting in lower rates of absorption 
for these drugs. 
Decreased first pass metabolism of lipid-soluble drugs resulting in higher rates of 
absorption for these drugs. 
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4. Which of the following drugs is likely to undergo increased distribution in an older 
patient, leading to a prolonged clinical effect? 
Paracetamol 
Digoxin 
Diazepam 
Atenolol 
5. Between the ages of 20 and 70 a person may have up to 50% reduction in renal 
function. It is this decline in renal function that is the major pharmacokinetic determinant 
of toxicity in older adult patients. Which measurement is the best indicator of renal 
function in a 70 year old man with severely reduced muscle mass? 
Cockroft-Gault formula 
MDRD equation 
Serum creatinine 
24 hour urine output 
6. Which of the following best describes the pharmacodynamics associated with anti-
hypertensives in older patients? 
Due to a decrease in baroreceptor function, older patients’ ability to adjust vascular tone 
and heart rate in response to volume depletion or vasoactive substances is reduced. 
Due to an increase in baroreceptor function, older patients’ ability to adjust vascular tone 
and heart rate in response to volume depletion or vasoactive substances in increased. 
Due to a decrease in baroreceptor function, older patients may require higher doses of 
anti-hypertensives to counteract their reduced ability to increase vascular tone. 
Due to an increase in baroreceptor function, older patients may require lower doses of 
anti-hypertensives. 
7. Which of the following is NOT a common adverse drug reaction associated with 
anxiolytics/hypnotics? 
Falls 
Confusion 
Urinary retention 
Postural hypotension 
8. Patients with closed-angle glaucoma should avoid which ONE of the following groups 
of drugs? 
Non-selective beta-blockers 
Corticosteroids 
Diuretics 
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Tricyclic antidepressants 
9. Which group of drugs most predictably increases delirium in older patients? 
Anti-hypertensives 
Anti-cholinergic drugs 
Anti-psychotic drugs 
Anti-diabetics 
10. For how long (maximum) should PPIs be used for at full therapeutic dose post 
endoscopic diagnosis of duodenal ulcer? 
4 weeks 
8 weeks 
12 weeks 
No limit 
(2 Marks for each correct answer) 
Case studies (30 marks in total) 
Comment on the appropriateness of the following five prescriptions, and list any 
changes you would make, or issues you would review, giving your reasons for doing 
so. These are real life scenarios. There may be multiple points to address in each 
case 
Case 1 
 
80 Year old male  
 
Active problems:  
Peptic Ulcer Disease since 2006  
Hypertension since 2004  
Recurrent gout since 2009  
Prostate Carcinoma since 2009 
 
History: 
R ankle injury-1992 
Diverticular disease 2003 
Deep Vein Thrombosis 1999 
Regular Medications:  
Pantoprazole 40mg od (Since 06)  
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Bendroflumethiazide/potassium od  
Aspirin 75mg od  
Paracetamol 500mg 2qds  
Glucosamine sachets i od  
Prostap 3  
 
Biochemical Data 
Total Chol = 2.7 mmol/L 
Urea: 8.1 mmol/L 
Creatinine: 110micromol/L 
Sodium: 147 mmol/L 
Potassium: 3.2 mmol/L 
eGFR: 59ml/min/1.73m2 
 
PSA 15.8  
BP: 130/75 mmHg 
 
1 mark for each of the following points raised…… 
1. Pantoprazole should be reduced to 20mg once daily 
2. Thiazide diuretic inappropriate with gout and metabolic disorder 
3. No indication for glucosamine 
4. Allopurinol should be considered for gout 
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Case 2 
 
70 year old male complaining of nausea and sporadic falls 
 
Current Diagnosis:  
Hypercholesterolaemia  
Ischaemic Heart Disease (IHD) 
Insomnia 
Gout 
 
History: 
Cataracts 
MI 2011 
 
Regular medications:  
Allopurinol 100mg od 
Bendroflumethiazide 2.5mg od  
Aspirin 75mg od 
Flurazepam 30mg od (past 3 years) 
 
Biochemical Data  
eGFR: 30ml/min/1.73m2 
Sodium: 136 mmol/L 
Potassium: 3.0 mmolL 
Urea: 11.2 mmol/L 
Creatinine: 140 mmol/L 
Urate: 582 micromol/L 
 
1 mark for each of the following points raised: 
1. Thiazide diuretic inappropriate with gout 
2. Long half-life benzodiazepine inappropriate with history of falls 
3. Statin should be considered 
4. Beta-blocker should be considered 
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Case 3 
 
74 year old female complaining of nausea and blackouts 
 
Current Diagnosis: 
Paroxysmal Atrial Fibrillation (2007) 
Non-obstructive coronary artery disease (coronary angiogram 2007) 
Recurrent Gout since 2006 (secondary to thiazide diuretic) 
Hypertension 
Hypercholesterolaemia 
Restless leg syndrome 
 
History: 
Non-Hodgkins Lymphoma 2005 
Vertigo (single episode) 2011 
 
Regular medications:  
Pravastatin 40mg d  
Verapamil (slow release) 240mg od  
Quinine sulphate 300mg od 
Perindopril 5mg/Indapamide 1.5mg od 
Digoxin 250mcg od 
Diclofenac 75mg bd  
Furosemide 20mg od  
Betahistine 16mg tds  
Paracetamol 1g prn  
Warfarin as per INR  
 
 
Biochemical details: 
Fasting Chol: 5.5mmol/L 
Urea: 10.4mmol/L 
Creatinine: 150 micromol/L 
Sodium: 140mmol/L 
Potassium: 3.5mmol/L 
eGFR: 37ml/min/1.73m2 
 
BP: 105/60 mmHg 
HR: 44 BPM 
ECG: Sinus rhythm with 1st degree heart block 
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1 mark for each of the following points raised (+ 1 mark floating for extra points 
raised): 
1. Digoxin dose should be reduced given reduced renal function 
2. Digoxin not effective in paroxysmal a-fib. 
3. Digoxin and verapamil together is inappropriate 
4. Indapamide contraindicated in gout 
5. Diclofenac inappropriate given reduced renal function 
6. Full dose of betahistine for prolonged period of time 
7. Statin dose may be insufficient 
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Case 4 
79 year old male complaining of recent fall and wrist fracture  
 
Diagnoses:  
Gout  
Insomnia  
Hypertension since 1987 
Hypercholesterolaemia 
OSteoporosis diagnosed in routine screening 2010 
 
History: 
Myocardial infarction 2001 no re-vascularisation  
 
Current Medicines:  
Allopurinol 300mg od  
Olanzapine 2.5mg nocte  
Clopidogrel 75mg od  
Aspirin 75mg od  
Nebivolol 2.5mg od  
Doxazosin XL 8mg od  
Irbesartan 600mg od  
Bendroflumethiazide 2.5mg od  
Atorvastatin 10mg od 
 
Biochemical data: 
Total Chol: 3.3mmol/L 
Urea: 11.8 mmol/L  
Creatinine: 161mmol/L 
Sodium: 141 mmol/L 
Potassium: 4.6mmol/L 
eGFR: 38ml/min/1.73m2 
 
Supine BP: 110/70 
Standing BP: 85/50 
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1.5 marks for each of the following points raised (+ 1 mark floating for extra 
points raised): 
1. No indication for dual antiplatelet therapy. 
2. Excessive anti-hypertensive therapy-stop alpha blocker 
3. No indication for olanzapine 
4. Calcium/Vitamin D should be considered given osteoporosis 
5. Bisphosphonate should be considered for same 
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Case 5 
77 year old female complaining of recurrent hypos, blackouts, sporadic confusion 
and chronic constipation 
 
Current diagnosis: 
Hypertension since 2004 
Non Insulin Dependant Diabetes Mellitus with poor monitoring of glucose 
Episode of depression 1989- no relpase 
 
Current Medications:  
Aspirin 75mg od  
Amlodipine 5mg od  
Lisinopril 20mg od 
Gliclazide 30mg od  
Quetiapine 100mg Bd  
Zolpidem 10mg nocte  
Glibenclamide 5mg od 
Dothiapen 150mg nocte 
 
History:  
Previous alcohol abuse-no relapse 
Stroke-good recovery-2012  
 
Biochemical Details:  
Total Chol: 6.5 mmol/L 
Urea: 6.1 mmol/L 
Creatinine: 86 mmol/L 
Sodium: 138 mmol/L 
Potassium 4.5mmol/L 
eGFR 60ml/min/1.73m2 
LFT normal 
No Urinalysis available 
 
BMI: 29.5 
 
1 mark for each of the following points raised: 
1. Glibenclamide not the best choice in older patients 
2. 2 X Sulfonylureas 
3. Constipation possibly casued by quetiapine 
4. No indication for quetiapine 
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5. Metformin may be more appropriate for diabetes in this patient due to 
obesity 
6. Statin should be considered  
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4 week assessment 
1.The excretion of which of the following drugs is likely to be reduced in an older 
patient (>65 years of age)? 
Diazepam 
Nifedipine 
Digoxin 
Propranolol 
2. With increasing age comes….. 
A decrease in distribution of lipid-soluble drugs, leading to a hangover effect. 
An increase in distribution of lipid-soluble drugs, leading to a ‘hangover effect’. 
A decrease in distribution of water-soluble drugs, leading to a ‘hangover effect’. 
An increase in distribution of water-soluble drugs, leading to a ‘hangover effect’. 
3. Reduction in liver blood flow rate may lead to what, in older patients? 
Increased first pass metabolism of water–soluble drugs leading to lower absorption rates of 
these drugs. 
Decreased first pass metabolism of water-soluble drugs leading to higher absorption of 
these drugs. 
Increased first pass metabolism of lipid-soluble drugs leading to lower rates of absorption 
for these drugs. 
Decreased first pass metabolism of lipid-soluble drugs leading to higher rates of absorption 
for these drugs. 
4. Which of the following drugs is likely to experience decreased distribution in an 
older patient? 
Morphine 
Digoxin 
Diazepam 
Nifedipine 
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5. Between the ages of 20 and 70 a person may have up to 50% reduction in renal 
function. In practice it is this decline in renal function that is the major 
pharmacokinetic determinant of toxicity in older adult patients. Which measure 
should be used to estimate kidney function in a 70 year old man with severely 
reduced muscle mass? 
Creatinine clearance 
eGFR 
6. Which of the following best describes the pharmacodynamics associated with 
anti-psychotics in older patients? 
Due to an increase in dopamine (1 and 2) receptors, extrapyramidal side-effects of anti-
psychotics are increased. 
Due to a decrease in dopamine (1 and 2) receptors, extrapyramidal side effects- of anti-
psychotics are increased. 
Due to an increase in dopamine (1 and 2) receptors, extrapyramidal side effects of anti-
psychotics are decreased. 
Due to a decrease in dopamine (1 and 2) receptors, extrapyramidal side effects of anti-
psychotics are decreased. 
7. Memory loss, constipation, urinary retention and exacerbation of glaucoma are 
most commonly associated with which family of drugs? 
NSAIDs 
Hypnotics 
Anit-muscarinincs 
Opioid analgesics 
8. Patients with pre-existing dementia should avoid which ONE of the following 
groups of drugs? 
Calcium-channel blockers 
Anti-psychotics 
Diuretics 
Tricyclic antidepressants 
9. Which group of drugs should be avoided in patients with a history of clinically 
significant hyponatremia? 
268 
 
Non- selective beta-blockers 
Serotonin selective re-uptake inhibitors 
Opioid analgesics 
Anti-diabetics 
10. What is the max dose of Aspirin for a patient aged 65 or older? 
75mg 
150mg 
225mg 
300mg 
(2 marks for each correct answer) 
 
Case studies (30 marks in total) 
Case 1 
 
70 year old male complaining of nausea and blackouts 
 
Current Diagnosis: 
Paroxysmal Atrial Fibrillation (2007) 
Non-obstructive coronary artery disease (coronary angiogram 2007) 
Recurrent Gout since 2006 (secondary to thiazide diuretic) 
Hypertension 
Hypercholesterolaemia 
Restless leg syndrome 
Worsening asthma 
 
History: 
Non-Hodgkins Lymphoma 2005 
Duodenal ulcer-resolved 
 
Regular medications:  
Pravastatin 40mg d  
Verapamil (slow release) 240mg od  
Quinine sulphate 300mg od 
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Perindopril 5mg/Indapamide 1.5mg od 
Digoxin 250mcg od 
Inegy 10/20 od 
Omeprazole 40mg BD 
Diclofenac 75mg bd  
Furosemide 20mg od  
Paracetamol 1g prn  
Warfarin as per INR  
 
 
Biochemical details: 
Fasting Chol: 3.8mmol/L 
Urea: 10.4mmol/L 
Creatinine: 150 micromol/L 
Sodium: 140mmol/L 
Potassium: 3.5mmol/L 
eGFR: 37ml/min/1.73m2 
 
BP: 105/60 mmHg 
HR: 44 BPM 
ECG: Sinus rhythm with 1st degree heart block 
 
1 mark for each of the following points raised (+ 1 mark floating for extra points 
raised….. 
1. Digoxin not effective in paroxysmal a-fib 
2. Digoxin and verapamil together is inappropriate 
3. PPI at max strength for resolved duodenal ulcer 
4. Diclofenac with reduced renal function 
5. 2 x statins 
6. Requires asthma therapy 
7. Digoxin dose too high given reduced renal function 
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Case 2  
71 Year old male complaining of constipation  
 
Active problems:  
Peptic Ulcer Disease since 2006  
Hypertension since 2004  
Prostate Carcinoma since 2009 
Moderate depression diagnosed 6 months ago 
Diverticular disease with sporadic constipation 
 
History: 
R ankle injury-1992 
Deep Vein Thrombosis 1999 
 
Regular Medications:  
Pantoprazole 40mg od (Since 06)  
Bendroflumethiazide 2.5mg od  
Aspirin 75mg od  
Paracetamol 500mg 2qds 
Amitriptyline 25mg  
 
Prostap 3 (leuprorelin) 
 
Biochemical Data 
Total Chol = 2.7 mmol/L 
Urea: 8.1 mmol/L 
Creatinine: 110micromol/L 
Sodium: 147 mmol/L 
Potassium: 3.2 mmol/L 
eGFR: 59ml/min/1.73m2 
 
PSA 15.8  
BP: 130/75 mmHg 
1 mark for each of the following points raised (+ 1 mark floating for extra points 
raised) 
1. PPI dose should be reduced to 20mg daily 
2. Thiazide diuretic not appropriate with metabolic derangement 
3. Amitriptyline inappropriate with constipation 
4. Fibre supplement should be considered 
 
 
271 
 
Case 3 
73 year old female complaining of recurrent hypos, blackouts, sporadic confusion 
and chronic constipation 
 
Current diagnosis: 
Hypertension since 2004 
Non Insulin Dependant Diabetes Mellitus with poor monitoring of glucose 
Recent episode of depression 
 
History:  
Previous alcohol abuse-no relapse 
Stroke-good recovery-2012 
 
Current Medications:  
Aspirin 75mg od  
Atenolol 25mg od  
Lisinopril 20mg od 
Citalopram 10mg od 
Gliclazide 30mg od  
Quetiapine 100mg Bd  
Zolpidem 10mg nocte  
Dothiapen 150mg nocte 
 
 
Biochemical Details:  
Total Chol: 6.5 mmol/L 
Urea: 6.1 mmol/L 
Creatinine: 86 mmol/L 
Sodium: 110 mmol/L 
Potassium 4.5mmol/L 
eGFR 60ml/min/1.73m2 
LFT normal 
No Urinalysis available 
 
BMI: 29.5 
1 mark for each of the following points raised: 
1. Beta-blocker inappropriate with diabetes. 
2. Citalopram inappropriate with decreased renal function 
3. Constipation possibly caused by quetiapine 
4. No indication for quetiapine 
5. Metformin may be better anti-diabetic as patient is obese 
6. Statin should be considered 
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Case 4 
77 year old female complaining of nausea and sporadic falls 
 
Current Diagnosis:  
Hypercholesterolaemia  
Ischaemic Heart Disease (IHD) 
Insomnia 
Gout 
 
History: 
Cataracts 
MI 2011 
 
Regular medications:  
Allopurinol 100mg od 
Bendroflumethiazide 2.5mg od  
Aspirin 75mg od 
Flurazepam 30mg od (past 3 years) 
 
Biochemical Data  
eGFR: 30ml/min/1.73m2 
Sodium: 136 mmol/L 
Potassium: 3.0 mmolL 
Urea: 11.2 mmol/L 
Creatinine: 140 mmol/L 
Urate: 582 micromol/L 
 
Fasting Chol: 6.8mmol/L 
1 mark for each of the following points raised: 
1. Thiazide diuretic inappropriate with gout 
2. Long half-life benzodiazepine inappropriate with history of falls 
3. Statin should be considered 
4. Beta-blocker should be considered 
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Case 5 
79 year old male complaining of recent fall and wrist fracture  
 
Diagnoses:  
Gout  
Insomnia  
Hypertension since 1987 
Hypercholesterolaemia 
Osteoporosis diagnosed in routine screening 2010 
Recent urinary incontinence-daily occurrence 
Mild allergies 
 
History: 
Myocardial infarction 2001 no re-vascularisation  
 
Current Medicines:  
Allopurinol 300mg od  
Olanzapine 2.5mg nocte  
Aspirin 75mg od  
Nebivolol 2.5mg od  
Doxazosin XL 8mg od  
Irbesartan 600mg od  
Bendroflumethiazide 2.5mg od  
Atorvastatin 10mg od 
Chlorphenamine 4mg tds 
 
Biochemical data: 
Total Chol: 3.3mmol/L 
Urea: 11.8 mmol/L  
Creatinine: 161mmol/L 
Sodium: 141 mmol/L 
Potassium: 4.6mmol/L 
eGFR: 38ml/min/1.73m2 
1.5 marks for each of the following points raised (+ 1.5 marks floating for extra 
points raised): 
1. Alpha blocker inappropriate with incontinence 
2. Chlorphenermine long term is inappropriate 
3. No indication for olanzapine 
4. Calcium/Vitamin D should be considered for osteoporosis 
5. Bisphosphonates should be considered for same 
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12 Week assessment 
1. The excretion of which drugs is likely to be reduced in an older patient (>65 
years of age)? 
Lipid-soluble 
Water-soluble 
2. With increasing age, drugs bound to muscle may 
Experience increased distribution leading to a hang-over effect. 
Experience decreased distribution leading to a hang-over effect. 
Experience increased distribution thereby requiring an increase in dose 
Experience decreased distribution thereby requiring a decrease in dose. 
3. The bioavailability of which one of these drugs is unlikely to be affected by age? 
Nifedipine 
Atenolol 
Propranolol 
Morphine 
4. Why is this so? 
It is a lipid-soluble drug therefore experiences decreased distribution in an older 
patient 
It is a water soluble drug therefore not affected by reduced liver blood flow rate 
It is a lipid soluble drug therefore not affected by liver blood flow rate 
It is a water soluble drug therefore experiences increased distribution in an 
older adult. 
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5. Between the ages of 20 and 70 a person may have up to 50% reduction in renal 
function. In practice it is this decline in renal function that is the major 
pharmacokinetic determinant of toxicity in older adult patients.Which measure 
should be used to estimate kidney function in a 70 year old man with severely 
reduced muscle mass? 
Creatinine clearance 
eGFR 
6. Which of the following best describes the pharmacodynamics associated with 
opioids in older patients? 
Due to a decrease in opioid receptors, likelihood of behavioural changes is 
increased in older patients. 
Due to an increase in opioid receptors, likelihood of behavioural changes is 
increased in older patients. 
7. Falls, confusion and postural hypotension are most commonly associated with 
which family of drugs? 
NSAIDs 
Hypnotics/anxiolytics 
Anit-muscarinincs 
Opioid analgesics 
8. Patients with pre-existing dementia should avoid which ONE of the following 
groups of drugs? 
Calcium-channel blockers 
Anti-histamines 
Anti-psychotics 
NSAIDs 
9. With regards to proton pump inhibitors, which of the following is true? 
They should not be used for more than eight weeks in older patients. 
They should not be used at all in older patients. 
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The max therapeutic dose can be used for up to eight weeks, after which, the 
dose should be reduce to a maintenance dose. 
The max therapeutic dose can be used for up to twelve weeks, after which, the 
dose should be reduce to a maintenance dose. 
10. True or false, ACE inhibitors are considered appropriate for older patients with 
chronic heart failure? 
True 
False 
 
(2 marks for each correct answer) 
 
Case studies (30 marks total) 
Case 1 
70 year old male complaining of nausea and sporadic falls 
 
Current Diagnosis:  
Hypercholesterolaemia  
Ischaemic Heart Disease (IHD) 
Insomnia 
Gout 
 
History: 
Cataracts 
MI 2011 
 
Regular medications:  
Allopurinol 100mg od 
Bendroflumethiazide 2.5mg od  
Aspirin 75mg od 
Flurazepam 30mg od (past 3 years) 
 
Biochemical Data  
eGFR: 30ml/min/1.73m2 
Sodium: 136 mmol/L 
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Potassium: 3.0 mmolL 
Urea: 11.2 mmol/L 
Creatinine: 140 mmol/L 
Urate: 582 micromol/L 
 
Fasting Chol: 6.8mmol/L 
 
1 mark for each of the following points raised……….. 
1. Thiazide diuretic inappropriate with gout 
2. Long half-life benzodiazepine inappropriate with history of falls 
3. Patient not taking any statin 
4. Patient not taking any benzodiazepine 
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Case 2 
 
72 year old male complaining of recent fall and wrist fracture  
 
Diagnoses:  
Gout  
Hypertension since 1987 
Hypercholesterolaemia 
Osteoporosis diagnosed in routine screening 2010 
Glaucoma 
Depression 
 
History: 
Myocardial infarction 2001 no re-vascularisation  
 
Current Medicines:  
Allopurinol 300mg od  
Aspirin 300mg od  
Nebivolol 2.5mg od  
Doxazosin XL 8mg od  
Irbesartan 600mg od  
Bendroflumethiazide 2.5mg od  
Atorvastatin 10mg od 
Amitriptyline 25mg nocte 
Xalatan eye drops nocte 
 
 
Biochemical data: 
Total Chol: 3.3mmol/L 
Urea: 11.8 mmol/L  
Creatinine: 161mmol/L 
Sodium: 141 mmol/L 
Potassium: 4.6mmol/L 
eGFR: 38ml/min/1.73m2 
 
Supine BP: 110/70 
Standing BP: 85/50 
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1.5 marks for each of the following points raised (+1.5 marks for extra points 
raised): 
1. No benefit to aspirin dose > 150mg 
2. TCA inappropriate with glaucoma 
3. Excessive antihypertensive therapy 
4. Calcium/Vitamin D should be considered for osteoporosis 
5. Bisphosphonate should be considered for same 
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Case 3 
74 year old female complaining of recurrent hypos, blackouts, sporadic confusion, 
worsening COPD. 
 
Current diagnosis: 
Hypertension since 2004 
Non Insulin Dependant Diabetes Mellitus with poor monitoring of glucose 
COPD 
Glaucoma 
 
Current Medications:  
Aspirin 300mg od  
Amlodipine 5mg od  
Lisinopril 20mg od 
Gliclazide 30mg od  
Zolpidem 10mg nocte  
Propranolol 10mg od 
Dothiapen 150mg nocte 
Ventolin inhaler 2puffs qds prn 
Atrovent nebules od (new) 
Seretide 250 inhaler bd 
Xalatan eye drops one drop nocte 
 
History:  
Previous alcohol abuse-no relapse 
Stroke-good recovery-2012  
 
Biochemical Details:  
Total Chol: 6.5 mmol/L 
Urea: 6.1 mmol/L 
Creatinine: 86 mmol/L 
Sodium: 138 mmol/L 
Potassium 4.5mmol/L 
eGFR 60ml/min/1.73m2 
LFT normal 
No Urinalysis available 
 
BMI: 29.5 
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1 mark for each of the following points raised: 
1. Beta-blocker inappropriate in diabetes 
2. Beta-blocker inappropriate in COPD 
3. Nebulised Atrovent inappropriate with glaucoma 
4. No benefit to aspirin dose greater than 150mg 
5. Metformin may be a better anti-diabetic as patient is obese 
6. Statin should be considered 
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Case 4 
80 Year old male complaining of constipation  
 
Active problems:  
Peptic Ulcer Disease since 2006  
Hypertension since 2004  
Recurrent gout since 2009  
Prostate Carcinoma since 2009 
Depression for last 6 months 
 
 
History: 
R ankle injury-1992 
Diverticular disease 2003 
Deep Vein Thrombosis 1999 
 
Regular Medications:  
Allopurinol 100mg od 
Pantoprazole 40mg od (Since 06)  
Bendroflumethiazide/potassium od  
Aspirin 75mg od  
Paracetamol 500mg 2qds  
Verapamil 120mg od 
Prostap 3  
 
Biochemical Data 
Total Chol = 2.7 mmol/L 
Urea: 8.1 mmol/L 
Creatinine: 110micromol/L 
Sodium: 147 mmol/L 
Potassium: 3.2 mmol/L 
eGFR: 59ml/min/1.73m2 
 
PSA 15.8  
BP: 130/75 mmHg 
1 mark for each of the following points rasied: 
1. PPI needs to be reduced to 20mg daily 
2. Thiazide diuretic inappropriate in presence of gout and metabolic disorder. 
3. Verapamil may be causing constipation 
4. Antidepressant may be required for depression  
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Case 5 
76 year old female complaining of nausea and blackouts 
 
Current Diagnosis: 
Paroxysmal Atrial Fibrillation (2007) 
Non-obstructive coronary artery disease (coronary angiogram 2007) 
Recurrent Gout since 2006 (secondary to thiazide diuretic) 
Hypertension 
Hypercholesterolaemia 
Restless leg syndrome 
 
History: 
Non-Hodgkins Lymphoma 2005 
Vertigo (single episode) 2011 
 
Regular medications:  
Pravastatin 40mg od  
Verapamil (slow release) 240mg od  
Quinine sulphate 300mg od 
Perindopril 5mg/Indapamide 1.5mg od 
Digoxin 250mcg od 
Diclofenac 75mg bd  
Furosemide 20mg od  
Betahistine 16mg tds  
Paracetamol 1g prn  
Warfarin as per INR  
 
 
Biochemical details: 
Fasting Chol: 6.0 mmol/L 
Urea: 10.4mmol/L 
Creatinine: 150 micromol/L 
Sodium: 140mmol/L 
Potassium: 3.5mmol/L 
eGFR: 37ml/min/1.73m2 
 
BP: 105/60 mmHg 
HR: 44 BPM 
ECG: Sinus rhythm with 1st degree heart block 
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1.5 marks for each of the following points raised (+1.5 marks floating for extra 
points raised): 
1. Digoxin dose should be reduced given reduced renal function 
2. Digoxin not effective in paroxysmal a-fib. 
3. Digoxin and verapamil together is inappropriate 
4. Indapamide contraindicated in gout 
5. Diclofenac inappropriate given reduced renal function 
6. Full dose of betahistine for prolonged period of time 
7. Statin dose may be insufficient 
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11.12 Appendix XII: CONSORT checklist for RCTs 
 
CONSORT 2010 checklist of information to include when reporting a randomised trial* 
 
Section/Topic 
Item 
No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title  
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)  
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale  
2b Specific objectives or hypotheses  
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio  
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons  
Participants 4a Eligibility criteria for participants  
4b Settings and locations where the data were collected  
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
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Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
 
6b Any changes to trial outcomes after the trial commenced, with reasons  
Sample size 7a How sample size was determined  
7b When applicable, explanation of any interim analyses and stopping guidelines  
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence  
8b Type of randomisation; details of any restriction (such as blocking and block size)  
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 
assessing outcomes) and how 
 
11b If relevant, description of the similarity of interventions  
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes  
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses  
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Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
 
13b For each group, losses and exclusions after randomisation, together with reasons  
Recruitment 14a Dates defining the periods of recruitment and follow-up  
14b Why the trial ended or was stopped  
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group  
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 
by original assigned groups 
 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended  
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)  
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses  
Generalisability 21 Generalisability (external validity, applicability) of the trial findings  
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Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence  
Other information 
 
Registration 23 Registration number and name of trial registry  
Protocol 24 Where the full trial protocol can be accessed, if available  
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders  
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